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ABSTRACT: 
Trypanosomiasis and Leishmaniasis are tropical diseases caused by the parasites 
Trypanosoma and Leishmania, that cause severe medical and economical problems 
for millions of people in the developing world. Trypanosomiasis can be divided into 
African and American trypanosomiasis, which are caused by Trypanosoma brucei and 
Trypanosoma cruzi respectively. There are more than 20 different species of 
Leishmania worldwide that cause Leishmaniasis, but the most severe infection, 
visceral leishmaniasis, is caused by Leishmania donovani. Both diseases are 
transmitted by blood sucking insects like the tsetse fly and the sand fly. 
The majority of existing drugs for trypanosomiasis and leishmaniasis are either too 
toxic or have low efficacy, and in some cases parasites have also developed 
resistance. There is therefore a pressing need to develop new chemotherapeutic 
agents, and in this context, the enzyme trypanothione reductase (TryR) has emerged 
as an attractive validated target for drug design. The natural product cadabicine, 
extracted from the plant Cadaba farinosa, is a diphenyl ether­containing macrocyclic 
spermidine alkaloid which has been identified as a potential inhibitor of TryR by 
virtual screening. 
In order to investigate the potential of cadabicine as a TryR inhibitor, an efficient 
synthetic route to the natural product was delivered. This work was focused on the 
preparation and combination of three key synthetic units, namely an orthogonally 
protected spermidine derivative and two functionalised cinnamic acid units. This 
approach lead to the formation of the macrocycle by an intramolecular nucleophilic 
aromatic substitution followed by a convenient conversion to the natural product. In 
the same manner cyclic and non­cyclic analogues of cadabicine were prepared, in 
order to examine the structure­activity relationship of these alkaloids to TryR. 
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1. INTRODUCTION 
1.1 KINETOPLASTID PROTOZOAN INFECTIONS. 
Trypanosomiasis and leishmaniasis are parasitic diseases caused by the parasites 
Trypanosoma and Leishmania which are single cell eukaryotes of the kinetoplastid 
order. After malaria, they are the major cause of death in the undeveloped World. 
Human trypanosomiasis can be split into African trypanosomiasis or sleeping 
sickness, caused primarily by Trypanosoma brucei and American trypanosomiasis or 
Chagas’ disease caused by T.cruzi. Leishmaniasis can be caused by 20 different 
species of Leishmania, but the most severe infection known as visceral leishmaniasis 
is caused by Leishmania donovani. Both trypanosomiasis and leishmaniasis are 
transmitted via the bite of a blood sucking insect that transfers the parasites from 
human to human. Once inside the human hosts, the parasites multiply and invade 
most tissues. Table 1.1 shows recent estimates of the occurrence and mortality rates 
of trypanosomiasis and leishmaniasis.1 
Disease Cases 
Disease Burden 
DALYs (thousands) 
Deaths (thousands) 
per year 
Per year Total Male Female Total Male Female 
African 
Trypanosomiasis 
300­500 
thousand 
1,525 996 559 48 31 17 
Chagas Disease 16­18 
million 
667 343 324 14 8 7 
Leishmaniasis 500 
thousand 
2,090 1,24 840 51 30 21 
Table 1.1 : Number of cases of infections and deaths estimated by WHO tropical disease 
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research. 
1.1.1 African trypanosomiasis 
African trypanosomiasis can affect both humans and animals. Human African 
trypanosomiasis (HAT) is also known as sleeping sickness, and can be fatal if left 
untreated. In cattle it causes the infection known as nagana which restricts cattle 
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industry in many prime areas of Africa. The disease affects 36 countries in sub­
Saharan Africa causing 50,000 deaths annually, with the increasing risk of major 
epidemics forming. 
Epidemic 
High endemicity 
Low endemicity 
At risk 
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Figure 1.1: Map of the distribution of African trypanosomiasis.
Trypanosomiasis is caused by the parasite Trypanosoma brucei. There are three sub­
species of Trypanosoma brucei; two of which cause infection to humans. These are 
T.b.gambiense which is found in West and Central Africa, and T.b.rhodesiense which 
is found in Eastern and South Africa. The species Trypanosoma brucei brucei does 
not affect humans, despite the fact that is structurally and biochemically 
indistinguishable from T.b.rhodesiense, but along with the species T.congolense and 
T.vivax, it causes nagana in cattle, sheep and goats. T.b.rhodesiense is more virulent, 
but much less common in occurrence than is T.b.gambiense. T.b.rhodesiense causes 
acute infection that emerges within a few weeks of a fly’s bite. As such, it is much 
easier to detect than T.b.gambiense, which may not show symptoms for years. Once 
T.b.gambiense does emerge, it is already in an advanced stage and difficult to treat.1 
African trypanosomiasis is transmitted between vertebrate hosts via the tsetse fly of 
the Glossina species. When an infected fly is taking a blood meal, it transfers 
trypanosomes to the host; this is the first stage of the trypanosome infectious cycle, 
where the parasites exist in the metacyclic stage. At this stage the parasites multiply 
and cause painful indurate swelling at the site of the bite. The parasites then migrate 
from the lymph to the bloodstream where they develop to the slender trypomastigote 
form. Once in this form they multiply by asexual binary fission and spread to the 
11 
intracellular spaces of other tissues. They are then transferred back to the tsetse fly, 
when the insect is taking a blood meal, where they develop to the procyclic form in 
the insect’s gut. The parasites then migrate to the insect’s salivary glands where they 
take on the epimastigote form and later the metacyclic form.1 
Epimastigote form 
Metacyclic 
form 
Metacyclic 
form 
Procyclic 
form 
Trypomastigote 
form 
3
Figure 1.2: Infectious life cycle of the Trypanosoma brucei. 
The infection can also be transmitted accidentally by coming into contact with the 
blood of an infected person or animal. 
Human African trypanosomiasis entails two main phases of the disease. At the early 
phase of the infection there are symptoms such as fever, joint pains, headaches, 
swollen tissues and itching. If the disease is diagnosed at this stage there is a high 
chance of cure. Once the parasite crosses the blood brain barrier, at the late stage of 
the disease and infects the central nervous system, the symptoms include confusion, 
sensory disturbances, loss of coordination, disturbance of the sleep cycle, coma and 
finally death. 
The parasites (both T.brucei and T.cruzi) are remarkably well adapted in using the

energy resources of both their insect and human hosts. Once in the insect mid­gut they

use the citric acid cycle in order to metabolise intermediates, whilst in the mammalian
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hosts they use glucose as the only form of energy and do not use the citric acid cycle. 
Unfortunately, no immunity against the parasites can be developed from the hosts, 
due to the parasites variable glycoprotein coat. Each metacyclic and bloodstream form 
of trypanosome are coated with a layer of glycoprotein known as a variable surface 
glycoprotein coat, which they change an unlimited number of times to 
immunologically distinct forms. This ability of the parasites makes the prospect of a 
vaccine unlikely, and thus chemotherapy remains the best available treatment. 
The World Health Organisation is concerned that the social and economic impact of 
sleeping sickness is often underestimated. Epidemics have serious social and 
economic consequences and the disease has been the major case of depopulation of 
large tracts of Africa. The fear it causes has lead to abandonment of fertile lands and 
is an impediment to development.2 
1.1.2 American trypanosomiasis. 
American trypanosomiasis or Chagas’ disease infects both humans and small 
mammals which act as reservoir hosts. It affects 18 countries in Latin America, 
including Central America and Mexico, causing 13,000 deaths annually. Furthermore, 
due to recent, significant migrations from endemic countries towards developed 
countries, the threat of the disease is expanding to reach areas outside traditional 
geographic boundaries. 
3
Figure 1.3: Map of the distribution of Chagas’ disease. 
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. The parasites 
are transmitted to human by blood­sucking bugs of variable genera such as assassin 
bugs, kissing bugs and reduviid bugs. The type of insect depends on the living 
conditions of humans. The faeces of the insects also contain parasites and they can 
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infect the host when they come in contact with broken skin. The parasite enters the 
host in the metacyclic phase, when the bug is taking a blood meal. It then multiplies at 
the site of bite causing local swelling or a skin nodule known as chagoma. At this 
stage the parasite invades host tissue cells and transforms to the amastigote phase 
where it multiplies to great numbers, filling the cell to its full capacity. The parasites 
then transform to the slender and mobile trypomastigote phase, where they burst the 
host cells and invade the bloodstream. The non­dividing extracellular trypomastigotes 
are then spread throughout the body where they invade the host’s tissues and 
transform back to the intracellular proliferative amastigote form. The disease can also 
be transmitted through blood transfusions with infected blood and congenitally, from 
infected mother to foetus.1 
Metacyclic 
form 
Amastigote 
form Trypomastigote Amastigote 
Amastigote 
form 
form form 
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Figure 1.4: Infectious cycle of parasite.
Upon infection, the human host can experience two phases of symptoms. First, the 
sufferers enter the acute phase, which lasts from two weeks to months, where they 
experience fever, local swelling, skin rashes, myocarditis and hepatosplenomegaly. 
Approximately 10% of patients die in the acute phase of the infection, while the ones 
who survive enter the second chronic phase which can last for more than a decade. 
During the second phase the parasite invades most of the host’s organs. The majority 
of the patients that enter the chronic phase do not experience any symptoms of the 
disease, while amongst the remainder, 32% develop cardiac and gastrointestinal 
symptoms that lead to death. 
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1.1.3 Leishmaniasis 
Leishmaniasis affects humans, with animals acting as a reservoir for the parasites. It 
affects 88 countries, 16 of which are in Europe including France, Italy, Greece, Malta, 
Spain and Portugal, and it causes 59,000 deaths annually. 
3
Figure 1.5: Map of distribution of Leishmaniasis.
There are more than twenty species of Leishmaniasis which are known to be 
pathogenic to humans. The severity of the disease depends on the species of the 
parasite. Visceral leishmanisis, otherwise known as Kala­azar (black fever) is the 
most severe infection, and is fatal if left untreated. It is caused by Leishmania 
donovani. The symptoms of visceral leishmaniasis are high fever, hyperpigmentation 
of the skin and swelling of the lymph nodes. The species L.chagasi found in South 
America and L.infantum found in the Mediterranean and the Middle East can also 
develop to visceral leishmaniasis. Cutaneous leishmaniasis is caused by L.major and 
L.mexicana. It is more common than visceral leishmaniasis but not as severe; it causes 
1­200 skin lesions which self­heal within a few months but leave unsightly scars. The 
species L.braziliensis and L.panamensis have a high risk in developing to 
mucocutaneous leishmaniasis; where the infection begins with skin ulcers that spread 
to tissues especially the nose and mouth, leading to almost their complete destruction. 
Another form of the infection is diffuse cutaneous leishmaniasis which is quite 
difficult to treat. It causes disseminated and chronic skin lesions resembling those of 
leprosy.1 
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The infection is transmitted to humans via the bite of female sandflies of the family 
Phlebotomus found in Europe, Asia and Africa or Lutzoyia found in America. The 
sandfly gets infected from the parasite when it is feeding from a reservoir host. The 
parasite exists in the amastigote form inside the insect. When the sandfly is taking a 
blood meal from a human host, the parasite is transferred to the host via the insect’s 
salivary glands. The amastigote form transforms to the promastigote form when it is 
ingested by the host’s macrophage cells. The promastigote then transforms back to the 
amastigote and multiplies until the cell bursts. The amastigote form can only survive 
in the macrophage cells, once released it infects new cells and so spreads the 
infection. Sandflies then become infected with the amastigotes when they feed from 
infected hosts, thus completing the infectious cycle of the parasite.1 
Amastigote 
form 
Amastigote 
form 
Promastigote 
form 
Amastigote 
form 
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Figure 1.6: Infectious cycle of leishmania parasites.
1.2 EXISTING CHEMOTHERAPIES. 
Numerous drugs have been developed to treat both leishmaniasis and 
trypanosomiasis, without giving promising results in reducing the spread of the 
infection. The problem of existing chemotherapies is that the majority of the drugs are 
toxic and have low efficacy. They are either very expensive to make, or difficult to 
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administer and parasites have already developed resistance to some of them. 
Furthermore the medical facilities and staff for long term treatment and follow up of 
patients do not exist in the affected regions. 
1.2.1 African trypanosomiasis 
Treating sleeping sickness has proven to be very difficult, especially when the 
parasites cross the blood­brain barrier, as few drugs are effective at this point. 
i) Suramin Sodium 
Suramin sodium (1) is a sulfonated naphthylamine polyanionic dyestuff introduced in 
the 1920s and is still used against sleeping sickness. It is chemically related to the 
dyes Trypan Red and Trypan blue, which also have anti­trypanosomal activity. 
Suramin is extremely polar and thus water soluble, and is administered by intravenous 
injection. It is very unstable in solution if the solution comes in contact with air, so it 
is dissolved immediately before administration. Due to its high polarity, it cannot 
cross the blood­brain barrier and so it is only used for the early phase of the infection. 
The selectivity of suramin is explained by the ability of trypanosome to accumulate 
the drug. However, its mode of action is not completely clear as it inhibits a number 
of trypanosomal enzymes, and thus multiple mechanisms are probably involved in its 
therapeutic effect. The use of suramin can cause a number of side effects including, 
vomiting, pruritus, utricaria, paresthesias, hyperesthesia of hands and feet, 
photophobia and peripheral neuropathy. Occasional side effects are kidney damage, 
blood dyscrasias, shock and optic atrophy.1 
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O

NH NH 
O O 
NH NH 
SO3Na NaO3S 
SO3Na SO3Na 
NH OHN O 
SO3Na (1) 
SO3Na 
Figure 1.7: Suramin Sodium (1). 
ii) Diamidines 
Synthalin (2) was the first diamidine to show activity against Trypanosoma, but today 
pentamidine (3) and diminazene (4) are more commonly used. Pentamidine (3) was 
first developed as a hypoglycemic agent, but was introduced as an anti­trypanocidal 
agent in 1941. Pentamidine (3), as all diamidines, is almost always fully protonated, 
making it hard to be absorbed if it is orally administered. Therefore, pentamidine (3) 
like suramin sodium (1) has to be administered intravenously, with the drug solution 
made just before administration because it is otherwise unstable. Diamidines are 
polar, cannot cross the blood­brain barrier, and are thus used only in the first phase of 
the infection. The activity of pentamidine (3) and other diamidines are dependent on 
their active uptake by the parasite via the high affinity purine transporter P2.4 The 
mechanism of action of pentamidine remains unclear, however Bailey et al,5 have 
reported that pentamidine binds to nucleic acids in DNA and RNA, while Shapiro and 
Englund5 reported that the drug promotes cleavage of the parasite’s circular DNA in a 
manner similar to that of topoisomerase II inhibitors. Diminazene (4) is approved for 
vetinary use as it is a more toxic diamidine, and its safety has not been fully evaluated 
yet.6 Some of the common side effects of pentamidine (3) include hypotension, 
hypoglycemia, vomiting, blood dyscrasis, renal damage, pain at the injection site and 
gastrointestinal disturbances. Rarer side effects include anaphylaxis, acute 
pancreatitis, hyperkalemia, and ventricular arrhythmias. 
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H 
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Figure 1.8: Diamidines (2) Synthalin, (3) Pentamidine, (4) Diminazine. 
iii) Arsenicals 
One of the first arsenical drugs that was effective against sleeping sickness was 
Atoxyl (5).7 Nevertheless, it was found to have serious side effects as it was highly 
toxic. Then in 1949 Melasoprol (6) was introduced, which was the only drug that was 
effective in the late stage of the infection. However, the parasites have since 
developed resistance to this drug, and now only eflornithine (7) is used for treatment 
of the late stage of the infection. Melasoprol (6) is actually a prodrug that converts to 
melarsen oxide. It has a relatively small half­life of 30 minutes and so it leaves the 
system within 24 hours.8 There has been some controversy about the mechanism of 
action of melasoprol, but Fairlamb et al.9 published that melarsoprol or melarsen 
oxide can form a stable adduct with trypanothione which is an essential substrate for 
redox homeostasis in trypanosomes. Melasoprol (6) can cause reactive 
encephalopathy in 5­10% of the patients treated and has a fatal outcome in 10­50% of 
these patients. The drug can also cause side effects such as hypertension, myocardial 
damage, vomiting and abdominal colic. It is a non­specific inhibitor of many different 
enzymes, which perhaps explains the many toxic side effects that it has. 
iv) Eflornithine (7) 
Eflornithine (7) was originally developed as an anti­cancer agent. It was reported by 
Metcalf et al.10 that it could block the biosynthesis of polyamines by inhibiting 
ornithine decarboxylase which is an enzyme vital for polyamine biosynthesis. Later in 
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the 1980s it was found to have anti­trypanosomal activity by Bacchi et al.11 against 
the early and late stage of T.b.gambiense associated infections. However, it has no 
activity against other species of Trypanosoma, except T.b.brucei, for reasons not fully 
understood. It is suggested that in the mechanism of action of eflornithine (7), the 
cysteine 360 in the active site of ornithine decarboxylase, acts as a nucleophile and 
attacks the drug, which is then covalently bound to the enzyme.12 It has also been 
reported that eflornithine (7) depletes putrescine and spermidine from T.b.brucei both 
in vitro and in vivo. As a result, the trypanosomes stop growing, and change to a short 
and stumpy form that cannot change their variable surface glycoprotein coat, and thus 
killed by the host’s immune system.13 The depletion of polyamines in eflornithine­
treated trypanosomes causes a 40% decrease in trypanothione which possibly could 
contribute to eflornithine’s mechanism of action as well as accounting for the 
synergistic effect with arsenical drugs in vivo.14 
N 
N 
N 
H2N 
NH2 
N 
As 
S 
S CH2OH 
H2N As 
O 
OH 
ONa 
(5) atoxyl 
H 
NH2 (6) melasoprol 
F2HC 
COOH 
H2N 
(7) eflornithine 
Figure 1.9: Arsenicals & eflornithine. 
1.2.2 American trypanosomiasis 
For American trypanosomiasis two drugs have been used for treatment of both the 
early and chronic phase of the disease. Unfortunately, the prospects of developing a 
vaccine against Chagas disease are slim, since T.cruzi antigens can cause 
autoimmunity. 
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i) Nifurtimox (8) 
Nifurtimox (8) is a nitrofuran derivative that is effective against both T.cruzi and 
T.brucei
15 but is no longer in use. The full mechanism of action of the drug is not yet 
known, but it is clear that one electron transfer reaction is needed in order to form a 
nitro ion radical. In turn, the nitro radical is thought to produce oxygen radicals and 
hydrogen peroxide and thus induce oxidative stress in the parasites. Some of the side 
effects induced by this drug include nausea, vomiting, abdominal pain, anorexia, 
restlessness, insomnia, paresthesia, polyneuritis, and seizures, as well as allergic 
reactions such as dermatitis, icterus, pulmonary infiltrates and anaphylaxis. 
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Figure 1.10: Nifurtimox (8) 
ii) Benznidazole (9) 
Benznidazole (9) is a nitroimidazole analogue and is now the drug of choice against 
Chagas disease. Unlike Nifurtimox, oxidative damage is not the key of action of 
Benznidazole, but it involves covalent and other bond interactions of nitroreduction 
intermediates with parasite components or binding to DNA lipids and proteins 
.Unfortunately some strains of T.cruzi have developed resistance to both drugs. 
N 
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N 
O 
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Figure 1.11: Benznidazole (9) 
1.2.3 Leishmaniasis 
Most cases of cutaneous leishmaniasis heal without treatment, but visceral 
leishmaniasis requires long courses of antimonial drugs or sodium stibogluconate. 
Recently, resistance to some drugs has been reported requiring the use of more toxic 
drugs such as amphotericin B.2 Most available drugs are costly, require long treatment 
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regimes and are becoming more and more ineffective, necessitating the discovery of 
new drugs.2 
i) Antimonials 
There are two main drugs that have been used in the past 50 years for the treatment of 
leishmaniasis. Sodium stibogluconate (10) and meglumine antimonate are both 
pentavalent derivatives of antimony. They are both prodrugs that need to be reduced 
from SbV to SbIII, in order to be active against the amastigote stage of the parasite, and 
the treatment of both drugs is the same. Their mode of action is not yet completely 
understood , but it has been reported that they could inhibit glucose catabolism and 
fatty acid oxidation in amastigotes,16 and also that they may inhibit trypanothione 
reductase.17 However, resistance to antimonial drugs has been reported, causing 
problems in Bihar in India and in some parts of Bangladesh.2 Side effects that can 
occur with pentavalent antimonial drugs include arrhythmias, transaminase elevations, 
muscle and joint pain, fatigue, nausea and pancreatitis. 
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Figure 1.12: Sodium Stibogluconate (10). 
ii) Paromycin (11) 
An alternative treatment to antimonial drugs is the antibiotic paromycin sulphate (11). 
It is effective against all forms of Leishmania and binds to the parasites’ polysomes 
inhibiting protein synthesis by causing misreading and premature termination of 
translation of mRNA.18 Unfortunately the drug is not currently commercially 
available. Some of the side effects of paromycin can cause are nephrotoxicity and 
damage to the eighth cranial nerve, resulting in hearing loss. 
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Figure 1.13: Paromycin (11) 
iii) Amphotericin B (12) 
Amphotericin B (12) is also an antibiotic which is highly effective against antimony­
resistant strains of Leishmania.19 It is effective against all forms of leishmaniasis and 
has a cure rate close to 100%, which is much better than that of paromycin (11). Its 
mechanism of action involves the drug binding with ergosterol on the parasite’s cell 
membrane. This causes pores to form on the cell membrane and an influx of ions into 
the cell leading to cell apoptosis.20 Even though resistance to this drug is very rarely 
reported, it is not widely used because of its high cost, the difficulty of the paranteral 
administration needed and the long treatment periods required. The major side effect 
of the drug is nephrotoxicity, while other acute side effects include fever, chills, 
muscle spasms, vomiting, headache and anaphylaxis. 
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Figure 1.14: Amphotericin B (12). 
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iv) Pentamidine (3) 
Other than treating African sleeping sickness, pentamidine (3) is also used against 
leishmaniasis. It has serious side effects and resistance has been reported, therefore is 
only used as a back up alternative therapy to antimonial drugs and amphotericin B. 
v) Miltefosine (13) 
Miltefosine (13) was initially developed as an anti­cancer drug, but failed the 
screening process and was subsequently found to have antileishmanial activity. In 
2004 the drug was in Phase IV trial in India. The trial involved 1200 patients, with 6 
month follow up for efficacy and safety and a 1.5 year follow up for male 
reproductive function.2 The significant advantage of using this drug is that it is orally 
administered unlike the other anti­leishmanial drugs. Up to now, it has shown very 
promising results with a cure rate of 98%. The exact mechanism of action of 
miltefosine is not known. The side effects of the drug are quite significant but 
tolerable; they include gastrointestinal distress and elevated aspartate 
aminotransferase levels. 
H C CHO 3 3 
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Figure 1.15: Miltefosine (13). 
1.3 NEW TARGETS FOR CHEMOTHERAPY. 
Despite the knowledge of many different enzyme pathways of the parasites and how 
they can be used as targets, not much development has taken place in terms of new 
chemotherapeutic agents. Ideally any new chemotherapeutic agent should have high 
efficacy and efficiency, low toxicity, low cost, and be easily administered. 
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1.3.1 Oxidative stress.

Trypanosoma and Leishmania parasites need a highly efficient thiol metabolism, to 
combat reactive oxygen species, making oxidative stress a new and very appealing 
chemotherapeutic strategy. Humans consume hundreds of litres of oxygen daily. 
Around 5% of that is converted to reactive oxygen species such as O2
.­, HO2
., ONOO ­, 
HO., and hydrogen peroxide. These species are highly toxic due to their ability to 
modify nucleic acids, thiol­containing proteins and membrane lipids. A cell is 
considered to be under oxidative stress, when the cell’s mechanisms to combat 
oxidative stress are challenged. Oxidative stress can also be used by the host as a 
defence mechanism against invaders.21 
1.3.2 Trypanothione and glutathione, TryR and GR. 
Humans depend on their glutathione redox cycle in order to combat oxidative stress. 
During this process the flavoenzyme glutathione reductase catalyses the NADPH­
dependent reduction of glutathione disulfide (14) to glutathione (15). This causes an 
increase in glutathione (15) levels compared to glutathione disulfide (14). In parallel, 
the enzyme glutathione peroxidase along with two other antioxidative enzymes 
converts glutathione (15) back to glutathione disulfide (14), while reducing the 
radicals superoxide and hydrogen peroxide. 
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Figure 1.16: Glutathione redox cycle. 
Trypanosomes lack these enzymes and substrates and depend instead on the 
analogous trypanothione redox system. In this system, the enzyme trypanothione 
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reductase catalyses the NADPH­dependent reduction of trypanothione disulphide (16) 
to trypanothione (N1,N8­bis(L­γ­glutamyl­L­cysteinyl­glycyl)spermidine) (17). 
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Figure 1.17: Trypanothione redox cycle. 
Trypanothione reductase has been found in all trypanosomatids so far examined. The 
two enzymes, TryR and GR both exist as homodimers and have three main domains, 
the FAD binding domain, NADPH binding domain and the interface domain. Despite 
the fact that TryR and GR are structurally and chemically similar,22 the TryR active 
site is more open than GR, in order to accommodate the bulkier substrate of 
trypanothione disulfide (16), and also the TryR active site has an overall negative 
charge compared with GR that has a positive charge.23 These differences are 
sufficient to account for why certain inhibitors are specific to TryR and do not affect 
GR. Targeted gene replacement studies have shown that TryR is vital for the survival 
of Leishmania and Trypanosoma when these organisms were put under oxidative 
stress conditions.24 It would therefore seem that the inhibition of this enzyme could 
provide a worthy target for drug design. Inhibitors of TryR have been identified from 
a variety of sources and by different approaches including rational drug design and 
HTS, as outlined in the following sections. 
1.4 EXISTING INHIBITORS OF TryR. 
1.4.1 Tricyclic compounds. 
One of the first tricyclic compounds to be identified as a selective competitive 
inhibitor of TryR and not GR was the drug mepacrine (18). 25 Since then more potent 
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inhibitors based on mepacrine, have been developed. Sulfonamide and urea 
derivatives of mepacrine containing an aromatic group in the N­9 side chain, are 10 
times more potent than mepacrine.26 Tricyclic compounds that have been used as 
antidepressants are also competitive inhibitors of TryR such as clomipramine (19), 
imipramine (20)27 and phenothiazene (21) (Fig. 1.18). The reason these compounds 
inhibit TryR is that their tricyclic core fits against a hydrophobic wall formed by 
Tyr21 and Met113, in the active site of the enzyme. Since then a second hydrophobic 
region in the active site, Z­site, formed by Phe395’, Pro397’, and Leu398’ has also 
been shown to accommodate hydrophobic ligands (Fig. 1.18). Chibale et al. 28 also 
evaluated a small library of xanthene based tricyclic compounds containing 
polyamine chains, which displayed inhibitory activity against TryR comparable to 
that of the tricyclic antidepressants. Tricyclic inhibitors that display other modes of 
inhibition have also been identified. For example Zani and Fairlamb29 identified 8­
methoxy­naptho[2,3­b]thiophen­4,9­quinone (23) as a non competitive inhibitor of 
TryR with a Ki = 5 �M. 
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Fig 1.18: Tricyclic compounds, inhibitors of TryR.
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1.4.2 Aminodiphenylsulfides. 
Due to the effectiveness of tricyclic antidepressants compounds as TryR inhibitors, a 
new class of aminodiphenylsulfide compounds was developed, based on the tricyclic 
core but with the middle ring open. This class of inhibitors are as powerful inhibitors 
as their tricyclic phenothazine analogues. Baillet et al 30 developed a series of 
diphenylsulfide derivatives with prolonged or branched polyamine chains (24)­ (31), 
which were good inhibitors but toxic (Fig 1.19). The same group, solved the toxicity 
problem, by introducing compounds containing 2­aminodiphenylsulfide moieties 
linked by a spermidine bridge which were competitive inhibitors with a Ki value of 
400 nM.31 The most potent compound in this series with an IC50 of 200nM was a 
bis(2­aminodiphenyldisulfide) (32) with an extra third bulky chain (Fig 1.19).32 
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Figure 1.19: Aminodiphenylsulfides as TryR inhibitors
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1.4.3 Subversive substrates. 
Subversive substrates (X) are reduced in single­electron steps to their respective 
radicals, and then react with oxygen to give superoxide anion radicals. This action 
converts an antioxidative disulfide reductase enzyme like TryR into a prooxidative 
enzyme. 
NADPH + 2X NADP + 2X˙¯ + H+ 
2X˙¯ + 2O2 2X + 2O2
˙¯ 
In TryR , NADPH and O2 are used as the subversive substrate is regenerated from its 
radical intermediate, thus the compounds act as catalysts for oxidative stress, having a 
strong impact on the redox metabolism of the parasite.21 Nitrofurans such as Chinifur 
(33) (Fig 1.20), a nitrofuran derivative with an aminoalkyl side chain is a TryR 
subversive inhibitor.33 Naphthoquinones such as menadione, plumbagin, lapacol and 
other 1,4­naphthoquinones are also well known subversive substrates for TryR. The 
most potent derivative of naphthoquinones contains two 1,4­naphthoquinone moieties 
linked by a polyamine spacer (34) (Fig.1.20).34, 35 
Figure 1.20: Subversive substrates.
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1.4.4 Inhibitors derived by HTS. 
High throughput screening a library of 100,000 lead­like compounds, identified 2­
iminobenzimidazoles as a novel class of TryR inhibitors (35)­(39).36 They display 
potent trypanocidal activity, but do not inhibit human GR and have low cytotoxicity 
against mammalian cells. The most potent examples are shown in Figure 1.21. 
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Figure 1.21 : 2­iminobenzimidazoles 
A number of other scaffolds have been identified as TryR inhibitors by HTS.37 Figure 
1.22, shows some recent examples. 
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Figure 1.22 : Examples reported by Martyn et al. 
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1.4.5 Polyamine­based inhibitors. 
One of the most studied type of inhibitors are polyamine based­compounds. 
Kukoamine A (44) is a natural spermine derivative, and is a mixed type inhibitor for 
TryR.38 Its corresponding spermidine analogue N1, N8­ bis(dihydrocaffeoyl) 
spermidine is a competitive inhibitor with Ki = 7.5 �M. Ponasik et al. 
38 proposed that, 
both the aryl moieties in the molecules interact with the hydrophobic region of the 
enzyme, so that these spermine and spermidine derivatives would adopt a non­
extended bound conformation. Due to the effectiveness of Kukoamine A as a TryR 
inhibitor, a lot of the resulting synthetic polyamine inhibitors were based on this 
structure, a polyamine unit with 2 or more hydrophobic substituents. Interestingly, 
spermine derivatives were found to be more effective than the corresponding 
spermidines.31 O’Sullivan et al39 tested a small library of alkyl aryl polyamine 
compounds, the most potent (45)­(47) are shown in Figure 1.23. Further investigation 
showed that the potency of the inhibitor was proportional to the degree of 
substitution; however the penta­substituted derivative was more effective than the 
hexa­substituted, suggesting that the active site had reached its capacity.40 The same 
group more recently screened a series of N­(3­phenylpropyl)­substituted spermines 
and spermidine derivatives, with the highly substituted N1 ,N1 ,N4 ,N8 ,N12­penta(3­
phenylpropyl)spermidne (48) as the most effective competitive inhibitor.40 Woster et 
al.
41 have also prepared a series of polymamine analogues, but these did not contain a 
spermine or spermidine backbone. Instead these had a 3­3­3 or 3­7­3 backbone with 
the 3­7­3 analogues showing potent antiparasitic activity. The most potent polyamine­
type inhibitors so far were reported by Bradley et al. 42 They prepared polyamine 
derivatives using indole aryl acids as capping groups. The bromoindole spermidine 
derivative (49) was the most potent inhibitor with Ki = 76 nM. 
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Figure 1.23 : Polyamine­based inhibitors of TryR.
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1.4.6 TryR peptide­mimetic substrates. 
This class of inhibitors involves compounds that mimic the structure of the TryR 
natural inhibitor, trypanothione disulfide. Tromelin et al 43 developed a good 
substrate­mimetc inhibitor for TryR that had been modified at the disulfide bridge to 
obtain non reducible derivatives. The cysteine residues containing the disulfide bridge 
were replaced by 3 natural amino diacids: djenkolic acid (50a), lanthionine (50b) and 
cystanthione (50c), with the djenkolic acid derivative being the best inhibitor as seen 
in Figure 1.24. Similarly Dixon et al 44 prepared a small focused library of polyamine­
peptide conjugates, that contained both competive and non­competitive inhibitors of 
TryR. Examples of Dixon’s44 best inhibitors are shown in Fig 1.24 (compounds 
(60a)­(60e). Recently Czechowicz et al 45 also prepared structural analogues of the 
natural substrate. Compound (61), the best inhibitor in the series (Ki = 16 �M), is an 
Fmoc protected analogue, which contains all the structural elements of the natural 
substrate except the redox­active disulfide moiety, which has been replaced by a pair 
of methylene groups. 
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1.4.7 Polyamine Alkaloids 
A further class of natural product inhibitors that are potential mimetics of the TryR 
substrate are macrocyclic polyamine alkaloids. The spermidine alkaloids lunarine 
(63) (isolated from Lunaria annua) and cadabicine (62) (isolated from Cadaba 
farinosa) were identified by virtual screening as potential inhibitors by Bond et al.46 
This analysis was based on their overall similarity to the cyclised trypanothione 
disulfide, which is the principal natural substrate of TryR , since both natural products 
contain spermidine in their macrocycle structure (highlighted in green). 
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Figure 1.25: Natural alkaloid inhibitors of TryR. 
Initial kinetic studies with optically pure lunarine from natural sources confirmed that 
it is a modest competitive inhibitor of TryR.46 It was subsequently shown47 that 
lunarine inhibits TryR in a time­dependent manner, with an observed inhibition 
constant Ki =114 �M.
46,48 In general; time dependent inhibition can arise from three 
different mechanisms (Fig. 1.26): 47 
Figure 1.26 : mechanisms of time­dependent inhibition.
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In classical inhibition mechanisms, the steady state equilibrium between enzyme and 
inhibitor is rapidly established (usually within milliseconds). Simple slow binding 
(mechanism B) occurs when the inhibitor binds to the enzyme like a classical 
inhibitor but with a slower binding rate such that the steady state is attained over a 
much longer timescale of several seconds or even min. With an enzyme isomerisation 
mechanism (C), the Michaelis–Menten complex (EI) is rapidly formed followed by 
slower conformational changes in either the enzyme or inhibitor resulting in a more 
tightly bound complex (EI*). Irreversible inhibition proceeds by the same rapid 
binding step followed by a rate­limiting covalent modification of the enzyme (D). 
Studies with lunarine and related compounds suggest that that mechanism C, 
involving formation of a covalent enzyme inhibitor species, is involved.49 Bond et 
al,46 suggested that this may result from conjugate addition of a redox­active cysteine 
residue in the TryR active site onto either one of the two α,β­unsaturated double 
bonds of lunarine. This is supported by the observation that time­dependent inhibition 
is associated with the NADPH­reduced form of the enzyme only46 and the detection 
of a possible covalent TryR­lunarine species by mass spectrometry.49 Time­dependent 
inhibitors such as lunarine offer an attractive alternative to many competitive 
inhibitors reported so far. It can be shown,1 that to maintain a potentially lethal level 
of inhibition of TryR in the presence of accumulating millimolar levels of 
trypanothione, competitive inhibitors of low nanomolar potency are required. 
Inhibitors that form a covalent enzyme­inhibitor species, where accumulating 
substrate cannot reverse inhibition should not require such high affinity to be 
effective. This idea is supported by the fact that synthetic racemic lunarine and 
derivatives, based on the tricyclic core of lunarine are moderately potent (Ki ~ 4 �M) 
TryR inhibitors, and also show activity against T.brucei trypomastigotes in vitro.49 
Although cadabicine was originally identified in the same virtual screening study as 
lunarine, so far no detailed analysis of its potential as a TryR inhibitor has been 
possible, owing to the lack of availability of the natural product. Its structural 
similarity to lunarine and results with other lunarine­like molecules suggest that it too 
may be a time­dependent inhibitor and an interesting lead for drug development. 
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1.5 AIMS 
The aims of this project were as follows: 
•	 Complete the first synthesis of the natural product cadabicine, applying 
procedures recently developed for related alkaloids. 
•	 To investigate in detail the inhibition of TryR by cadabicine, using a 
spectrophotometric assay. 
•	 The synthesis and evaluation as TryR inhibitors, of other potential inhibitors 
based on the cadabicine diphenyl ether scaffold. 
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2. RESULTS AND DISCUSSIONS 
2.1 RETROSYNTHESIS OF CADABICINE 
The proposed synthetic approach to cadabicine is outlined in Scheme 2.1. The key 
features are formation of the macrocycle by a nucleophilic aromatic substitution 
reaction, and the preparation of two functionalised cinnamic acid units (65) and (66), 
for coupling to a novel orthogonally protected spermidine unit, derived from the triply 
protected compound (68). 
The aim of this synthesis was to generate a fully protected spermidine derivative (64) 
that could be conveniently converted to the natural product. The choice of the 
protecting groups need to be compatible with the fluoronitrophenyl unit since it is 
potentially sensitive to both reduction and nucleophiles, and also the cinnamic acid 
units which are reducible. 
Boc protection for the N4 of spermidine and allyl ester protection for the phenol group 
were chosen with this in mind and to provide a simple final deprotection strategy. 
With N4 protected with an acid­labile group, a protecting group that can be selectively 
cleaved by nucleophiles (in the presence of Boc) was suggested for N1, such as the 
Dde or phthaloyl group. Troc protection was initially chosen for N8, since it can be 
removed in the presence of phthaloyl and Boc with simple and cheap chemistry. 
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Scheme 2.1: Retrosynthetic strategy for the synthesis of cadabicine 
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2.2 SYNTHESIS OF ORTHOGONALLY PROTECTED SPERMIDINE

DERIVATIVES 
Aliphatic polyamines are widely found in a variety of biological systems having many 
interesting functions. These range from being part of toxins in spiders and wasps, 
through neurotransmission in humans and fruit ripening in plants, to ligands in 
inorganic chemistry; which makes them compounds of high synthetic interest. A 
problem often encountered in the synthesis is the selective protection of the amino 
groups. There are two ways to synthesise regioselectively derivatised polyamines. 
Either the existing primary and secondary amino functions in the polyamine may be 
selectively protected, or the desired polyamine skeleton can be assembled from 
scratch using protected building blocks. For the preparation of cadabacine, both 
approaches were followed. In one case, the polyamine skeleton was assembled via 
Mitsunobu chemistry using appropriately protected building blocks. Alternatively, the 
primary and secondary amino functions were differentiated via regioselective 
formation of a hexahydropyrimidine ring intermediate. In both cases, selective 
protection of the spermidine component allows regioselective acylation with the 
cinnamic acid units. 
2.2.1 Fragment synthesis 
In this approach the polyamine skeleton is assembled to the desired length by 
combining selectively protected alkylamine derivatives with other nitrogen containing 
compounds with the formation of new C­N bonds. This type of synthesis potentially 
offers a greater degree of flexibility in the design and preparation of a variety of 
complex polyamine analogues and conjugates. 
Conjugate addition of amino components to acrylonitrile, is one of the oldest and 
more frequently used methods for extending a polyamine chain by one or two 
aminopropyl moieties. This approach has been applied by Israel,50,51 reacting 
diaminoalkanes (69) with one or two molecules of acrylonitile, followed by catalytic 
hydrogenation of the nitrile group using Ni, or with LiAlH4. Either route provides 
easy access to various spermine (73) or spermidine­type molecules (71) (Scheme 
2.2). 
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(CH2)n 
alc NH3 (CH2)n 
NH2 
(70) 25oC, 3­4 atm NH2 
(71) 
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CH2=CHCN 
NH2 
(CH2)n 
(69) 
NH2 
2 moles 
CH2=CHCN 
NHCH2CH2CH2NH2

(CH2)n (72) alc NH3 
(CH2)n (73)

NHCH2CH2CN 25
oC, 3­4 atm NHCH2CH2CH2NH2

NHCH2CH2CN 
H2­Ni 
n = 3, 4 
Scheme 2.2: Israel’s approach to polyamine synthesis.
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Conversion of primary amines to the corresponding secondary amines appears 
deceptively simple. However, alkylation of primary amines with alkyl halides or 
sulfonates frequently leads to the formation of the undesired tertiary amine and/or 
quaternary ammonium salts. Furthermore, reductive alkylation with aldehydes or 
ketones using NaBH3CN often produces tertiary amines , unless the desired secondary 
amine is sterically hindered (Scheme 2.3).52 
R2 X R2 R2 R2 
R1 NH2 R1 NH R1 N R1 N R2 
+base R2 R2 X
­
R2R2 CHO R2 
R1 NR1 NH2 R1 NH 
R2reductive 
alkylation 
Scheme 2.3: Conversion of primary amines to the corresponding secondary amines. 
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However, the reductive alkylation of an azide by a borane, provides an efficient 
chemoselective synthesis of secondary amines as discovered by H.C. Brown.53 An 
extension of this work has been employed by Carboni,54 who used aliphatic amino 
azides as key building blocks for polyamine synthesis (Scheme 2.4). The amino alkyl 
azide hydrochlorides were converted to diamine dihydrochlorides, by reductive 
alkylation using the appropriate dichloroboranes, followed by methanolysis. The 
diamine dihydrochlorides were then reacted with sodium azide followed by treatment 
with sodium hydroxide to give the corresponding azide, and hence increase the chain 
length. The azide was then either reduced by catalytic hydrogenation in order to give 
the primary amine, or by reductive alkylation followed by methanolysis in order to 
increase the chain further. 
N 
R1 
R2 N3 
n 
HCl 
X 
BCl2 
n(1) 
(2) MeOH 
N 
R1 
R2 NH 
n 
X 
n 
(1) NaN3 
(2) NaOH 
2 HCl 
(74) 
(76) 
R1 NH2 3 HCl H2, Pd/C 
R1 N3 
(77) NN 
n nn n 
NH NH HCl R2R2 
(75) 
(1) R BCl2 
(2) MeOH 
X = Cl,Br 
Scheme 2.4: Aliphatic amino azides in polyamine syntheses 
Golding et al55 has also used azides as synthons in polyamine synthesis (Scheme 2.5). 
This approach begins with Z­protected aminobutanol, which is converted to the azide 
(80) via a Mitsunobu reaction. The azide is then reacted with triphenylphosphine in a 
Staudinger reaction to give the iminophosphorane (81) which is in turn reacted with 
N 
R1 
R2 NH 
n 
NHR 
n 
3 HCl 
(78) 
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HN 
Z 
N 
PPh3 
HN 
Z 
N 
CHR 
HN 
H 
N R 
(79) 
(82) 
(81) 
(80) 
2­methylpropanal 
PPh3 
NaBH4 
an aldehyde in an aza­Witting reaction to give an imine (82) which is finally reduced 
in situ to give a secondary amine (83). 
HN3/benzene 
PPh3, DIAD 
Z 
(83) 
55 
Scheme 2.5: Golding’s approach to polyamine synthesis. 
Bergeron56 has taken Israel’s approach one step further in order to generate an 
orthogonally protected spermidine and spermine. He successfully and in high yield 
monobenzylated putrecine (84) with benzaldehyde under reductive amination 
conditions. The monoprotected diamine (85) was further Boc protected to give the 
doubly protected (86). In order to increase the length of the chain, cyanoethylation of 
(86) with acrylonitrile was employed to give the nitrile (89) which was subsequently 
reduced with Raney Ni to give (90). Finally acylation of the primary amino group in 
(90) with trifluoroacetic anhydride according to the method described by O’Sullivan57 
gave the desired orthogonally protected spermidine (91). As for the synthesis of 
spermine, he started with spermidine precursor (90), in which N8 is free, where 
cyanoethylation and further reduction provided the spermine skeleton (93). The 
primary amino N12 was then acylated with trifluoroacetoxy succinimido ester in order 
to selectively protect the primary over the secondary amine. The remaining N8 
42 
secondary amine was then protected with the 2,2,2­trichloro­tert­butoxycarbonyl 
(TCBoc) group to give (95) which is stable to acidic and basic conditions and can be 
removed without affecting any of the other protecting groups by mild metal reduction 
(Scheme 2.6). 
benzyldehyde 
formic acid BOC­ON 
H2N(CH2)nNH2 H2N(CH2)nNH ­Bn 
Boc­ HN(CH2)nNH ­Bn 
acrylonitrile or 
4­chlorobutyronitrile 
(84) 
(85) 
(86) 
Bn Raney Nickel Bn 
Boc­ HN(CH2) N(CH2) CN Boc­ HN(CH2)nN(CH2)xCH2NH2 n x
trifluoroacetic 
anhydride 
acrylonitrile 
(89) (90) 
Bn O Bn 
Boc­ HN(CH2)nN(CH2)xCH2NHCCF3 (91) Boc­ HN(CH2)nN(CH2)xCH2NHCH2CH2CN (92) 
n=4, x=3 
Orthogonally protected spermidine Raney Nickel 
Bn 
Boc­ HN(CH2)nN(CH2)xCH2NH(CH2)3NH2 (93) 
N­(trifluoroacetoxy)succinimide 
Bn 
Boc­ HN(CH2)nN(CH2)xCH2NH(CH2)3NHCOCF3 (94) 
2,2,2­trichloro­1,1­dimethylethyl 
chloroformate 
Bn TCBoc 
Boc­ HN(CH2)nN(CH2)xCH2NH(CH2)3NHCOCF3 (95) 
n=3, x=4 
Orthogonally protected spermine 
Scheme 2.6 : Bergeron synthesis of orthogonally protected spermidine and spermine 
derivatives. 
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Hesse58 has also described the synthesis of an orthogonally protected spermine by 
fragment synthesis as a building block for a fully N­functionalised pentamine, 
homocaldopentamine (101). This approach begins with mono­Boc protected 1,4­
diaminobutane (96), then the remaining primary amine was further protected with a 
trimethylsilylethylsulfonyl group. The chain was then elongated by alkylation using 
1,3­dibromopropane and potassium carbonate as base, creating the bromide which 
was finally converted to the spermidine reagent (99) using allylamine. This triply 
protected spermidine (99) was then coupled to the building block (100) to give the 
fully penta N­protected homocaldopentamine (101), where all five groups can be 
independently removed. TFA was used to remove Boc, CsF to remove SES, mild Zn 
reduction to remove TcBoc, (Ph3P)4Pd to remove the allyl group, and mild reduction 
using Ph3P with water to reduce the azido group. 
SES­Cl 
4M K2CO3 
BocHN 
NH2 BocHN 
NHSES 
BocHN 
N 
SES 
Br 
1,3­dibromopropane 
K2CO3 
BocHN 
N 
SES 
H 
N 
allylamine 
KF/celite 
triply protected spermidine 
(96) 
(97) 
(98) 
(99) 
+ 
SES TcBoc 
DIPEA, NaI N N N N3TsO N N3 BocHN 
TcBoc 
(101) 
(100) 
Scheme 2.7: Synthesis of penta N­protected homocaldopentamine. 
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2.2.2 Spermidine by Fragment Synthesis 
For the synthesis of cadabacine we chose to apply chemistry developed by 
Fukuyama,59 which uses the 4­ or 2,4­dinitrophenylsulfonyl group (Ns or DNs) as 
both a protecting and activating group in the synthesis of amines (Figure 2.1). 
NO2 
Ns DNs 
NO2NO2 
SO2SO2 
Figure 2.1: 2,4­dinitrobenzenesulfonyl and 2­nitrobenzenesulfonyl protecting groups 
The alkylation of sulfonamides of this type under conventional or Mitsunobu 
conditions with another nitrogen­containing unit allows a polyamine skeleton to be 
constructed. In this case, the initial plan of synthesis adopted was to take a 
diaminoalkane and protect one primary amine function with a nitrophenylsulfonyl 
group. The remaining primary amino function would then be protected with a 
compatible protecting group, and then the formation of a new C­N bond would be 
achieved by an alkylation or Mitsunobu reaction of the doubly protected 
diaminoalkane with a suitably orthogonally protected amino component, in order to 
make a triply protected spermidine derivative. 
Troc­phenyl carbamate (104) was synthesised in order to selectively protect just one 
of the primary amino groups of the diamine,60 to give compound (105) in 57% yield. 
Compound (105) was then reacted with 2,4­dinitrobenzenesulfonyl chloride, to make 
the desired doubly protected diamine61 (107) in 68% yield (Scheme 2.8). 
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Scheme 2.8: Preparation of doubly protected diamine. 
In order to make the orthogonally protected spermidine, a number of displacement 
reactions were tried.62 The doubly protected diamine was reacted with 3­bromopropyl 
phthalimide, potassium carbonate and tetrabutylammonium iodide (Scheme 2.9). This 
reaction gave a complex mixture of products, and although the formation of the 
desired product (108) was confirmed by NMR, it was not possible to isolate it. 
O 
N 
OH H 
N Troc O Br N N N N Troc 
DNs H K2CO3 
(107) tetra­butylammonium iodide 
O DNs (108) 
DMF 
50°C 
12hrs CONFIRMED BY NMR, BUT NOT ISOLATED 
Scheme 2.9: Displacement reaction with DNs­protected diamine.
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The reaction was repeated, using the 2­nitrobenzenesulfonyl protected diamine (109) 
(prepared in the same way as (107)), which resulted in the desired product (110) but 
in low yield (15% ­ Scheme 2.10). The reaction was repeated using caesium 
carbonate, but although (110) was successfully obtained, there was no change in the 
yield. 
N 
H 
H 
N 
N 
O 
O Br 
K2CO3 
N N 
H 
N 
O 
O 
Troc 
tetra­butylammonium iodide 
Troc 
Ns 
Ns 
DMF 
(109) 
(110) 
50°C 
12hrs 
15%yield 
Scheme 2.10: Displacement reaction with Ns­protected diamine 
It was suspected that the bulk of the phthalimido group in the three carbon unit was 
hindering alkylation reactions. Therefore, a different protecting group was used, 
which can be removed under the same conditions as phthaloyl. The Dde protecting 
group was adopted. The reagent for the introduction of Dde (112) was synthesised by 
reacting equal amounts of dimedone with DCC and acetic acid, using DMAP as a 
catalyst. This gave (112) in 66% yield. (112) was then used to protect 3­
aminopropanol63 and give (113), one of the protected building blocks needed for the 
triply protected spermidine (Scheme 2.11). 
HN 
OH 
Dicyclohexyl carbodimide OH 
DMAP O OO O OAcetic acid O H2N OH 
Ethanol DMF 
R.T reflux 80oC 
12hrs 
(111) 66% (112) 
75% (113) 
Scheme 2.11: Preparation of Dde­protected amino propanol (113) . 
The doubly protected diamine (107), was now reacted with Dde­amino propanol 
(113), via a Mitsunobu reaction, to give the desired triply protected spermidine (116). 
The reaction was successful, but triphenylphosphine oxide, which is a by­product of 
the reaction was found to co­elute with the desired material. To overcome this 
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problem, the Mitsunobu reaction was repeated using polymer­supported 
triphenylphosphine,64 which gave the desired product (116) in 40% yield, without 
contamination (Scheme 2.12). The use of different Mitsunobu reagents was also 
investigated, such as diethyl azodicarboxylate (DEAD) and dibenzyl azodicarboxylate 
(DBAD), but there was no difference in the yield of (116). 
O N 
O 
N O DEAD 
O 
O N 
O 
N O 
O 
DBAD 
Figure 2.2: Structure of Mitsunobu reagents DEAD, DBAD.
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SO2 O

Dde 
Troc 
N 
N 
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N 
O2N 
(107)	 DBAD or DEAD (116) 
DNs 
Triphenyl phosphine

Toluene

NO2	 60
oC 
12 h 
40% 
Scheme 2.12: Mitsunobu Reaction. 
The DNs group in the triply protected spermidine (116) was removed using 
thioglycolic acid65 presumably via the Meisenheimer complex (Scheme 2.13) to give 
the desired DNs­deprotected material (117) in 84% yield. 
R1R1 
NN 
R2 SO2R2 SO2 
HSCH2COOH R1S NO2NO2 R 
NH 
R2 
NO2NO2 
Scheme 2.13: DNs deprotection via the Meisenheimer complex.
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(117) was Boc­protected using Boc­anhydride, to give the orthogonally protected

spermidine (68) in 92% yield. The Troc group was then removed using zinc and

acetic acid,66 which gave the desired N­8 deprotected product (118) in 50% yield

(Scheme 2.14).

H HSCH2COOH H 
Dde N 
Troc 
Dde N 
N 
H DIPEA, DCM H H 
NN Troc N 
DNs R.T, 84% (117) 
Boc2O 
DCM 
(116) 
R.T 
92% 
Zinc, Acetic Acid 
H 
Dde Dde NH2N 
N N Troc N 
H Water, R.T 
(118) Boc 50% 
(68) 
Boc 
Scheme 2.14: Fragment synthesis of triply protected spermidine. 
2.2.3 Selective Functionalisation. 
In selective functionalisation synthesis starts with an intact spermidine. Primary 
amines can be selectively protected in the presence of secondary functions with a 
number of different protecting groups, such as the phthaloyl (using PhthN­CO2Et), 
benzyloxycarbonyl (using Z­CN)67 , tert­butoxycarbonyl (using Boc­Osu), 
trifluoroacetyl (using Tfa­OEt)57 , the Trt (using Trt­Cl)68, the Mtr (using Mtr­Cl)69 
and the N­1­(4,4­dimethyl­2,6­dioxocyclohexylidenyl) (using 2­acetyl dimedone)70 
groups. Reagents like Z­CN give selectivity for primary over secondary because they 
are less reactive than related reagents like Z­Cl. The same is true for ethyl 
trifluoroacetate, which is used in O’Sullivan’s57 approach – this is less reactive than 
trifluoroacetyl chloride or trifluoroacetic acid anhydride. These protecting groups may 
be introduced to polyamines in high yields and can be removed using relatively mild 
conditions, such as hydrazinolysis (Phth, Dde), acidolysis (Z, Boc, Trt, Mrt), catalytic 
hydrogenolysis (Z, Trt) and hydrolysis with weak bases (Tfa).71 
N

H
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For example Murahashi67 has protected spermidine with benzoyl cyanide (120) to 
give N1, N8­bisbenzoylspermidine. Since a variety of acyl cyanides can easily be 
prepared, he also directly acylated spermidine with trans­cinnamoyl cyanide to obtain 
an excellent yield of the alkaloid maytenine (121). 
OH RuCl2(PPh3)3 
O 
CN (120) CN t­BuOOH 
(119) 
spermidine 
O 
N 
H 
NH 
NH 
O 
Maytenine 
(121) 
67 
Scheme 2.15: Murahashi’s synthesis of Maytenine.
Following protection of primary amino functions, the secondary amino functions may 
be derivatised, or blocked with different (orthogonal) protecting groups, followed by 
deprotection of the primary amino functions if necessary. For example, Blagbrough72 
selectively differentiated the two secondary and one primary amino group of 
spermine, by first preparing N1­Tfa­spermine using CF3CO2Et at low temperatures. 
N1,N4,N9­tris(benzyloxycarbonyl)spermine and N1,N4,N9­tris(­tert­butoxycarbonyl) 
spermine, were obtained in moderate yields after chromatographic purification. 
50 
O 
F3C N 
H 
N 
H 
H 
N NH2 (122) 
i) dibenzyl dicarbonate, 
then conc. NH3 
or 
ii) di­tert­butyl dicarbonate, 
then conc. NH3 
R 
H 
R 
for i) R = Z 48% (123)

ii) R = Boc 50% (124)

72 
Scheme 2.16: Indirect functionalisation of spermine.
Macrocyclic polyamines, have been synthesised the same way, starting with N1,N8­
Tfa spermidine.73 Golding et al.74 has used a similar approach, to reliably and 
efficiently prepare N1,N8­disubstituted spermidine derivatives, from spermidine either 
directly or via intermediate protection at N4 with the 4­azidobenzyloxycarbonyl 
group, and/or at N1 and N8 with the trifluoroacetyl group. Similar methodology was 
applied in the synthesis of N4,N9­bis(trityl)spermine starting from N1,N12 ­
bis(trifluoroacetyl)spermine.75 
The classical and most often used method for the protection of the secondary amino 
groups in polyamines that bear the N­monosubstituted 1,3­diamine moiety like 
spermidine and spermine, has been developed by Ganem et al.76,77 and involves their 
reaction with formaldehyde. Reaction of spermidine and spermine with formaldehyde 
leads to the corresponding mono­ (127) and bishexahydropyrimidine (128) derivatives 
(Scheme 2.17). 
NH2 
(127) 
N N 
N NH2R 
HN N 
spermidine (125) 1.8eq formalin 
or 
spermine (126) 0oC, 50 min 
HN N 
N NH 
(128) 
77 
Scheme 2.17: Ganem’s hexahydropyrimidine polyamine derivatives.
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The mono­hexahydropyrimidine is a very interesting intermediate, as it can be 
selectively acylated at the primary amino function to deliver N8 functionalised or 
protected spermidine, which in turn can be used in the synthesis of N1 functionalised 
spermidine. Alternatively amino functions can be acylated to provide a N1, N8­
functionalised spermidine. In either case the methylene protective group can easily be 
removed via a Knoevenagel condensation using ethylhydrogen malonate and pyridine. 
This methodology has been used for the synthesis of the antihypertensive agent 
Kukoamine A78 (44) and related spermine and spermidine derivatives.38 (Scheme 
2.18) 
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Scheme 2.18: Synthesis of Kukoamine A. 
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2.2.4 Spermidine synthesis by Selective Functionalisation

Ganem’s methodology was applied here for the synthesis of cadabicine (62). 
Spermidine (125) was reacted with formaldehyde, to give the tetrahydropyrimidine 
derivative (128) in 92% yield. The primary amino group of compound (128) could 
now be selectively Boc protected using tert­butylphenyl carbonate60 to give 55% of 
the monoprotected hexahydropyrimidine compound (129a) and 10% of the doubly 
protected (129b). 
H2N 
H 
N 
NH2 
HN N 
NH2HCHO (aq) 
H2O, under N2, 
5 ºC­rt, 2 h, 
92% tert­butylphenyl carbonate 
EtOH, reflux, o/n 
(125) 
(128) 
HH NN HN N Boc BocN N Boc + 
(129b) 10% (129a) 
55% 
Scheme 2.19: Selective fucntionalisation of spermidine. 
The methylene protecting group was removed via Knoevenagel condensation, by 
reacting (129a) with mono­ethylmalonate and pyridine, to give the N8­Boc protected 
spermidine (130). Without any further purification (130) was used directly in the next 
step, where N1 primary amino group was selectively protected using 2­acetyl 
dimedone (Dde)70 to produce the N1, N8 bi­functionalised spermidine (131) in 57% 
yield over the two steps. The remaining N4 secondary amine was then protected with 
the benzyloxycarbonyl group using benzyl chloroformate to give the orthogonally 
protected spermine (132) in 80% yield. Any of the three protecting groups, Boc, Z, 
Dde, can be independently removed from one another. For the synthesis of cadabicine 
N1 was initially deprotected using hydrazine in DMF and allyl alcohol to give the N1 
deprotected spermidine (133) in 82% yield. Even though in this instance there are no 
such moieties, if N8 was to be acylated first with the cinnamic acid derivative, there 
would be the double bond from the cinnamoyl group to consider, and in this case allyl 
alcohol would prevent its reduction (Scheme 2.20). (See Section 2.3). 
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Scheme 2.20: Synthesis of orthogonally protected spermidine 
2.3 SYNTHESIS OF CINNAMIC ACID DERIVATIVES AND 
COUPLING TO SPERMIDINE DERIVATIVES. 
2.3.1 Synthesis of cinnamic acid derivatives. 
Compound (65) was prepared via Heck coupling of 4­bromo­1­fluoro­2­nitrobenzene 
with tert­butyl acrylate to give the corresponding cinnamic acid ester (135) in 50% 
yield as shown in Scheme 2.21. DIPEA was used as base, instead of the more used 
triethylamine, since it had previously been observed that adducts from SNAr reaction 
of the latter with the Heck product were also obtained. This was avoided by the use of 
a more bulky tertiary amine. The cinnamic acid ester (135) was then reacted with 
trifluoroacetic acid to cleave the tert­butyl ester and give compound (65) in 95% 
yield. 
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CO2tBu CO2H 
Br 
Pd(OAc)2

DIPEA
 CF3CO2H 
O2N DCM CO2tBu O2N 95% O2NF DMF 
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(134) (135) 
(65) 
Scheme 2.21: Preparation of compound (65) 
For the preparation of compound (66), 3,4­dihydroxybenzaldehyde was first 
regioselectively alkylated with allyl bromide and lithium carbonate (Scheme 2.23) to 
give 4­allyloxy­3­hydroxybenzaldehyde (139) in 40% yield. It was published by 
Pfister79 that regioselectivity can be achieved in the alkylation of compounds of this 
type because of the greater acidity of the 4­hydroxyl compared to the 3­hydroxyl, due 
to the presence of an electron withdrawing 1­substituent (Scheme 2.22.). 
O O 
LiCO3 
HO MeI HO 
DMF 
HO MeO 90% 
(137) 
(136) 
Scheme 2.22: Pfister’s selective alkylation. 
Other products obtained from this reaction were the 3­allyloxy­4­
hydroxybenzaldehyde in 5% yield as well as traces of the dialkylated product. The 
free hydroxyl group of compound (139) was protected with a triisopropylsilyl group 
in 92% yield. 
CHO CHO TIPSCl CHO 
LiCO3 imidazole

allyl bromide
 Et3N 
DMF DMF OTIPS OH OH 
92% 40% 
OOH O 
(140) 
(138) (139) 
Figure 2.23: Selective alkylation and TIPS protection. 
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Finally, the doubly protected benzaldehyde derivative (140) was converted to (66) by 
a Doebner condensation with malonic acid in the presence of pyridine and piperidine. 
When the reaction was carried out at 150°C for 1 h, the desired cinnamic acid was 
obtained in only 25% yield, along with the desilylated derivative (142). Lowering the 
temperature to 50° avoided cleavage of the TIPS group, giving the desired product 
(66) in acceptable yield (55%). However under these conditions, decarboxylation of 
the diacid intermediate was incomplete and this derivative was also isolated. 
Fortunately, the diacid (141) could be readily converted to (66) by prolonged heating 
in an inert solvent (Scheme 2.24).80 
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Scheme 2.24: Preparation of compound (66).
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2.3.2 Activation of cinnamic acids. 
For coupling to a suitably protected spermidine derivative, both cinnamic acids were 
converted to their pentafluorophenyl and succinimido ester derivatives. 
The activated pentafluorophenyl cinnamic acid esters (143) and (144) were derived 
by reacting the cinnamic acid derivatives (66) and (65) with pentafluorophenol and 1­
(3­dimethylaminopropyl)­3­ethylcarbodiimide hydrochloride, in the presence of 
DMAP as catalyst. 
COOH 
TIPSO 
O 
CO2C6F5 
O 
Pentafluorophenol 
EDC, DMAP 
DCM 
R.T 
80% 
TIPSO 
DCM 
O2N R.T O2N

F 86% F

(65) (144) 
Scheme 2.25: Preparation of pentafluorophenyl activated cinnamic acid esters (144) and 
(143). 
The preparation of the cinnamic acid succinimido esters (145), and (146) was 
achieved successfully by coupling the cinnamic acids (66) and (65) with N­hydroxy 
succinmide in the presence of DCC. 
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Scheme 2.26: Preparation of succinimido activated cinnamic esters (145) and (146). 
2.3.3 Coupling activated cinnamic esters to spermidine derivatives. 
Starting with the orthogonally protected spermidine (118) derived by fragment 
synthesis, the pentaflurophenyl activated cinnamic acid ester (143) was coupled to the 
free N8 amino group, to give the monoacylated compound (147) in 60% yield 
(Scheme 2.27). The selective removal of the N­1 Dde group was then attempted. 
Using hydrazine and allyl alcohol, the N1 deprotected derivative (148) was obtained 
in 86% yield. According to Rohwedder81, the use of allyl alcohol and shorter reaction 
times for Dde deprotection, ensures that the possible side reaction of partial reduction 
of C=C double bonds is significantly reduced. Competing reduction is due to 
contamination of commercial hydrazine by diimide, which is scavenged by adding 
allyl alcohol. In this case the reaction was monitored by TLC, and was stopped when 
the starting material was consumed, after less than 10 minutes. No reduction of either 
the allyl ether or cinnamoyl unit was observed. Compound (148) was then coupled 
with activated cinnamic acid (144) to give the diacylated spermidine derivative (64), 
which was ready to undergo intramolecular cyclisation as seen in Scheme 2.1. 
58 
(118) 
Boc 
H 
Dde 
N N 
NH2 
CO2C6F5 
DIPEA, rt 
o/n (143) 
60% 
TIPSO 
O 
Boc (147) O

H

N N OTIPS 
Dde N 
H 
O 
2% N2H4/DMF 
allyl alcohol 
86% 
Boc (148) O 
N OTIPS 
N 
H2N 
H 
O 
CO2C6F5 
DIPEA, DMAP 
(144) 0oC ­ rt. o/n 
O2N 
F 
O2N 
Boc O 
H 
N N OTIPS 
F N 
H 
O 
(64) O 
Scheme 2.27: Synthesis of doubly acylated spermidine (64). 
Meanwhile, coupling the activated cinnamic acid (143) directly to the 
hexahydropyrimidine derivative (128) was investigated. The first attempt to acylate 
the hexahydropyrimidine (128) with the pentafluorophenyl activated cinnamic ester 
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(143) was unsuccessful due to the lack of selectivity of the pentafluorophenyl 
activating group for the primary amino function over the secondary. Therefore 
activation via the succinimido ester was used which has been reported by Garnelis et 
al 
82 to be selective for primary amines. Direct selective acylation of the primary 
amino function of the hexahydropyrimidine derivative (128), with the activated 
cinnamic ester (145) in the presence of base, gave the desired monoacylated product 
(149) in 65% yield, as well as the diacylated product in 4% yield. In order to obtain 
the desired spermidine derivative for reaction with activated ester (146), it was then 
necessary to open the hexahydropyrimidine ring of (149). This was achieved via a 
Knoevenagel reaction with ethyl hydrogen malonate in pyridine, which gave the 
desired compound (150) in 83% yield. This type of reaction has previously been 
described by Ponasik et al38 for the synthesis of Kukoamine A (44) derivatives, and 
also by Husson et al 83 in the preparation of the spermidine natural product maytenine 
(121). In both these cases the Knoevanagel reaction was performed at significantly 
higher temperatures and for longer reaction times. As it was preferred here to avoid 
any possible cleavage of the TIPS protecting group in (149), the temperature was kept 
at 50°C, which appeared to have no effect on the efficiency of the ring opening. 
Direct selective acylation of the primary amino function of the spermidine derivative 
(150), with the activated cinnamic ester (146) was then attempted. The desired doubly 
acylated spermidine (151) was successfully isolated, but in a disappointing yield of 
15%, with several other products being observed. 
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Scheme 2.28: Doubly acylated spermidine (151). 
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Since the yield for the second acylation reaction was inadequate, a new strategy was 
adopted. It was felt that the bulk of the triisopropyl silyl protecting group could be the 
reason why the second acylation was not very successful. One way this problem could 
be investigated, was to couple the pentafluorophenyl activated cinnamic acid (144), 
on the protected spermidine (133) first, followed by the coupling of the TIPS 
containing activated cinnamic acid (143). To do this, the N1 free amine of the 
orthogonally protected spermidine (133) synthesised by selective functionalisation in 
section 2.2.4, was coupled to activated cinnamic acid (144), to give the monoacylated 
compound (152) in 92% yield. In turn the Boc group was then cleaved, to give 
compound (153). This was finally ready to be coupled to the other activated cinnamic 
acid (143) to give the diacylated compound (154) in 75% yield. This method is much 
more efficient compared to the previous two and was adopted in generating more 
diacylated material for the continuation of the project (Scheme 2.29). 
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Scheme 2.29: Synthesis of diacylated spermidine derivative (154). 
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2.4 INTRAMOLECULAR CYCLISATION OF CADABICINE AND 
FINAL FUNCTIONALISATION. 
2.4.1 Diphenyl Ether Synthesis 
Diphenyl ethers occur widely in a number of organic compounds throughout the life 
sciences and material chemistry. A number of compounds containing diphenyl ethers 
are biologically active, such as the antibiotic vancomycin84, antitimour compounds 
bouvardin and bastadin85, antimitotic agents like combretastatins86 to name but a few. 
2.4.2 Ullmann and Buchwald­Hartwig Diphenyl Ether Reactions. 
i) Intermolecular Coupling reactions. 
The classic synthesis of diphenyl ethers is under Ullmann conditions, which involve 
the coupling of aryl halides with phenols in the presence of copper powder or copper 
salts (Scheme 2.30). However it requires harsh conditions, with at least stoichiometric 
amounts of copper, large excess of phenols and high temperatures. This is due to the 
poor nucleophilicity of the phenoxide ion and the usually low reactivity of the aryl 
halides involved. 87 
OH X Cu O 
+ 
120­170oC 
(155) 
(156) (157) 
X = halides 
Scheme 2.30: General scheme for Ullmann type coupling. 
Several ligands have been reported to improve the solubility of the cuprous ions 
which are the catalytic species in the Ullmann reaction, and when used along with a 
base this can improve the efficiency of the coupling, even at low temperatures. 88 
Examples include 2,2,6,6­tetramethylheptane­3,5­dione (TMHD)89 , suitable for 
coupling various aryl bromides with phenols; N,N­di­methyglycine90,91 suitable for 
both electron rich aryl halides and reaction at lower temperatures; Hauptman’s 92 
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variety of bi­dentate pyridine containing ligands; 1,10­phenanthrolines24 suitable for 
aryl iodides and Cristau’s93 multidentate chelating ligands Chxn­Py­Al (159), 
salicyclaldoxime (Salox) (160) and dimethylglyoxime (DMG) (161), which allow 
reaction at the lowest so far reported temperature for Ullmann diphenyl ether 
synthesis (Figure 2.3). 
OO 
Me 
Me Me 
N 
N N 
N 
Me 
Me 
Me 
(159) 
(158)	TMHD Chxn­Py­Al 
OH 
N 
HO N N	 OH 
OH 
(161) 
(160) 
Salox	 DMG 
Figure 2.3: Examples of ligands used in Ullmann diphenyl ether synthesis. 
Other research groups instead of adding a ligand in order to improve the solubility of 
the catalytic cuprous ions, modify the catalyst itself. Gujaghur and Venkataraman 94,95 
have used air and moisture stable Cu(PPh3)Br and copper phenanthroline complexes 
(165), (166) to successfully couple electron deficient aryl bromides to phenols 
(Scheme 2.31). Using Cu(PPh3)Br gave good yields (55­88%) in the coupling of 
electron rich aryl bromides with electron rich phenols, however electron deficient 
phenols failed to react. While use of copper­phenanthroline complexes, was also not 
succesful for aryl bromides with ortho substituents. 
Me Me 
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Br OH 
i or ii O 
R' RR R' 
(162) (163) (164) 
R = NO2, CN, Me, NMe2, OMe, COOMe; R' = Me 
N N N N 
Cu Cu

Ph3P Br Ph3P Br

(165) (166) 
Scheme 2.31: Reaction and conditions: i) Cu(PPh3)3Br, Cs2CO3 (3 equiv), NMP, 100°C, 
48h. ii) Cu(neocup)(PPh3) (10mol%), CsCO3, toluene, 110°C, 36 h. 
Diphenyl ether synthesis was also reported to be successful without the use of ligands 
by Xia et al,96 by using Raney Nickel­Aluminium alloy along with various copper 
salts as illustrated in Scheme 2.32. This method was only suitable for coupling ortho 
and para substituted phenols with inactivated bromides and iodides. 
X OH 
Oi 
R' RR R' 
58­99% 
(169) 
(167) (168) 
R = H,Me; R' = H,Me, t­Bu; X = Cl,Br,I 
Scheme 2.32: Reagents and conditions: i) CuI (10mol%), K2CO3, Raney Ni­Al alloy (10­
50 mg/mmol halide), dioxane, 110°C, 24 h. 
Solid phase methods also have been used for the synthesis of diphenyl ethers, by 
using a triazene group as a linker.97 The couplings were performed under mild 
conditions using a soluble copper complex CuBr·SMe2. Using this method a number 
of highly substituted diphenyl ethers were obtained in high purity and good yields. 
Another way to avoid the harsh Ullmann reaction conditions, was employed by 
Buchwald98 and Hartwig99 by using palladium­catalysed diphenyl ether synthesis 
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with the aid of ligands, such as (S)­(­)­2,2’­bis(diphenylphosphino)­1,1’­binaphthyl 
(BINAP), 1,1’­bis(diphenylphosphino) ferrocene (DPPF), P(o­tolyl)3 and 1,1’­bis(di­
tert­butylphosphino)ferrocene (DtBPF). Using this method diphenyl ethers could be 
obtained at significantly lower temperatures compared to the Ullmann method, even 
as low as room temperature. The only major disadvantage is the relative expense of 
the palladium reagent. 
A number of different ligands have since been reported, to facilitate the process. 
Buchwald et al 98 developed a variety of sterically bulky ligands containing two tert­
butyl (170)­(173) or adamantyl groups (174) (Figure 2.4), suitable for coupling a wide 
range of electron­deficient, electronically neutral and electron­rich aryl halides or 
triflates with a variety of phenols in high yields. 
(170) (172) 
(171) 
Me2N Ph 
P(t­Bu)2 P(t­Bu)2 P(t­Bu)2 
P(Adamantyl)2 
NMe2 
P(t­Bu)2 
(174) 
(173) 
Figure 2.4: Buchwald’s sterically bulky ligands. 
Other examples include phosphine ligands based on 2­phosphino N­aryl pyrrole and 
indole structures (scheme 2.33), developed by Beller et al. 100 This variation of the 
Pd­catalysed method, produces diphenyl ethers in excellent yields using low catalyst 
concentrations with high turnover numbers. 
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P(t­Bu)2 PAd2 N Ph N Ph 
N N 
(178) 
Ph (179) Ph (180) (181) 
Beller's novel monophosphine ligands 
Scheme 2.33: Reagents and conditions: i) Pd(OAc)2, K2CO3, ligand (1mol%), toluene, 
120°C, 20 h. 
ii) Intramolecular Coupling Reactions. 
Dominguez et al 101, 102 has successfully used CuBr.SMe2 in pyridine at 120°C in 
order to achieve the intramolecular coupling of 4,5­(o,o’­halohydroxy) arylpyrazoles 
(182) to give dibenzoxepines (183) (scheme 2.34). In contrast with intermolecular 
couplings, variation of substituents with different electronic properties appeared to 
have little influence and hence did not affect the isolated yields of dibenzoxepines, 
indicating the efficiency of this reaction in dibenzoxepine ring closure. 
N 
N 
R5 
Y2 
R6 
R7 
R8 
Ph 
R4 
R3R1 
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R2 R3 
R4 
Ph 
(182) (183) 
Y1, Y2 = OH or halogen 
Scheme 2.34: Reagents and conditions: i) CuBr.SMe2, NaH, pyridine, 120°C. 
The synthesis of one of the most important antibiotics, vancomycin, has been 
approached using this chemistry. For example, Nicolaou and Boddy 103,104 used a 
soluble CuBr.SMe2 complex in order to obtain the diphenyl ether intermediate (184) 
from its non cyclic precursor (185) (Scheme 2.34). 
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Scheme 2.34: Reagents and conditions: i) CuBr.SMe2, K2CO3, pyridine. 
Wang and Harvey 105 have also used palladium­catalysed intramolecular diphenyl 
ether formation to successfully obtain polycyclic xanthenes and furans. 
2.4.3 Synthesis of Diphenyl Ethers via SNAr. 
Direct nucleophilic coupling of phenols to aryl halides is best achieved within 
electron deficient skeletons, as seen mainly in the synthesis of natural products such 
as vancomycin, piperazinomycin and combrestatins. Nitro, triazenyl and 
methylcarbonyl are groups most commonly used to activate the aryl halides for SNAr 
with phenols, with the nitro group being the most favourable due to its strong electron 
withdrawing effect. This makes reactions possible under relatively mild conditions 
which are compatible with peptide bonds and other potentially sensitive moieties 
occuring in natural products. 
i) Intermolecular SNAr 
Wang et al 106,107 successfully and in high yields, synthesised a number of diphenyl 
ethers from electron deficient phenols and aryl halides using microwave activation. 
The group also developed an efficient method for direct coupling of aryl tert­
butylmethylsilyl (TBDMS) ethers to electron deficient aryl halides or aryl triflates, 
using cesium carbonate (Scheme 2.35). Interestingly this method was selective for 
phenolic TBDMS esters in the presence of aliphatic TBDMS ethers. 
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(186) (190) 
X = F, Cl, Br, OTf; R = COMe, COPh, NO2, SO2Me; Ar = Ph, C6H4­p­Me, quinolin­8­yl 
Scheme 2.35: Reagents and conditions: i) K2CO3, DMSO, MW (300W). 5­10min; ii) 
Cs2CO3 (1 equiv), DMF, 100°C, 8h. 
Similarly Urgaonkar and Verkade 108, efficiently coupled electron poor aryl fluorides 
to aryl trimethylsilyl or TBDMS ethers, using proazaphosphatrane. Even though this 
method gave diphenyl ethers in high yields using milder conditions compared to 
Wang’s methodology, unfortunately it only works on aryl fluorides. 
F OTMDMS 
Oi 
R' RR R' 
(193) 
(191) (192) 
R = CO3Et, CHO, CN, NO2; R' = CN, Cl, Br, OMe 
P 
N N 
N 
N 
i­Bu 
i­Bu 
i­Bu 
Proazaphosphatrane (194) 
Scheme 2.36: Reagents and conditions: i) 10 mol%, proazaphosphatrane, toluene or 
DMF, r.t. or 80°C, 1 h. 
In the same fashion Zhu et al,109 and more recently Zhao and Wang110 have reported 
using tetrabutylammonium fluoride in order to couple trimethylsilyl ethers with 
electron deficient aryl halides to form diphenyl ethers (Scheme 2.37). 
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Scheme 2.37: Reagents and conditions: i) TBAF, Et3N, EtOH, DMF, 100°C, 12h 
ii) Intramolecular SNAr. 
In an early example of the intramolecular SNAr approach with an activated halide, 
Beugelmans et al,111 described the synthesis of a vancomycin ring analogue, using 
potassium carbonate as base in DMF (Scheme 2.38). Interestingly, it was noted that 
the reaction can be performed without high dilution of the reaction mixture, which is 
commonly the case for intramolecular cyclisation, in order to favour intra­ over inter­
molecular cyclisations. 
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Scheme 2.38: Agents and conditions i) K2CO3, DMF. 
One of the most noteworthy applications of intramolecular SNAr is in the synthesis of 
vancomycin as reported by Zhu et al,112 where the macrocycle AB­C­O­D was 
cyclised as a whole, rather than synthesising the component rings AB and C­O­D 
individually. This was successfully achieved using potassium carbonate and crown 
ether 18­C­6 in THF (Scheme 2.39). Zhu 113 also described intramolecular SNAr on 
solid support using potassium carbonate, where the precursor is bound to Wang resin 
via an ester linkage. 
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Scheme 2.39: Agents and conditions: i) K2CO3, 18­C­6, THF, 50°C. 
Intramolecular SNAr has been also used by Blagbrough
73 for the diphenyl ether 
closure of 23­, 24­ (codonocarpine and nitrocadabine), and 28­membered macrocyclic 
polyamine lactams (Scheme 2.40). It has been proposed that the two aryl rings come 
in close proximity during the cyclisation reaction, due to π­orbital stacking 
interactions between the electron rich phenol ring and the deficient o­fluoro­
nitrophenyl ring84 . However macrocycle formations of this type, have also been 
successfully achieved when the aryl hydroxyl group is replaced by an alkyl hydroxyl 
group, suggesting that π­π interactions are not necessary for cyclisations to occur.114 
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Scheme 2.40: When n=0 i) 5 eq CsF, DMF, 18 h, 79%. When n=1 ii) 3 eq CsF, DMF, 18 
h, 71%. iii) 3 eq K2CO3, 10 eq 18­crown­6, DMSO, 50°C, 5 h, 66%. 
2.4.4 SNAr additions to Metal­Arene Complexes. 
SNAr addition using metal­arene complexes is a mild method to synthesise diphenyl 
ethers. A normally non­reactive and non­activated aromatic halide component for the 
SNAr is activated by forming a metal arene complex. An example of SNAr additions to 
metal­arene complexes is reported by Pearson and Belmont, 115 where peptide aryl 
ether rings of ristocetin and teiplanin molecules are synthesised via a ruthenium 
complex (Scheme 2.41). The toxic ruthenium complex can be efficiently recovered 
and recycled. 
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Scheme 2.41: Agents and conditions i) Cp(MeCN)3RuPF6, DCE, reflux; ii) (t­Bu)2C6H3O
­
K
+
, 18­C­6, THF; iii) MeCN, hv. 
Ruthenium­induced intramolecular cyclisation has also been successfully used for the 
construction of the diphenyl ether macrocyclic compound (212) (Scheme 2.42), as 
described by Venkatraman et al116 . 
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Scheme 2.42: Reagents and conditions i) Cs2CO3, DMF; ii)MeCN, hv, 20% (over two 
steps) 
Similar reactions using ruthenium complexes have been also used by Lindel and 
Schmid 117 . 
2.4.5 Miscellaneous methods for diphenyl ether formation. 
i) Coupling of Phenols with Arylboronic Acids. 
Chan118 and Evans119 were first to report the synthesis of diphenyl ethers by copper 
(II)­promoted cross­coupling of phenols with arylboronic acids in the presence of 
molecular sieves. The major advantage of this method is that the reaction proceeds at 
low temperature, hence tolerating a wide variety of substituents on both reactants as 
well as achieving high yields. Petasis et al, 120 and later Sagar et al, 121 described a 
one­pot reaction for the conversion of arylboronic acids to phenols, and subsequent 
intramolecular coupling of both species to form symmetrical diphenyl ethers (Scheme 
2.43). 
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Scheme 2.43: Reagents and conditions i) H2O2 (30%), DCM; ii) Cu(OAc)2, Et3N, DCM, 
MS, 25°C; iii) Cu(OAc)2, Et3N, H2O, DCM­MeCN, 25°C. 
Hitotsuyanagi et al 122 applied this approach for the efficient intramolecular coupling 
of the dipeptide precursor (215), for the synthesis of the macrocycle L,L­cyclo­
isodityrosine (216) (Scheme 2.44). 
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Scheme 2.44: Reagents and conditions i) Cu(OAc)2, Et3N, DCM, MS, r.t., 48h. 
ii) Diphenyl Ether Synthesis via Oxidative Coupling 
The synthesis of diphenyl ethers can also be accomplished by oxidative coupling of 
2,6­dihalophenols. This method has been used in the synthesis of vancomycin 123 
using thallium nitrate as an oxidant, and more recently in the synthesis of bastadin (a 
cyclic tetramer of brominated tyrosine derivatives containing two diphenyl ether 
moieties) using cerium(IV) diammonium nitrate as an oxidant.85 
iii) Diphenyl Ether Synthesis via Benzyne Mechanism. 
This method involves the synthesis of diphenyl ethers from silylaryl triflates with 
phenols124 (Scheme 2.45). The advantage of this reaction is that it occurs at room 
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temperature, and phenols with electron withdrawing groups such as formyl and nitro 
as well as halides are tolerated. 
X OH 
X OSiMe3 i 
R' R' 
68­98% 
OTf 
(219) 
(217) (218) 
X = H, OMe; R' = H, Me, CHO, OMe, NO2, Br, I, OH 
Scheme 2.45: Reagents and conditions i) CsF, MeCN, 25°C, 2.5 d. 
iv) Diphenyl Ether Synthesis by Fischer Chromium Carbene 
Mediated Benzannulation. 
A less common method is to build one of the aromatic rings of the diphenyl ether via 
a 3+2+1 cycloaddition between an aryloxy­ or alkylamino­ substituted Fischer 
carbene, and an alkyne. A recent example by Pulley et al 125 describes the 
benzannulation between Fisher chromium carbene complexes (221) and alkynes 
(222), giving diphenyl ethers (223) as shown in scheme 2.46. The main advantage of 
this approach is that it allows for a wide range of substituents on both aryl 
components. 
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Scheme 2.46: Reagents and conditions i) 50­55°C, 16­36 h. 
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2.4.6 Intramolecular SNAr cyclisation for Cadabicine 
As highlighted in the retrosynthesis (section 2.1), our synthetic strategy for cadabicine 
was based on an intramolecular SNAr reaction with a spermidine intermediate 
derivatised with suitable activated halide and phenol containing units. As noted in the 
previous section, this approach should be compatible with a range of protecting 
groups on both spermidine and aromatic componenets as required here. Following 
from section 2.3, the linear compound (154) was cyclised via SNAr intramolecular 
coupling, using TBAF in THF (Scheme 2.47). The reaction was performed in dilute 
conditions (1 mM/mL), in order to favour intra over inter molecular coupling. In this 
reaction the TIPS group was cleaved and compound (154) was cyclised in one step to 
give the macrocycle (224).110 
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Scheme 2.47: SNAr Cyclisation 
The reaction was monitored by HPLC, confirming that the reaction was fast, clean 
and efficient (Figure 2.5). 
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Figure 2.5: SNAr macrocyclisation compound (224). Upper trace linear compound (154). 
Lower trace cyclised compound (224). 
The reaction was also repeated at a 10­fold higher concetration and was again 
monitored by HPLC. There was no difference in the yield obtained of the macrocycle 
(224), or in the efficiency of the reaction. 
Having successfully obtained (224), the final steps required in order to obtain 
cadabicine, were to remove the nitro group and cleave the allyl and Z protecting 
groups. The standard procedure for the reduction of the nitro group involves catalytic 
hydrogenation using palladium on carbon126 or Raney nickel.127 However this method 
was not suitable, as it would reduce the double bonds of the macrocycle and the allyl 
and Z protecting groups. In contrast, the use of SnCl2 for mild and chemoselective 
reduction of aromatic nitro groups to anilines has been well documented.128 The 
reduction of the nitro group in the macrocycle (224), was initially attempted using tin 
chloride in DMF.129 This method was monitored by TLC and MS, but unfortunately 
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failed, giving multiple products, and the desired aniline was not observed. Therefore 
the method was modified according to Satoh’s130 protocol, which uses SnCl2, and 0.1 
eq NaBH4 in EtOH at 60°C. This method is reported to be compatible with α,β­
unsaturated alkenes and successfully reduced compound (224) to the corresponding 
amine (225) in high yield (Scheme 2.48). The reduction was monitored by HPLC, 
which showed complete disappearance of starting material and the formation of a 
single reduced product (Figure 2.6). 
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Scheme 2.48: Reduction of aromatic nitro group.
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Figure 2.6: Reduction of (224) using Satoh’s protocol. 
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Deamination of (225) proved to be a critical and very challenging step. Such 
transformations of aromatic amines have usually only been carried out in simple 
systems using relatively harsh conditions. The transformation is typically achieved in 
two steps, involving diazotization followed by reduction, in a ‘one­pot’ diazotisation­
dediazotisation reaction using sodium nitrite in hypophosphorus acid. These reaction 
conditions cannot tolerate sensitive moieties or protecting groups. Furthermore the 
aryldiazonium salts are unstable, and many of these reaction proceed via radicals, and 
thus lead to side reaction such as dimerisation. Doyle et al131 developed a method for 
rapid deamination of arylamines by tert­butyl nitrite, using DMF as a solvent and 
hydrogen donor. A number of other solvents were investigated showing that DMF is 
by far the best H donor thus facilitating these types of reaction. It was therefore 
decided to attempt the deamination of macrocycle (225) in the same manner. The 
reaction was monitored by HPLC, and gave rise to two main products in a ratio of 
1:1; one of which was the desired intermediate (226) (Figure 2.7). 
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Figure 2.7: HPLC trace of Deamination reaction using tert­butyl nitrite.
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The two peaks were isolated via HPLC purification, and further analysed by MS, 1D 
and 2D NMR studies in order to identify the unknown product (227). Following MS 
analysis the unknown compound had a mass 2 units lower than the desired compound 
(226). It was thought that this compound could correspond to a product formed by 
Pschorr type ring closure. This hypothesis was confirmed by NMR studies. 2­D NMR 
studies including COSY, and carbon­hydrogen (HMBC, HSQC) showed the distinct 
difference between the two. The COSY for desired compound (226) showed a clear 
interaction between H1 and H2, while this interaction was not present in the Pschorr 
intermediate (227) spectra. Moreover the carbon­hydrogen correlation showed an 
interaction between C­2 and H­2, as well as C­3 and H­3, while this interaction was 
not present for compound (227). 
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Scheme 2.49: Deamination reaction using tert­butyl nitrite. 
During repetitions of this reaction it was observed that the addition time of the aniline 
(225), to the DMF/tert­butyl nitrite, was very important in determining the resulting 
ratio of the two products. If the addition was fast (under 1 min) the reaction gave 
predominately the Pschorr product (227), while if the addition was slow over 20 min, 
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this gave a ratio of approximately 1:1 by HPLC. Increasing the addition time beyond 
20 min, did not change the ratio in preference of the desired product; it remained 1:1. 
In order to improve the yield of the desired deaminated material a recently reported 
milder deamination reaction was attempted. This involes a mild diazotisation using 
sodium nitrite and acetic acid followed by in situ reduction by bisulfite, a mild 
reducing agent, and its corresponding conjugate acid, a weak acid.132 The reaction 
was initially attempted using EtOH and water as solvents, as suggested in the 
literature. This generated the desired derivative (226) in a 3:1 ratio to the Pschorr 
derivative (227) as shown in Figure 2.8. 
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Figure 2.8: Deamination using EtOH/H2O as solvents. 
In order to improve the ratio towards the desired deaminated compound (226), a 
mixture of EtOH/DMF was used as a solvent, as it has been previously suggested that 
DMF is the best H­donor in these types of reaction. Thus, the aniline (225) was 
dissolved in a solution of ethanol/DMF, water and acetic acid at room temperature, 
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and a solution of sodium nitrite in water was added followed immediately by the 
addition of aqueous solution of sodium bisulfite. This method now gave 
predominantly the desired deaminated compound (226), as it shown in Figure 2.9. 
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Figure 2.9: HPLC trace form NaNO2 deamination using EtOH/DMF as solvent. 
The deaminated material (226) was in turn allyl deprotected using (Ph3P)Pd 
133 to give 
the deprotected material (228). This was in turn subjected to final deprotection of the 
Z group. Deprotection of a Z group is usually performed by hydrogenolysis, however 
this method would also reduce the double bonds in the molecule. Therefore 
compound (228) was Z deprotected using TMS­I69 which is a mild method compatible 
with α,β unsaturated alkenes (Scheme 2.50). Following purification by column 
chromatography and HPLC, cadabicine (62) was isolated in 83% yield as the 
trifluoroacetate salt. 
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Scheme 2.50: Allyl and Z deprotection 
2.5 SYNTHESIS OF CADABICINE ANALOGUES 
2.5.1 Cyclic analogues 
Having established the synthesis of cadabicine (62), a small group of analogues was 
prepared in order to investigate structure­activity relationship. Macrocyclic 
polyamine alkaloids closely related to cadabicine, such as lunarine (63) have been 
shown to inhibit TryR in a competitive, time­dependent manner, resulting from 
conjugate addition of a redox­active cysteine residue in the TryR active site onto an 
α,β­unsaturated carbonyl unit.48,47 In principle cadabicine could also inhibit TryR in a 
similar fashion. Docking experiments suggested that cadabicine could bind with its 
diphenyl ether unit in a hydrophobic region of the TryR active site normally occupied 
by the spermidine unit of the substrate. One such high scoring structure also placed an 
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activated double bond on one side of the molecule, 4.9Å from one of the redox active 
Cys residues of the enzyme, providing support for the proposed interaction shown in 
Figure 2.11. 
a b 
Figure 2.10: a) T[SH]2 bound in TryR active site. b) Selected results of GOLD docking 
calculations for cadabicine and TryR. 
FAD 
­S 
O 
OH 
Cys­58 
O 
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Figure 2.11: Possible time­dependent inactivation of TryR by cadabicine. 
In order to investigate the significance of the α,β­unsaturated alkene units, and 
whether they could contribute to time dependent inhibition, a saturated tetrahydro 
analogue of cadabicine was synthesised. Allyl deprotected compound (228), was 
subjected to hydrogenolysis using Pd/C, which removed the Z group while reducing 
the double bonds to give compound (229) in 77% yield (Scheme 2.51). 
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Scheme 2.51: Synthesis of tetrahydro analogue of cadabicine. 
Based on the macrocyclic template another four analogues were synthesised, featuring 
changes in the substituents of the diphenyl ether unit in order to examine possible 
electronic/steric effect upon the enzyme interaction. The amino cadabicine analogue 
(231) was synthesed by allyl deprotecting the reduced intermediate (225), to give 
compound (230) which was then treated with TMS­I to remove the Z group (Scheme 
2.52). 
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Scheme 2.52: Synthesis of the amino cadabicine. 
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The amino­allyl cadabicine analogue (232) was then synthesised by Z deprotecting 
compound (225), using TMS­I in 80% yield (Scheme 2.53). 
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Scheme 2.53: Synthesis of amino­allyl cadabicine. 
In a similar fashion, the nitro cadabicine (234) and nitro­allyl cadabicine (233) 
analogues were synthesised (Scheme 2.54). In this instance though, the Z group was 
removed prior to the allyl group, thus illustrating the orthogonality of these protecting 
groups. 
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Scheme 2.54: Synthesis of nitro cadabicine analogues. 
2.5.2 Non­cyclic analogues. 
Two non­cyclic analogues of cadabicine were synthesised. This type of analogues was 
chosen since bis­polyamine functionalised disulfides such as the naturally occurring 
N
1­glutathionylspermidine disulfide, and the synthetic bis­dimethylaminopropyl­ and 
bis­N4­methylpiperazinyl amides of Ellman’s reagent (DTNB)134, are known TryR 
substrates. Moreover in previous research on lunarine (63), non­cyclic analogues were 
investigated; while retaining the tricyclic scaffold, they featured spermidine or 
dimethylaminopropylamine side chains and were found to be time dependent 
inhibitors and significantly more active than natural lunarine (Figure 2.12).49 
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Figure 2.12: Lunarine and non­cyclised polymanime derivatives. 
Using the same concept, two non­cyclic cadabicine analogues containing two 
spermidine chains were synthesised. Starting with the doubly protected spermidine 
(131), N4 was Boc protected using Boc anhydride. In this case there was no need for 
three orthogonal protecting groups, since both Boc protecting groups would be 
removed at the same time (Scheme 2.55). N1 was then Dde deprotected with 2% 
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hydrazine to yield N1 free amine spermidine compound (238) in 52% yield (scheme 
2.55). 
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Scheme 2.55: Synthesis of the spermidine unit for the acyclic analogues. 
The standard way of synthesising compounds such as (238), is by reacting 1,4 
diamino butane with acrylonitrile, Boc protecting the two amino functions and then 
reducing the nitrile group using Raney Nickel . The reason the doubly Boc protected 
spermidine (238), was synthesised as in scheme 2.55, is because compound (238) was 
available from the previous synthetic work (section 2.2.4) and also allows the 
potentially difficult and low yielding Raney Nickel reduction to be avoided. 51 
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Scheme 2.56: Fractional synthesis of spermidine derivatives. 
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Compound (238) was in turn coupled to activated cinnamic acid derivative (144) and 
separately also to activated cinnamic acid derivative (143) to give the two spermidine­
cinnamic acid compounds (241) and (242) in excellent yields (Schemes 2.57 and 
2.58). 
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Scheme 2.57: Preparation of compound (241). 
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Scheme 2.58: Preparation of compound (242).
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The two cinnamic amides (242) and (241) were treated with TBAF to form the 
diphenyl ether via intermolecular SNAr. This gave the desired diphenyl ether (244), 
however the reaction did not proceed to completion. (244) was isolated in 36% yield 
together with unchanged (241) (32%) and desilylated derivative (243) (29%). 
Therefore the starting materials (241) and (243) were recycled and reacted again using 
K2CO3, which proceded to completion and gave the desired ether (244) in almost 
quantitative yield (Scheme 2.59). 
N 
H 
N 
H 
N 
Boc 
Boc 
O 
F 
(241) 
NO2 + 
N 
H 
N 
H 
N 
Boc 
Boc 
O 
AllylO 
RO R = TIPS 
R = H 
(242) 
(243) 
i) TBAF, THF or ii) K2CO3, DMF 
0oC­r.t. r.t., o/n, 98% 
3 h, 36% 
O 
O 
N 
H 
H 
N 
O 
NO2 
N 
N 
H 
Boc 
N 
H 
N 
Boc 
Boc 
Boc 
O 
(244) 
Scheme 2.59: Intermolecular SNAr route to (244). 
The bis spermidine­containing diphenyl ether (244) was then Boc deprotected (4M 
HCl/dioxane) to give analogue (245) as seen in Scheme 2.60. 
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Scheme 2.60: Preparation of analogue (245). 
An interesting point about the non­cyclic analogues is that unlike the macrocyclic 
derivatives the spermidine­related peaks in the NMR are very broad, probably due to 
restricted rotation about the diphenyl ether linkage (atropisomerism). 
As for the allyl deprotected analogue, diphenyl analogue (244) was allyl deprotected 
first using (Ph3P)4Pd in 53% yield. Boc protection was carried out using 1.25 M HCl 
in MeOH (Scheme 2.61). When the deprotection was attempted in dioxane as 
previously, the reaction was incomplete. This was due to the precipitation of partly 
deprotected intermediates, hence methanol was needed to improve solubility and 
avoid this problem. 
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Scheme 2.61: Synthesis of acyclic cadabicine analogue (247). 
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2.6 INHIBITION ASSAYS 
Cadabicine, its various analogues and clomipramine, a well known competitive 
inhibitor of TryR, were assayed against TryR using the DTNB [5,5’­dithiobis­(2­
nitrobenzoic acid)] coupled assay, which has been developed by Hamilton et al. 48 
DTNB is included in the assay mixture to mediate the rapid re­oxidation of the 
product T[SH]2 back to T[S]2. Therefore T[SH]2 is continually recycled, thus the 
concentration of the substrate remains constant for the duration of these prolonged 
assays, so that any decrease in enzyme activity over time would be assigned to time­
dependent inhibition rather than substrate depletion (Scheme 2.62b). Reaction 
progress in the assay can be monitored by measuring the absorbance of the TNB 
anion which is yellow coloured at 412 nm. (Scheme 2.62a). 
Scheme 2.62: (a) Mechanism of DTNB­mediated re­oxidation of T[SH]2 : i) TryR­
catalysed reduction of T[S]2; ii) mixed­disulfide formation by reaction with DTNB in 
situ; iii) rapid intramolecular disulfide exchange reaction regenerates T[S]2; iv) possible 
reaction of the mixed­disulfide intermediate with DTNB (when in too large an excess) to 
give the bis­disulfide. (b) Schematic of the DTNB­coupled assay. 
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In order to determine whether cadabicine and analogues were reversible or 
irreversible inhibitors, an assay that determined the decrease in enzyme activity over 
time was devised. This was done by pre­incubating the enzyme with the inhibitor 
along with NADPH, for 10 min; enough time to ensure binding, before adding the 
substrate, DTNB and NADPH mixture. The increasing absorbance of TNB at 412 nM 
over time (40 min) was then measured. Clomipramine was assayed along with 
cadabicine and the analogues. Clomipramine is a well known reversible inhibitor of 
TryR, and was assayed for comparison. 
N 
N 
Figure 2.13: Clomipramine (19) 
Cl 
For all the new components studied, the increase in absorbance at 412 nM was linear 
with time, as observed for clomipramine (Figure 2.14). Thus in this assay, no time­
dependent inhibition was observed. Cadabicine and analogues follow clomipramine’s 
profile, as reversible inhibitors. 
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Figure  2.14:  Series  1  : Clomipramine,  Series  2:  (150),  Series  3:  (152),  Series  4:  (154), 
Series 5 : (155), Series 6: (172), Series 7: Cadabicine, Series 8: (174) 
 
In order to measure the IC50 values of cadabicine and analogues, a similar assay was 
devised.  The  enzyme  TryR  was  pre­incubated  with  the  inhibitor  (at  various 
concentrations) and NADPH for 5 min to ensure sufficient binding. The substrate was 
then added, and absorbance at 412 nm was measured over time. Each concentration of 
inhibitor was analysed in triplicate. An example of  the microplate assay  is shown in 
Figure  2.15.  The  assay  mixtures  contained  1%  (v/v)  DMSO,  so  as  not  to  interfere 
significantly  with  the  enzyme  activity,  with  the  exception  of  one  clomipramine 
standard  and  cadabicine,  which  both  contained  10%  (v/v)  DMSO.  The  results 
obtained in forms of IC50 values in Table 2, standard deviation and Hill’s coefficient 
are summarised.   
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Figure 2.15: Picture of the DTNB microassay plate­ colour formation. Inhibitors tested 
in triplicate at various concentrations. 
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Figure 2.16: Cadabicine and analogues. 
99 
Compound IC50 (µM) SD (µM) Hill coefficient 
Clomipramine (19) 
Standard 
5.5 0.15 ­1.6503 
Clomipramine (19) 
Standard 
10% (v/v) DMSO 
15.8 3.79 ­0.8344 
DMSO N/D N/D N/D 
(233) Data failed to fit­ No inhibition 
(234) 29.6 7.90 ­2.1932 
(232) 9.3 7.23 ­1.3191 
(247) Data failed to fit­ No inhibition 
(245) 4.7 2.37 ­2.5207 
(231) Data failed to fit­ No inhibition 
Cadabicine (62) 446.9 195.65 ­0.8318 
(229) 20.6 5.08 ­2.3307 
Table 2: Assay results. 
The Hill coefficient is a measure of cooperativity in a binding process. A coefficient 
of 1 indicates completely independent binding, regardless of how many additional 
ligands are already bound. Numbers greater than one indicate positive cooperativity, 
while numbers less than one indicate negative cooperativity. 
As seen from the Table, cadabicine is a very weak inhibitor. Even though the 
computer modelling (Figure 2.10) suggests that there is a possibility that one of the 
active double bonds is positioned in a favourable orientation for nucleophilic attack, 
close to an active Cys residue, this does not appear to occur in practice. That is, 
inhibition is reversible; no time­dependent inhibition effects that might be associated 
with covalent modification of the enzyme (as observed with lunarine) are apparent. 
Although the precise mode of inhibition cannot be deduced, cadabicine is clearly a 
very weak inhibitor. However compound (229), the tetrahydro analogue of 
cadabicine, is as potent as the standard clomipramine, but again the mode of 
inhibition cannot be deduced from this preliminary study. The absence of the double 
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bonds in (229), would improve its conformational flexibility, and hence allow (229) to 
mould more efficiently in the TryR active site. The TryR active site is quite rigid,46 
therefore relatively flexible inhibitors are more likely to be favoured. This scaffold is 
an interesting inhibition motif for further study. A variety of tetrahydro analogues can 
potentially be synthesised, with different groups present in the diphenyl ether, or 
changes in the polyamine chain, or even acyclic tetahydro analogues. 
Compound (233) does not inhibit TryR, while the phenol containing compound (234) 
is a moderate reversible inhibitor. Compound (232) is a good reversible inhibitor, the 
best in the series, but its allyl deprotected analogue (231) has negligible inhibition. 
Despite the fact that lunarine­based non­cyclic inhibitors were found to be time 
dependent inhibitors, cadabicine based non­cyclic analogue (247) does not inhibit 
TryR, but (245) has an apparent IC50 of 4.7. However since the compound is yellow 
coloured and DTNB is also yellow, this could be a false positive. Even though these 
structures are more flexible than cadabicine, the nature of their flexibility could be to 
their disadvantage. The spermidine chains would make the molecules too flexible to 
readily adapt the appropriate configuration in order to fit in the enzyme’s active site. 
To summarise, cadabicine is not a time­dependent TryR inhibitor as proposed, but a 
weak reversible inhibitor. None of the analogues showed time­dependent inhibition 
but compounds (234), (232) and (229) are good reversible inhibitors. Overall, the 
changes to the substitution pattern of the diphenyl ether moiety of cadabicine 
examined here, do not seem to have any significant effect on TryR. 
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2.7 CONCLUSIONS & FUTURE WORK 
The total synthesis of the natural alkaloid cadabicine has been successfully completed. 
This was achieved by developing an efficient route to triply orthogonally protected 
spermidine, both by fragment synthesis, and selective functionalisation. Furthermore a 
key step to the synthesis was the efficient and facile cyclisation of the functionalised 
linear spermidine derivative (154) to the macrocycle (224). This methodology can be 
generally applied in the synthesis of alkaloid macrocycles. We used methods and 
techniques that are mild and sensitive to moieties most commonly found in polyamine 
alkaloids. 
A small series of cyclic and non­cyclic analogues of cadabicine analogues were 
synthesised, and evaluated as TryR inhibitors. Cadabicine based on its structural 
similarity to lunarine a known time­dependent TryR inhibitor, and from docking 
experiments, was expected to show time­dependent inhibition. From the TryR 
inhibition assays, performed in this study, it appears that cadabicine is a weak 
reversible inhibitor of TryR. However the tetrahydro analogue (229) showed some 
promising results. The double bonds present in cadabicine could cause the compound 
to be more rigid, and affect its flexibility in properly fitting into the TryR active site. 
The tetrahydro analogue (229) lacks the double bonds making it more flexible hence 
the better inhibition results. The scaffold of (229) makes a promising template for 
inhibitor design. Future work would include the synthesis of both cyclic and non­
cyclic analogues based on (229) scaffold, as potential TryR inhibitors. It would also 
be worth exploring further, to determine the mode of inhibition of these types of 
compounds as well as testing their biological activity against Trypanosoma and 
Leishmania species. 
Another scaffold worth investigating is the Pschorr tricyclic derivate (227) that we 
came across in the deamination studies. The scaffold of (227) is very closely related 
to those of tricyclic antidepressant inhibitors of TryR. It would be interesting to 
examine if cyclic or non­cyclic analogues based on that motif would inhibit TryR, and 
their mode of inhibition, both retaining and not retaining the double bonds. 
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3. EXPERIMENTAL 
3.1 GENERAL 
Chemical reagents were purchased from Sigma, Aldrich, Fluka, Acros, Lancaster and 
Novabiochem. Anhydrous DCM was obtained by distillation over calcium hydride, 
anhydrous THF and Et2O over sodium/benzophenone. All other solvents were 
purchased from Fisher Scientific. Analytical TLC was performed using silica gel 60 
F254 pre­coated on aluminium sheets (0.25 mm thickness) and reverse phase analytical 
TLC was performed with RP­18 F254 pre­coated on aluminium sheets (0.27 mm 
thickness). Column chromatography was performed on silica gel 60 (35­70 micron) 
from Fisher Scientific. Melting points were recorded on a Reichert­Jung Kofler block 
apparatus and are uncorrected. 1H and 13C NMR were recorded using a Bruker 
Advance DPX 500MHz FT, JEOL JMN GX­270MHz or EX­400MHz spectrometers. 
J values are given in Hz. High resolution mass spectrometry was performed using a 
Bruker MicroTOF autospec electrospray ionisation mass spectrometer. Analytical RP­
HPLC was performed on a Dionex HPLC system (system 1) equipped with a Dionex 
Acclain 3 µm C­18 (150 x 4.6mm) column with a flow rate of 1 mL/min or a Dionex 
UltiMate 3000 HPLC system (system 2) equipped with a Phenomenex Gemini 5µm 
C­18 (150 x 4.6 mm) column with a flow rate of 1 mL/min. Preparative RP­HPLC 
was performed on a Dionex HPLC system equipped with a Phenomenex Gemini 5µm 
C­18 (250 x 30 mm) with a flow rate of 22.5 mL/min. Mobile phase A was 0.1% TFA 
in water, mobile phase B was 0.1% TFA in acetonitrile, mobile phase C was 0.1% FA 
in water, mobile phase D was 0.1% FA in acetonitrile unless specified. 
Analytical HPLC gradient: T = 0 min, D = 5%; T = 20 min, D = 95%; T = 20.1 min, 
D = 5%; T = 28.1 min, D = 5%. 
Preparative HPLC gradient : T = 0 min, B = 5%; T = 20 min, B = 95%; T = 20.1 min, 
B = 5%; T = 28.1 min, B = 5%. 
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3.2 DOCKING CALCULATIONS 
Methods for the generatation of Ligands and Performance of Docking Calculations: 
The molecules were created in Sybyl 7.1 and all preparation calculations were 
preformed within the Sybyl 7.1 molecular modelling package. The molecules were 
built using the molecule building tools from the provided structures and were then 
minimised using the MMFF94s force field. Each compound was subjected to 10 pico 
seconds of simulated annealing of heating to 350 K followed by cooling to 150 K. 
This was repeated for 20 cycles, then the lowest energy conformation was then re­
minimised using the MMFF94s force field as implemented within Sybyl 7.1. The 
docking calculations were preformed in the GOLD135 docking program from the 
CDCC. The docking site was described by a 12 angstrom radius encompassing the 
active site from the PDB crystal structure of TryR using the bound ligand as a 
reference. Each ligand was docked in a total of 25 times. 
3.3 INHIBITION ASSAYS 
T. cruzi was obtained from Prof. Alan Fairlamb (University of Dundee). The enzyme 
was supplied as 70% ammonium sulfate precipitates.48 
TryR molecular weight calculated as 53867.8 Da based on the Swissprot sequence 
calculated using protparam (http://www.expasy.ch/tools/protparam.html). Protein 
concentrations were determined using the Bio­Rad DC assay in a microtitre plate with 
1.5, 0.75, 0.325, 0.1625 mg/mL BSA as standard. This assay measures the protein 
main­chain. The stock solution of TryR was determined to be 0.971 ± 0.039 mg/mL 
(18 ± 0.72 µM). 
The standard assay mixture contained TryR, buffer, NADPH, T[S]2, DTNB and 
various concentrations of inhibitor. Inhibitor stock solutions were made up using 
buffer and DMSO, so that the final assay mixture contained no more than 1% (v/v) 
DMSO, so as not to interfere significantly with enzyme activity. Enzyme activity was 
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measured by the increase in absorbance at 412nm due to the formation of TNB; using 
a P.E. Lamda EZ201 UV­visible recording microplate spectrophotometer. 
IC50 determinations using 5 µM substrate, used 3.6 nM of enzyme in the assay. All 
absorbances read at 40 minutes incubation. Determinations of clomipramine and 
Compound (62) used dilutions of compound in 50% DMSO/buffer. DMSO 
concentration was held constant at 10% (v/v) in addition to the small amount of 
DMSO in the buffer. Protein concentrations in these experiments were 10.8 nM and 
absorbances were read at 30 minutes. In all determinations control experiments 
showed that longer incubation times resulted in higher absorbances, i.e. DTNB was 
not limiting. Data was analysed with SigmaPlot 11.0 using the four parameter logistic 
equation using y­replicatants and log10 concentration scale. 
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3.4 COMPOUND DATA

Carbonic acid phenyl ester 2,2,2­tricholoroethyl ester [104]

Cl 
Cl 
Cl 
O O 
O 
A stirred solution of trichloroethanol (7.5 g, 0.05 mol) and pyridine (5 mL) in DCM 
(8 mL) was treated with phenyl chloroformate (7.83 g, 0.05 mol) added over 1 h. The 
reaction mixture was stirred for an additional 3 h. Water (15 mL) was added. The 
organic phase was washed with aqueous sulfuric acid (2 M, 2x15 mL), dried 
(MgSO4), filtered and evaporated to dryness to give 104 as a white solid (13.0 g, 
96%); mp: 29­31ºC; δH (500MHz, CDCl3): 4.80 (2H, s, CH2), 7.15 (2H, d, J 7.5, 
Ar), 7.21 (2H, t, J 7.5, Ar), 7.34 (1H, t, J 7.5, Ar); δC (125MHz, CDCl3): 77.31 
(CH2), 94.17(CCl3), 120.95 (Ar), 126.55 (Ar), 129.67 (Ar), 150.86 (Ar), 152.63 
(C=O); [Found: (ES+) 290.9355 [M+Na]+, C9H7Cl3O3Na requires 267.9353]. 
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(4­Amino­butyl)­carbamic acid 2,2,2­trichloroethyl ester [105] 
H2N 
H 
N O 
O 
Cl 
Cl 
Cl 
A stirred solution of 104 (15.52 g, 0.0576 mol) in absolute ethanol (200 mL), was 
treated with 1,4­diaminobutane (5.07 g, 0.0576 mol). The mixture was stirred 
overnight at room temperature. Water was added (200 mL) and the pH was adjusted 
to 3 by addition of aqueous HCl (1M), followed by extraction with DCM (2 x 400 
mL). The aqueous phase was then made strongly basic by addition of aqueous NaOH 
(1M) and extracted with DCM (2 x 400 mL). The organic phase was dried (MgSO4), 
filtered and evaporated to dryness to give 105 as a yellow oil (9.62g, 63%); δH 
106 
(500MHz, DMSO): 1.30­1.36 (2H, m, CH2CH2), 1.41­1.47(2H, m, CH2CH2), 1.51­
1.54 (1H, br, NH),1.73­2.00 (2H, br, NH2), 2.52 (2H, t, J 6.8, CH2N), 3.01(2H, q, J 
6.8, CH2N), 4.78(2H, s, CH2CCl3). δC (100MHz, DMSO): 26.54 (CH2), 28.95(CH2), 
40.20 (CH2­NH), 42.18 (CH2­NH), 75.29 (CH2CCl3), 96.37 (CCl3), 165.85 (C=O). 
[Found: (ES+) 263.0104 [M+H] +, C7H14Cl3N2O2 requires 263.0115]. 
[4­(2,4­Dinitro­benzenesulfonylamino)­butyl]­carbamic acid 2,2,2­trichloroethyl 
ester 
61 
[107] 
O2N 
NO2 
S 
O 
H 
N 
O 
N 
H 
O 
O 
Cl 
Cl 
Cl 
A stirred solution of 105 (0.5 g, 0.0018 mol) in DCM (8 mL), was treated with 2,6­
lutidine (0.204 g, 0.0018 mol), followed by 2,4­dinitrosulfonyl benzene chloride 
(0.506 g, 0.0018 mol). The mixture was stirred at 0ºC for 10 min, and then stirred for 
a further 3 h at room temperature. Purification by silica gel chromatography (0­50% 
ethyl acetate/hexane) gave 107 as a yellow oil (0.654 g, 70%); δH (500MHz, CDCl3): 
1.54 (4H, m, 2xCH2), 3.13 (4H, q, J 6.5, CH2NH), 4.62 (2H, s, CH2CCl3), 5.03 (1H, t, 
J 5.7, NH), 5.51 (1H, t, J 6.0, NH), 8.29 (1H, d, J 8.6, Ar), 8.49 (1H, dd, J 8.6, 2.5, 
Ar), 8.60 (1H, d, J 2.5, Ar); δC (125MHz, CDCl3): 21.11 (CH2), 26.92 (CH2), 40.41 
(CH2NH), 43.44 (CH2NH), 74.46 (CH2CCl3), 95.58 (CCl3), 120.85 (Ar­CH), 127.23 
(Ar­CH), 132.63, (Ar­CH), 139.12 (Ar­CSO2), 148.22 (Ar­CNO2), 149.86 (Ar­
CNO2), 154.75 (C=O). [Found: (ES
+) 492.9752 [M+H] +, C13H16Cl3N4O8S requires 
492.9749]. 
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[4­(2­Nitro­benzenesulfonylamino)­butyl]carbamic acid 2,2,2­trichloro­ethyl 
ester 
61 
[109] 
Cl 
Cl O2 H 
S N O 
N Cl 
H 
O 
NO2 
Preparation as for compound 107 on a 7.7mmol scale but using 2­nitro sulfonyl 
chloride, gave 109 (0.8g, 24%) as a yellow oil. δH (500MHz, CDCl3): 1.51­1.56 (4H, 
m, CH2CH2), 3.065 (2H, q, J 6.3, NHCH2), 3.16 (2H, q, J 6.3, NHCH2), 4.64 (2H, s, 
CH2CCl3), 7.66­7.70 (2H, m, Ar H­4, Ar H­5), 7.78­7.82 (1H, m, Ar­6), 8.05­8.09 
(1H, m, Ar­3). δC (67.5MHz, CDCl3): 21.38 (CH2), 26.87 (CH2), 40.62 (NH­CH2), 
43.37 (NH­CH2), 74.54 (CH2CCl3), 100.00 (CCl3), 125.56 (Ar­3), 131.20 (Ar­6), 
132.98 (Ar­5), 133.76 (Ar­4), 138.79 (Ar­SO2), 148.50 (Ar­ NO2), 154.74 (C=O); 
[Found: (ES+) 447.9894 [M+H]+, C13H17Cl3N3O6S requires 447.9898]. 
{4­[[3­(1,3­Dioxo­1,3­dihydro­isoindol­2­yl)­propyl­(2­nitro­benzenesulfonyl)­
63 
amino]­butyl}­carbamic acid 2,2,2­trichloro­ethyl ester [110] 
N 
O 
O 
N 
O2S 
H 
N O 
O 
Cl 
Cl 
Cl 
O2N 
A stirred solution of 109 (0.204 g, 0.4 mmol) in DMF (25 mL), was treated with 3­
bromopropyl phthalimide (0.11 g, 0.4 mmol) and potassium carbonate (0.167 g, 1.2 
mmol). The reaction mixture was heated at 50ºC overnight. The solvent was 
evaporated and the residue was taken up in ethyl acetate (25 mL) and washed 
sequentially with 10% citric acid (2 x 25 mL), saturated NaHCO3 (2 x 25 mL) and 
brine (2 x 25 mL). The organic layer was dried (MgSO4), and purified by silica gel 
chromatography (10­50% EtOAc/Hex) to give 110 (0.023 g, 9%), as a yellow oil. δH 
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(500MHz, CDCl3): 1.55­1.72 (4H, m, NCH2(CH2)2CH2N), 1.918 (2H, quintet, J 7.3, 
NCH2CH2CH2NH), 3.33­3.41 (4H, m, Ns­N(CH2)2), 3.70 (2H, t, J 7.4, Dde­NCH2), 
3.71 (2H, q, J 6.5, HNCH2), 4.70 (2H, s, CH2CCl3), 7.60­7.72 (3H, m, Ar­4,5,6(Ns)), 
7.72­7.74 (2H, m, Ar3,4(Phth)), 7.84­7.87 (2H, m, Ar2,6(Phth)), 7.97 (1H, dd, J 1.5, 
7.6, Ar­3(Ns)). δC (67.5MHz, CDCl3): 25.89 (NCH2CH2CH2N), 26.87 
(NCH2CH2CH2CH2N), 27.49 (NCH2CH2CH2CH2N), 35.54 (NCH2), 40.69 (NCH2), 
45.74 ((Ns)­NCH2), 47.77 ((Ns)­NCH2), 74.49 (CH2­CCl3), 123.48 ((Ns)­Ar3), 
124.32 ((Dde)­Ar­2), 130.81 ((Dde)­Ar­6), 131.79 ((Dde)­Ar­1), 132.02 ((Dde)­Ar­
3), 133.13 ((Ns)­Ar­4), 133.70 ((Ns)­Ar­5), 134.22 ((Ns)­Ar­1), 168.37 ((Dde)­C=O); 
[Found: (ES+) 657.0366 [M+Na]+, C24H25Cl3N4NaO8S requires 657.0351]. 
70 
2­(1­Hydroxy­ethylidene)­5,5­dimethyl­cyclohexane­1,3­dione [112] 
OH 
O O 
A solution of dimedone (6.0 g, 42.8 mmol), dicyclohexylcarbodiimide (8.83 g, 42.8 
mmol), acetic acid (2.56 g, 42.8 mmol), and dimethylaminopyridine (0.523 g, 42.8 
mmol) in DMF (70 ml) was stirred overnight at room temperature. The precipitate 
that formed was removed by filtration, and the filtrate was poured into water (100 
mL) and extracted with ethyl acetate (4x60 mL). The organic phase was dried 
(MgSO4) and evaporated to dryness. Purification by silica gel chromatography (0­5% 
MeOH/DCM) gave 112 as a yellow oil (7.88 g, 66%). δH (500MHz, CDCl3): 1.10 
(6H, s, C(CH3)2), 2.37 (2H, s, CH2), 2.54 (2H, s, CH2), 2.61 (3H, s, C=CCH3). δC 
(125MHz, CDCl3): 28.26 (C(CH3)2), 28.67 (C(CH3)2), 30.73 (C(CH3)2), 46.94 
(CH2), 52.52 (CH2), 112.41 (C=COH), 195.29 (C=O), 197.99 (COH), 202.57 (C=O). 
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2­[1­(3­Hydroxy­propylamino)­ethylidene]­5,5­dimethyl­cyclohexane­1,3­dione
[113] 
H 
N OH 
O O 
A stirred solution of 112 (2.00 g, 0.0109 mol) in ethanol (3 mL), was treated with 3­
amino propanol (0.816 g, 0.0109 mol). The mixture was heated at 80ºC under reflux 
for 30 min. The mixture was cooled, and the solvent was evaporated. Recrystallisation 
from ethyl acetate­hexane gave 113 as white crystals (2.103 g, 87%); mp: 106­108ºC; 
δH (270MHz, CDCl3): 0.98 (6H, s, C(CH3)2), 1.88 (2H, quintet, J 6.4, CH2CH2CH2), 
2.31 (4H, s, CH2­Dde), 2.52 (3H, s, C=CCH3), 3.09 (1H, br, NH), 3.53 (2H, q, J 6.4, 
CH2NH), 3.72 (2H, t, J 5.8, CH2OH), 13.63 (1H, br, OH). δC (67.5MHz, CDCl3): 
18.05 (C=CCH3), 28.33 (C(CH3)2), 30.20 (HNCH2CH2CH2OH), 31.63 (C(CH3)2), 
38.70 (CH2NH), 40.37 (CH2), 59.14 (CH2OH), 107.95 (C=CCH3), 173.88 (C=CCH3), 
198.10 (C=O). 
{4­[{3­[1­(4,4­Dimethyl­2,6­dioxo­cyclohexylidene)­ethylamino]­propyl}­(2,4­
dinitro­benzenesulfonyl)­amino]­butyl}­carbamic acid 2,2,2­trichloro­ethyl ester 
[116] 
O O 
H 
N N 
N 
H 
O 
O 
Cl 
Cl 
Cl 
SO2 
NO2O2N 
A suspension of 107 (1.150g, 2.32mmol), 7 (0.0556g, 2.32mmol), diethyl­
azodicarboxylate (0.405g, 2.32mmol), and polymer­supported triphenylphosphine 
(2.117 g, 2.32 mmol), in toluene (5 mL) was reacted at room temperature overnight. 
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The polymer­supported reagent was filtered off, and the filtrate was evaporated to 
dryness. Purification by silica gel chromatography (0­50% ethyl acetate/DCM) gave 
116 as a yellow oil (0.679 g, 41%); δH (500MHz, CDCl3): 1.05 (6H, s, C(CH3)2), 
1.55­1.61 (4H, m, 2xCH2), 1.68­1.74 (2H, m, CH2), 2.36 (2H, br, CH2), 2.44 (2H, br, 
CH2), 2.56 (3H, s, C=CCH3), 3.28 (2H, q, J 6.4, CH2NH), 3.39 (2H, t, J 6.4, CH2NH), 
3.43­3.52 (4H, m, 2xCH2NH), 4.73 (2H, s, CH2CCl3), 5.72 (NH), 8.33 (1H, d, J 8.6, 
Ar), 8.49 (1H, d, J 2.1, Ar), 8.53 (1H, dd, J 2.1, J 8.6, Ar), 13.45 (NH); δC (67.5MHz, 
CDCl3): 18.02 (CH3), 25.21 (CH2), 26.70 (CH2), 27.79 (CH2), 28.21 (CH3), 30.09 
(C(CH3)2), 40.29 (CH2NH), 40.34 (CH2NH), 44.93 (CH2NH), 47.58 (CH2NH), 61.40 
(CH2), 74.32 (CH2­CCl3), 95.68 (CCl3), 108.07 (C=CCH2), 119.78 (Ar), 126.30 (Ar), 
132.82 (Ar), 138.24 (Ar­SO2), 147.93 (Ar­NO2), 149.71 (Ar­NO2), 154.80 (C=O), 
173.93 (C=CCH2), 198.02 (C=O). 
(4­{3­[1­(4,4­Dimethyl­2,6­dioxo­cyclohexylidene)­ethylamino]­propylamino}­
butyl)­carbamic acid 2,2,2­trichloro­ethyl ester [117] 
O O 
H 
N 
H 
N 
N 
H 
O 
O 
Cl 
Cl 
Cl 
A stirred solution of 116 (0.64 g, 0.89 mmol) in DCM (10 mL), was treated with 
thioglycolic acid (0.13 mL, 1.8 mmol) and DIPEA (0.32 mL, 1.8 mmol). The reaction 
was stirred at room temperature for 3 h. The reaction mixture was diluted with DCM 
(15 mL) and washed with saturated NaHCO3 (2 x 25 mL) and brine (2 x 25 mL). The 
organic phase was dried (MgSO4) and evaporated to dryness to give 117 as a pale 
yellow oil (0.365 g, 84%). δH (500MHz, CDCl3): 1.03 (6H, s, C(CH3)2), 2.56 (3H, s, 
C=CCH3), 2.36 (4H, s, 2x CH2), 1.53­1.66 (4H, m, 2x CH2), 1.87 (2H, quintet, J 6.8, 
CH2), 2.66 (2H, t, J 6.7, CH2NH), 2.74 (2H, t, J 6.7, CH2NH), 3.24 (2H, q, J 5.9, 
CH2NH), 3.50 (2H, q, J 4.6, CH2NH), 4.72 (2H, s, CH2CCl3), 6.11 (1H, s, NH),13.43 
(1H, s, NH). δC (67.5MHz, CDCl3): 17.94 (C=CCH3), 27.19 (CH2), 27.54 (CH2), 
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28.28 (CH2), 29.30 (C(CH3)2), 30.12 (C(CH3)2), 41.12 (NHCH2), 41.34 (NHCH2), 
46.66 (NHCH2), 49.26  (NHCH2), 52.90 (CH2), 74.38 (CH2CCl3), 95.82 (CCl3), 
107.90 (C=CCH2), 154.70 (C=O), 173.55 (C=CCH3), 200.04 (C=O). [Found: (ES
+) 
484.1517 [M+H] +, C20H33Cl3N3O4 requires 484.1531]. 
{3­[1­(4,4­Dimethyl­2,6­dioxo­cyclohexylidene)­ethylamino]­propyl}­[4­(2,2,2­
trichloro­ethoxycarbonylamino)­butyl]­carbamic acid tert­butyl ester [68] 
O O 
H 
N N 
N 
H 
O 
O 
Cl 
Cl 
Cl 
O O 
A stirred solution of 116 (0.32 g, 0.66 mmol) in DCM (5 mL), was treated with Boc 
anhydride (0.144 g, 0.66 mmol), and the mixture was stirred at room temperature 
overnight. The reaction mixture was diluted with DCM (20 mL) and extracted with 
10% citric acid (2 x 25 mL), saturated NaHCO3 (2 x 25 mL), and brine (2x 25 mL). 
The organic phase was dried (MgSO4) and evaporated to dryness to give 68 (0.356 g, 
95%) as a yellow oil. δH (500MHz, CDCl3): 0.99 (6H, s, C(CH3)2), 1.36 (9H, s, 3x 
CH3­Boc), 1.43­1.46 (4H, m, 2x CH2),1.84 (2H, quintet, J 6.9, CH2), 2.29 (4H, s, 2x 
CH2), 2.48 (3H, s, C=CCH3), 3.14 (2H, br, CH2N), 3.18 (2H, q, J 6.4, CH2NH), 3.23 
(2H, t, J 6.8, CH2N), 3.34 (2H, q, J 6.5, CH2NH), 4.65 (2H, s, CH2CCl3), 5.73 (1H, 
br, NH),13.42 (1H, br, NH). δC (67.5MHz, CDCl3): 17.93 (C=CCH3), 25.17 (CH2), 
25.64 (CH2), 26.84 (C(CH3)2), 27.38 (CH2), 28.40 (CH3­Boc), 30.08 (C(CH3)2), 
40.65 (NHCH2), 41.05 (NHCH2), 44.40 (NHCH2), 46.54 (NHCH2), 53.38 (CH2), 
74.33 (CH2CCl3), 79.82 (C(CH3)3), 95.82 (CCl3), 107.89 (C=CCH2), 146.59 (C=O), 
155.46 (C=O), 173.61 (C=CCH3), 200.04 (C=O). [Found: (ES
+) 584.2059 [M+H]+, 
C25H41Cl3N3O6 requires 584.2055]. 
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(4­Amino­butyl)­{3­[1­(4,4­dimethyl­2,6­dioxo­cyclohexylidene)­ethylamino]­
propyl}­carbamic acid tert­butyl ester [118] 
O O 
H 
N N 
NH2 
O O 
A stirred solution of 68 (0.160 g, 2.739 mmol) in acetic acid (4.5 mL) and water (0.5 
mL), was treated with activated zinc dust (0.54 g, 8.217 mmol). The mixture was 
stirred at room temperature for 3 h. The insoluble materials were filtered off through 
celite. The filtrate was evaporated to dryness and the residue was dissolved in diethyl 
ether (10 mL). The solution was extracted with water (5 x 5 mL). The extracts were 
combined and evaporated to dryness to give 118 (0.060 g, 47%) as a colourless oil. δH 
(270MHz, CDCl3): 0.99 (6H, s, C(CH3)2), 1.40 (4H, s, minor CH3­Boc rotamer), 
1.41(5H, s, minor CH3­Boc rotamer), 1.55­1.72 (4H, m, CH2), 1.80­1.94 (2H, m, 
CH2), 2.32 (4H, s, 2x CH2­Dde), 2.52 (3H, s, C=CCH3), 3.10­3.32 (4H, m, 2x CH2­
N), 3.34­3.59 (4H, m, 2x CH2­N), 5.73 (2H, br, NH2), 13.46 (1H, br, NH). δC 
(67.5MHz, CDCl3): 18.05 (C=CCH3), 25.17 (CH2), 25.64 (CH2), 28.34 (C(CH3)2), 
28.49 (CH2), 30.08 (C(CH3)2), 30.19 (C(CH3)3), 43.11 (NCH2), 43.19 (NCH2), 44.44 
(NCH2), 44.48 (NCH2), 53.13 (2x CH2), 79.73 (C(CH3)3), 107.99 (C=CCH3), 173.644 
(C=CCH3). [Found: (ES
+) 410.3010 [M+H]+, C22H40N3O4 requires 410.3013]. 
4­Allyloxy­3­hydroxy­benzaldehyde [139] 
HO 
O 
O 
H 
A 100 mL flask was equipped with a stirrer, 3,4­Dihydroxy benzaldehyde (2.004 g,

0.0145 mol) and lithium carbonate (2.692 g, 0.0365 mol). The flask was placed under
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vacuum and flushed with argon three times. Anhydrous DMF (30 mL) was syringed 
in the reaction mixture, followed by freshly distilled dry allyl bromide (3.1 mL, 
0.0358 mol) and the reaction mixture was heated at 55ºC for 60 h. The solvent was 
then evaporated and the residue was taken up in ethyl acetate (40 mL) and washed 
sequentially with water (2 x 25 mL), 0.1M HCl (2 x 25 mL) and brine (2 x 25 mL). 
The organic layer was dried (MgSO4), and evaporated to dryness. The residue was 
purified by silica gel chromatography (5%­25% AcOEt/Hexane) to give 139 (1.02 g, 
40%) as a white solid; mp: 57­59ºC; δH (500MHz, CDCl3): 4.67 (2H, dt, J5.5, 1.4, 
ArOCH2), 5.31­5.46 (2H, m, C=CH2), 5.95­6.11 (1H, m, HC=CH2), 6.93 (1H, d, J8.2, 
Ar­2), 7.35 (1H, d, J2.0, Ar­5), 7.37 (1H, dd, J8.2, 2.0, Ar­6), 9.80 (1H, s, CHO). δC 
(67.5MHz, CDCl3): 70.12 (CH2HC=CH2), 111.44 (HC=CH2), 114.40 (Ar­5), 119.43 
(Ar­2), 124.46 (Ar­6), 130.79 (Ar­1), 131.86 (HC=CH2), 146.30 (Ar­3), 150.79 (Ar­
4), 191.17 (CHO). [Found: (ES+) 179.0699 [M+H]+, C10H11O3 requires 179.0703]. 
4­Allyloxy­3­triisopropylsilanyloxy­benzaldehyde [140] 
O 
H 
O 
O 
Si 
A stirred solution of 139 (1.037 g, 8.5 mmol) in DCM (15 mL), was treated 
sequentially with imidazole (0.02 g, 0.293 mmol), triethylamine (1.1 mL, 7.02 mmol) 
and triisopropyl silyl chloride (1.128 g, 5.85 mmol). The mixture was stirred under 
argon overnight, and then the reaction was quenched with water (15 mL). The organic 
layer was separated and washed with 0.1M NaOH (15 mL) and brine (15 mL). The 
organic phase was dried (MgSO4) and evaporated to dryness to give 140 (1.793 g, 
90%) as a dark red oil. δH (270MHz, CDCl3): 1.03 (18H, d, J 8.4, 6xCH3(TIPS)), 
1.18­1.43 (3H, m, 3xCHCH3), 4.59 (2H, dt, J 5.5, 1.4, ArOCH2), 5.28 (1H, m, 
HC=CH2), 5.40 (1H, m, HC=CH2), 5.96­6.13 (1H, m, HC=CH2), 6.90 (1H, d, J 8.2, 
Ar­2), 7.36 (1H, d, J 1.98, Ar­6), 7.41 (1H,dd, J 8.2, 2.0, Ar­5), 9.78 (1H, s, CHO). 
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δC (67.5MHz, CDCl3): 12.87 (CH3), 17.98 (CH2(CH3)2), 69.58 (CH2CH=CH2), 
112.41 (CH2CH=CH2), 118.46 (Ar­5), 119.40 (Ar­2), 126.11 (Ar­6), 130.18 (Ar­1), 
132.54 (CH=CH2), 146.24 (Ar­3), 155.66 (Ar­4), 191.05 (CHO). [Found: (ES
+) 
357.1840 [M+Na]+, C19H30NaO3Si requires 357.1856]. 
(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acrylic acid [66]

O 
O 
Si 
O 
OH 
Method A: A stirred solution of 140 (4.84 g, 14.5 mmol) in pyridine (20 mL), was 
treated with malonic acid (1.51 g, 14.5 mmol) and piperidine (0.5 mL). The reaction 
mixture was heated 50ºC for 4 h, then the solvent was evaporated and the residue was 
re­dissolved in EtOAc (40 mL). The organic layer was washed with 5% citric acid (40 
mL), water (40 mL) and brine (40 mL). The organic phase was dried (MgSO4) and 
evaporated to dryness. Purification via silica gel column chromatography 10%­50% 
EtOAc/Hex gave 66 (2.99 g, 55%) as a white solid along with the diacid 141 (620 mg, 
10%). 
Method B: A stirred solution of 140 (1.63 g, 4.9 mmol) in pyridine (15 mL), was 
treated with malonic acid (0.51 g, 4.9 mmol) and piperidine (0.1 mL). The reaction 
mixture was heated 150ºC for 4 hours, then the solvent was evaporated and the 
residue re­dissolved in EtOAc (30 mL). The organic layer was washed with 5% citric 
acid (30 mL), water (30 mL) and brine (30 mL). The organic phase was dried 
(MgSO4) and evaporated to dryness. Purification via silica gel column 
chromatography 10%­50% EtOAc/Hex gave desired product 66 (0.44 g, 25%) as a 
white solid along with deprotected material 142 (0.16 g, 15%). 
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Method C: A stirred solution of 141 (370 mg, 0.88 mmol) in toluene (7 mL) was 
heated under reflux (125ºC) for 48 h. The solvent was evaporated to dryness and the 
residue was purified via silica gel column chromatography 0%­50% EtOAc/Hex to 
give 66 (170 mg, 52%). 
mp: 95­99ºC; δH (270MHz, CDCl3): 0.65(18H, d, J 7.8, 3xCH3), 0.73­0.93(3H, m, 
3xCHCH3), 4.50(2H, d, J 6.01, ArOCH2), 5.26­5.49 (2H, m, CH=CH2), 6.09­6.24(1H, 
m, CH=CH2), 6.38(1H, d, J 17.6, ArCH=CH), 7.02(1H, d, J 9.8, Ar­2), 7.28­7.32(2H, 
m, Ar­5,6), 7.96(1H, d, J 17.6, ArCH=CHCOOH). δC (67.5MHz, CDCl3): 12.91 
(CH(CH3)2), 18.01 (CH(CH3)2), 69.56 (CH2), 113.21 (Ar­5), 114.44 (Ar­2), 116.22 
(HC=CH2), 119.59 (HC=CHCOOH), 123.17 (Ar­6), 127.13 (Ar­1), 132.20 
(HC=CH2), 138.80 (Ar­3), 146.01 (HC=CHCOOH), 152.58 (Ar­4), 172.33 (C=O). 
[Found: (ES+) 377.2153 [M+H]+, C21H33O4Si requires 377.2143 ]. 
2­(4­Allyloxy­3­triisopropylsilanyloxy­benzylidene)­malonic acid [141] 
O 
O 
Si 
COOH 
HOOC 
δH (400MHz, CDCl3): 1.09 (18H, d, J 7.6, 6x CH3), 1.21­1.32 (3H, m, 3xCH(CH3)2), 
4.57 (2H, d, J 5.2, OCH2), 5.35­5.46 (2H, m, CH=CH2), 5.90­6.09(1H, m, CH=CH2), 
6.86 (1H, d, J 8.8, ArCH=C), 7.21­7.24 (2H, m, Ar­5,6), 7.86 (1H, s, Ar­2). δC 
(100MHz, CDCl3): 13.02 (3xCH(CH3)2), 18.12 (3xCH(CH3)2, 69.34 (OCH2), 112.89 
(Ar), 118.15 (HC=CH2), 120.07 (C(COOH)2), 121.83 (Ar), 124.78 (Ar­HC=C), 
126.03 (Ar), 132.54 (CH=CH2), 145.72 (Ar­HC=C), 146.78 (Ar­O), 153.37 (Ar­O), 
170.18 (COOH), 172.19 (COOH). [Found: (ES+) 421.2037 [M+H]+, C22H33O6Si 
requires 421.2041]. 
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(E)­3­(4­Allyloxy­3­hydroxy­phenyl)­acrylic acid [142]

HO O 
O OH 
mp: 176­178ºC; δH (270MHz, DMSO): 4.56 (2H, dt, J 5.7, 1.6, ArOCH2), 5.24­5.52 
(2H, m, CH=CH2), 6.08­6.24 (1H, m, CH=CH2), 6.37 (1H, d, J 17.6, ArCH=CH), 
7.14 (1H, d, J 9.0, Ar­2), 7.26­7.33 (2H, m, Ar­5,6), 7.71 (1H, d, J 17.6, 
ArCH=CHCOOH), 9.54 (1H, br, Ar­OH). δC (100MHz, DMSO): 68.90 (CH2­O), 
113.52 (Ar­2), 114.40 (ArCH=CH), 116.36 (Ar­5), 117.61 (CH=CH2), 120.85 (Ar­6), 
127.26 (Ar­1), 133.66 (CH=CH2), 144.17 (Ar­3), 146.90 (ArCH=CH), 148.64 (Ar­4), 
167.81 (COOH); [Found: (ES+) 221.812 [M+H]+, C12H13O4 requires 221.0808 ]. 
(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acrylic acid pentafluoro­
phenyl ester [143] 
O 
O 
O 
O 
F F 
F 
FF 
Si 
A stirred solution of 66 (1.5 g, 4 mmol) in DCM (15 mL) under argon, was treated 
sequentially with 4­dimethylaminopyridine (50 mg, 4 mmol), pentafluorophenol (75 
mg, 4 mmol) and 1­(3­dimethylaminopropyl)­3­ethylcarbodiimide hydrochloride (78 
mg, 4 mmol). The reaction mixture was allowed to stir overnight at room temperature. 
The reaction mixture was then diluted with DCM (10 mL) and was washed with 5% 
NaHCO3 (2 x 25 mL) and brine (25 mL). The organic phase was dried (MgSO4), 
evaporated to dryness and purified by silica gel chromatography (DCM) to give 143 
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(1.7g, 80%) as a yellow oil. δH (270MHz, CDCl3): 1.02 (18H, d, J 7.8, 3xCH3), 1.20­
1.31 (3H, m, 3xCHCH3), 4.50 (2H, d, J 6.01, ArOCH2), 5.26­5.49 (2H, m, CH=CH2), 
6.09­6.24(1H, m, CH=CH2), 6.36 (1H, d, J 17.6, ArCH=CH), 6.82 (1H, d, J 9.8, Ar­
2), 7.28­7.32 (2H, m, Ar­5,6), 7.86 (1H, d, J 17.6, ArCH). [Found: (ES+) 543.1988 
[M+H]+, C27H32F5O4Si requires 543.1985]. 
(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acrylic acid succinimido ester 
[145] 
O 
TIPSO 
O 
O 
N 
O 
O 
A stirred solution of 66 (0.21 g, 0.56 mmol) and N­hydroxysuccinimide (0.065 g, 
0.056 mmol) in THF (5 mL), was cooled to 0ºC and then treated with N,N`­
dicyclohexylcarbodiimide (0.116 g, 0.056 mmol). The reaction mixture was allowed 
to attain to room temperature overnight. The precipitate that formed was removed by 
filtration, and the filtrate was evaporated to dryness. The residue was re­dissolved in 
EtOAc (15 mL), then filtered and the filtrate was washed sequentially with 5% 
NaHCO3 (15 mL), 5% citric acid (15 mL) and brine (15 mL). The organic phase was 
dried (MgSO4) and evaporated to dryness to give 145 as a yellow oil (0.119g, 43%). 
δH (270MHz, CDCl3): 1.08 (18H, d, J 6.9, 3xCH3), 1.19­1.33 (3H, m, 3xCHCH3), 
2.87 (4H, s, 2xCH2), 4.56 (2H, d, J 5.5, ArOCH2), 5.25­5.45 (2H, m, CH=CH2), 5.97­
6.11 (1H, m, CH=CH2), 6.35 (1H, d, J 16.0, ArCH=CH), 6.83 (1H, d, J 7.4, Ar­2), 
7.07­7.13 (2H, m, Ar­5,6), 7.79 (1H, d, J 16.0, ArCH=CH). δC (67.5MHz, CDCl3): 
12.89 (CH(CH3)3), 18.01 (CH3), 25.65 (CH2), 69.54 (OCH2), 108.54 (Ar), 113.08 
(Ar), 118.28 (C=CH2), 119.54(Ar), 124.01 (ArCH=CH), 126.56 (Ar), 132.80 
(CH=CH2), 146.08 (Ar­O), 150.26 (ArCH=CH), 153.42 (Ar­O), 162.45 (OC=O), 
169.63 (NC=O). [Found: (ES+) 496.2122 [M+Na]+, C25H35NlO6SiNa requires 
496.2126]. 
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(E)­tert­butyl 4­(3­(4­(allyloxy)­3­(triisopropylsilyloxy)phenyl)acrylamido)butyl 
(3­(1­(4,4­dimethyl­2,6­dioxocyclohexylidene)ethylamino)propyl) carbamate 
[147] 
O O 
H 
N N 
N 
H 
O O 
O 
O 
O 
Si 
A stirred solution of 118 (60 mg, 12.78 mmol) in dry DCM (5 mL) under argon, was 
treated with 143 (94 mg, 17.36 mmol), followed by DIPEA (46 �L, 25 mmol) and 
DIMAP (1.56 mg, 1.27 mmol). The mixture was stirred overnight at room 
temperature. The reaction mixture was then quenched with 5% citric acid (20 mL), 
and was extracted with DCM (20 mL) and washed with 5% NaCO3 (20 mL), water 
(20 mL) and brine (20 mL). The organic phase was dried, concentrated in vacuo and 
purified by silica gel chromatography (0­5% methanol/ DCM), to give 147 (57 mg, 
59%) as a yellow oil. δH (270MHz, CDCl3): 0.95 (6H, s, C(CH3)2), 1.02 (18H, d, J 
7.4, Si(CH)3(CH3)3), 1.15­1.25 (3H, m, Si(CH)3(CH3)3), 1.37 (9H, s, C(CH3)3), 1.47­
1.58 (4H, m, 2xCH2­Dde), 1.77­1.88 (2H, m, NCH2CH2CH2N), 2.25­2.32 (4H, m, 
NCH2(CH2)2CH2N), 2.49 (3H, s, C=CCH3), 3.11­3.26 (4H, m, NCH2), 3.33 (4H, q, J 
5.5, NCH2), 4.47 (2H, d, J5.5, CH2CH=CH2), 5.27 (2H, dd, J 1.2, 10.5, 
CH2CH=CH2), 5.89 (1H, br, NH),  5.93­6.03 (1H, m, CH2CH=CH2), 6.14 (1H, d, 
J15.6, ArCH=CH), 6.73 (1H, d, J 8.9, Ar­2), 6.95­6.98 (2H, m, Ar­5,6), 7.42 (1H, d, J 
15.6, ArCH=CH), 13.50 (1H, br, NH). δC (100MHz, CDCl3): 12.78 (C=CCH3), 
13.07 (CH(CH3)2), 17.90 (CH3­TIPS), 25.93 (CH2). 28.21 (CH3­Boc), 28.36 (CH2), 
28.40(CH2), 30.07 (CH3­Dde), 30.93 (C(CH3)2), 39.14 (CH2N), 43.02 (CH2N), 44.38 
(CH2N), 46.36 (CH2N), 52.35 (CH2), 69.48 (OCH2), 80.01 (C­Boc), 107.88 (Ar), 
113.26 (Ar), 113.29 (C=CCH3), 117.82 (CH=CH2), 119.35 (CH=CH), 121.66 (Ar), 
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128.04 (Ar), 133.08 (CH=CH2), 140.89 (Ar), 145.72 (CH=CH), 152.57 (Ar), 155.12 
(C=O), 166.38 (NC=O), 173.55 (C=CCH3), 192.31 (C=O). 
(3­Amino­propyl)­{4­[(E)­3­(2­triisopropylsilanyloxy­4­vinyloxy­phenyl)­
acryloylamino]­butyl}­carbamic acid tert­butyl ester [148] 
A solution of 147 (57 mg, 0.0758 �mol), in 2% hydrazine/ DMF (1 mL) was treated 
with allyl alcohol (1 mL, 0.152 mol). The reaction was stirred at room temperature for 
5 minutes. The solvent was removed under vacuo and the mixture was purified by 
silica gel chromatography (1:5:44, NH3: MeOH : DCM) to give 148 (37 mg, 86%) as 
a yellow oil. δH (500MHz, CDCl3): 1.04 (18H, t, J 7.5, 3xCH(CH3)2), 1.15­1.31 
(3H, m, 3xCH(CH3)2), 1.38 (9H, s, C(CH3)3), 1.42­1.54 (4H, m, NCH2(CH2)2CH2N), 
1.58­1.66 (2H, m, NCH2CH2CH2N), 2.63 (2H, br, NH2), 3.08­3.24 (4H, m, 
NCH2(CH2)2CH2N), 3.29­3.36 (4H, m, H2NCH2CH2CH2N), 4.47 (2H, d, J 5.5, 
CH2CH=CH2), 5.20 (1H, dd, J 10.5, 1.5, CH2CH=CH2) 5.32 (1H, dd, J 17.2, 1.5, 
CH2CH=CH2), 5.94­6.03 (1H, m, CH2CH=CH2), 6.07­6.18 (1H, m, ArCH=CH), 6.74 
(1H, d, J9.0, Ar­2), 6.96­6.99 (2H, m, Ar­5,6), 7.42 (1H, d, J 15.5, ArCH=CH), 8.89 
(1h, br, NH); δC (100MHz, DMSO): 12.10 (CH­TIPS), 17.89 (CH3­TIPS), 25.60 
(CH2), 25.81 (CH2), 26.63 (CH2), 28.09 (CH3­Boc), 38.35 (NCH2), 38.89 (NCH2), 
40.15 (NCH2), 40.60 (NCH2), 68.94 (OCH2), 79.22 (C(CH3)3), 113.71 (Ar), 117.55 
(CH=CH2), 119.72 (CH=CH), 128.07 (Ar), 133.79 (CH=CH2), 138.57 (Ar), 146.95 
(HC=CH), 147.91 (Ar), 155.01 (C=O), 155.12 (Ar), 165.49 (C=O (Boc)); [Found: 
(ES+) 604.4146 [M+H]+, C33H58N3O5Si requires 604.4145]. 
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(E)­3­(4­Fluoro­3­nitro­phenyl)­acrylic acid tert­butyl ester [135]

F 
O2N O 
O 
A stirred solution of 1­fluoro­4­bromo­2­nitrobenzene (3.0 g, 0.014 mol) in 
anhydrous DMF (30 mL) under argon, was sequentially treated with palladium acetate 
(31 mg, 0.0136 mol), triphenyl phosphine (0.170 g, 0.0648 mol), tert­butyl acrylate 
(2.15 mL, 0.015 mol) and DIPEA (2.3 mL, 0.0136 mol). The reaction mixture was 
heated at 100ºC under reflux, and stirred overnight. The solvent was evaporated and 
the residue was redissolved in ethyl acetate and then washed with water (2 x 30 mL), 
and brine (2 x 30 mL). Purification by silica gel chromatography (5% EtOAc/ hexane) 
gave 135 (1.8g, 48%) as a red­orange solid; mp: 69­71ºC; δH (270MHz, CDCl3): 
1.57 (9H, s, C(CH3)3), 6.43 (1H, d, J 15.9, ArCH=CH), 7.28­7.38 (1H, m, Ar­6), 7.56 
(1H, d, J 15.9, ArCH=CH), 7.72­7.78 (1H, m, Ar­2), 8.23 (1H, d, J 6.9, Ar­5). δC 
(67.5MHz, CDCl3): 28.20 (CH3), 81.40 (C(CH3)3), 114.76 (HC=CHCOO
tBu), 119.06 
(Ar­5), 123.35 (Ar­2), 132.04 (Ar­1), 134.51 (Ar­6), 139.55 (Ar­3), 154.00 
(HC=CHCOOtBu), 157.96 (Ar­4), 165.38 (C=O); [Found: (ES+) 290.0800 [M+Na]+, 
C13H14FNNaO4 requires 290.0799]. 
(E)­3­(4­Fluoro­3­nitro­phenyl)­acrylic acid [65] 
O2N O 
F OH 
A stirred solution of 135 (1.7 g, 6.4 mmol) in DCM (14 mL), was treated with 
trifluoro acetic acid (14.7 mL, 0.19 mol). After 1h the solvent was evaporated and the 
residue co­evaporated several times with diethyl ether. Purification by crystallisation 
from EtOAc/ hexane gave 65 (1.05 g, 78%) as a yellow solid; mp: 215­217ºC; δH 
(270MHz, DMSO): 6.69 (1H, d, J 16.1, ArCH=CH), 7.62­7.70 (2H, m, Ar­5,6), 
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8.17­8.21 (1H, m, Ar­2), 8.50 (1H, d, J 16.4, ArCH=CH). δC (67.5MHz, DMSO): 
119.82 (HC=CHCOOH), 122.57 (Ar­5), 126.39 (Ar­2), 132.45 (Ar­1), 135.96 (Ar­6), 
141.20 (Ar­3), 153.68 (HC=CHCOOH), 154.38 (Ar­4), 167.74 (COOH); [Found: 
(ES+) 212.0353 [M+H]+, C9H7FNO4 requires 212.0354]. 
(E)­3­(4­Fluoro­3­nitro­phenyl)­acrylic acid pentafluorophenyl ester [144]

F 
O2N O 
O 
F F 
F 
FF 
A stirred solution of 65 (0.542 g, 2.57 mmol), in dry DCM (10 mL) under argon, was 
treated sequentially with DMAP (0.032 g, 0.257 mmol), pentafluorophenol (0.473 g, 
2.57 mmol), and 1­(3­dimethylaminopropyl)­3­ethylcarbodiimide hydrochloride 
(0.398 g, 2.57 mmol). The reaction mixture was allowed to stir overnight at room 
temperature. The reaction mixture was then diluted with DCM (10 mL) and was 
washed with 5% NaHCO3 (2 x 15 mL) and brine (15 mL). The organic phase was 
dried (MgSO4), evaporated to dryness and purified by silica gel chromatography 
(DCM) to give 144 (0.831 g, 86%) as a red oil. 
(E)­3­(4­Fluoro­3­nitro­phenyl)­acrylic acid 2,5­dioxo­pyrrolidin­1­yl ester [146] 
O2N O O 
F O N 
O 
A strirred solution of 65 (140 mg, 0.66 mmol) in DMF (5 mL) at 0°C, was treated

sequentially with DMAP (8 mg, 0.066 mmol), N­hydroxy succinimide (76 mg,

0.66mmol) and 1­(3­dimethylaminopropyl)­3­ethylcarbodiimide hydrochloride (127
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mg, 0.66 mmol). The reaction mixture was stirred overnight at room temperature. The 
solvent was removed in vacuo and the residue was redissolved in DCM (10 mL) and 
washed sequentially with 10% citric acid (10 mL), sat. NaHCO3 (10 mL), water (10 
mL) and brine (10 mL). The organic phase was dried (MgSO4) and evaporated to 
dryness to give 146 (125 mg, 61%) as an orange oil. δH (270MHz, DMSO): 2.51 
(4H, s, 2x CH2), 7.23 (1H, d, J 15.9, ArCH=CH), 7.78­7.88 (1H, m, Ar­6), 8.12 (1H, 
d, J 15.9, ArCH=CH), 8.31­8.39 (1H, m, Ar­2), 8.73 (1H, d, J 6.9, Ar­5). δC 
(67.5MHz, DMSO): 25.55 (2x CH2), 114.66 (HC=CH), 119.06 (Ar), 119.48 (Ar), 
127.08 (Ar), 136.27 (Ar), 136.37 (Ar), 146.62 (HC=CH), 154.62 (Ar), 162.06 (2x 
C=O), 170.37 (C=O). 
77 
4­(Tetrahydro­pyrimidin­1­yl)­butylamine [128] 
HN N 
NH2 
A solution of spermidine (2.08 g, 14.3 mmol) in distilled water (50 mL) was cooled to 
5ºC and stirred under nitrogen. Aqueous formaldehyde (0.4 g, 13.0 mmol) was then 
slowly added. The reaction mixture was stirred for 2 h allowing to reach room 
temperature. The aqueous layer was then saturated with solid NaCl and extracted with 
chloroform (6x 50 mL). The combined chloroform extracts were dried (MgSO4) and 
concentrated to dryness to give 128 (2.07g, 92%) as a clear oil. δH (400MHz, 
CDCl3): 1.40­1.50 (4H, m, 2xCH2,), 1.54­1.62 (2H, m, CH2), 1.63­1.70 (3H, br, NH2, 
NH), 2.22 (2H, t, J 7.2, NCH2), 2.50­2.56 (2H, m, NCH2), 2.67 (2H, t, J 6.6, NCH2), 
2.78 (2H, t, J 5.6, NCH2), 3.35 (2H, s, NCH2N). δC (100MHz, CDCl3): 24.27 (CH2), 
27.13 (CH2), 31.77 (CH2), 42.00 (NCH2), 45.17 (NCH2), 53.08 (NCH2), 55.38 
(NCH2), 69.93 (NCH2N). 
123 
(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­N­[4­(tetrahydro­pyrimidin­1­

yl)­butyl]­acrylamide [149]

HN N 
H 
N 
O 
O 
OTIPS 
A stirred solution of 128 (190 mg, 1.2 mmol) in DCM (10 mL), was treated 
sequentially with DIPEA (0.21 mL, 1.2 mmol) and 145 (550 mg, 1.2 mmol). The 
reaction mixture was stirred for 3 h at 0ºC. The solvent was removed in vacuo. 
Purification by silica gel chromatography (0%­10% MeOH/DCM, then 1:9:90 NH3 
(aq): MeOH: DCM) gave 149 as a yellow oil (255 mg, 40%). δH (270MHz, CDCl3): 
1.05 (18H, d, J 7.1, 3xCH3), 1.11­1.31 (3H, m, 3xCHCH3), 1.45­1.7 (6H, m, 3XCH2), 
2.15­2.32 (2H, m, NCH2), 2.49­2.62 (2H, m, NCH2), 2.74­2.85 (2H, m, CH2), 3.23­
3.45 (4H, m, 2xNCH2), 4.41­4.54 (2H, m, ArOCH2), 5.18­5.4 (2H, m, CH=CH2), 
5.92­6.80 (1H, m, CH=CH2), 6.22 (1H, d, J 15.7, ArCH=CH), 6.40­6.57 (1H, m, NH), 
6.68­6.80 (1H, m, Ar­2), 6.92­7.04 (2H, m, Ar­5,6), 7.45 (1H, d, J 15.7, ArCH=CH). 
δC (67.5MHz, CDCl3): 12.89 (CH(CH3)3), 18.02 (CH3), 24.29 (CH2), 26.81 (CH2), 
27.61 (CH2), 39.51 (HNCH2), 45.08 (HNCH2), 53.05 (NCH2), 54.86 (NCH2), 69.55 
(HNCH2N), 69.82 (OCH2), 113.33 (Ar), 117.94 (CH=CH2), 118.64 (Ar), 119.49 (Ar), 
121.85 (ArCH=CH)), 128.04 (ArCH=CH), 133.18 (OCH2CH=CH2), 140.53 (Ar­O), 
145.81 (ArCH=CH), 151.43 (ArO), 166.39 (C=O). [Found: (ES+) 516.3610 [M+H] +, 
C29H50N3O3Si requires 516.3616]. 
124 
(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­N­[4­(3­amino­propylamino)­
butyl]­acrylamide [150] 
H2N N 
H 
H 
N 
O 
O 
O 
Si 
A solution of 149 (250 mg, 0.5 mmol) in absolute ethanol (8 mL), was treated with 
ethyl hydrogen malonate (321 mg, 2.5 mmol), and pyridine (0.157 mL, 2 mmol). The 
reaction mixture was stirred at 50ºC for 2.5 hours. The solvent was then removed in 
vacuo and the residue was dissolved in saturated NaHCO3 (5 mL), and extracted with 
DCM (9x 5 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to give 150 (192 mg, 79%) as a pale yellow oil. δH (270MHz, 
CDCl3): 1.06 (18H, d, J 7.1, 3xCH3), 1.17­1.30 (3H, m, 3x CHCH3), 1.47­1.73 (6H, 
m, CH2), 2.35­2.85 (8H, m, HNCH2) 3.22­3.45 (2H, m, NH2), 4.51 (2H, d, J 4.6, 
ArOCH2), 5.22­5.40 (2H, m, CH=CH2), 5.95­6.09 (1H, m, CHCH2), 6.18 (1H, d, J 
15.7, ArCH=CH), 6.72­6.80 (1H, m, Ar­2), 6.92­7.11 (2H, m, Ar­5,6), 7.46 (1H, d, J 
15.7, ArCH=CH). δC (100MHz, CDCl3): 167.01 (C=O), 151.30 (Ar­O), 145.72 
(ArCH=CH), 140.36 (Ar­O), 133.11 (CH=CH2), 127.99 (Ar), 121.57 (ArCH=CH), 
119.56 (Ar), 118.66 (Ar),  117.79 (CH=CH2), 113.31 (Ar), 69.48 (OCH2), 48.97 
(HNCH2), 48.58 (HNCH2), 39.29 (HNCH2), 38.65 (HNCH2), 29.67 (CH2), 27.14 
(2xCH2), 17.90 (C(CH3)3), 12.79 (C(CH3)3). [Found: (ES
+) 504.3618 [M+H]+, 
C28H50N3O3Si requires 504.3616]. 
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(E)­N­(3­{4­[(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acryloylamino]­
butylamino}­propyl)­3­(4­fluoro­3­nitro­phenyl)­acrylamide [151] 
H 
N 
H 
N 
N 
H 
O 
O 
F 
O2N 
O 
O 
Si 
A stirred solution of 150 (50 mg, 0.1 mmol) in DCM (2 mL), was treated with 146 (31 
mg, 0.1 mmol) in the presence of DIPEA (9 �L, 0.1 mmol). The reaction mixture was 
stirred at 0ºC for 2 h. At this stage no reaction had taken place; the pH of the reaction 
mixture was found to be 7, therefore another equivalent of DIPEA (9 �L, 0.1 mmol) 
was added to ensure that the pH of the reaction mixture was 9. The reaction mixture 
was stirred for a further 1 hour, then it was evaporated to dryness and the residue 
purified by silica gel chromatography (0%­10% MeOH/DCM, then 1:9:90 NH3 (aq): 
MeOH: DCM) to give 151 as a yellow oil (18 mg, 26%). δH (400MHz, CDCl3): 1.06 
(18H, d, J 7.2, 6xCH3), 1.21­1.35 (3H, m, 3xCH(CH3)2), 1.52 (1H, br, NH), 1.62­1.65 
(4H, m, 2xCH2), 1.77­1.80 (2H, m, CH2), 2.68­2.79 (4H, m, 2xHNCH2), 3.09 (1H, br, 
NH), 3.28 (1H, br, NH), 3.36­3.50 (4H, m, 2xHNCH2), 4.51 (2H, d, J 5.2, OCH2), 
5.24­5.40 (2H, m, HC=CH2), 5.99­6.06 (1H, m, HC=CH2), 6.20 (1H, d, J 15.2, 
ArCH=CH), 6.47(1H, d, J 15.6, ArCH=CH), 6.76 (1H, d, J 9.2, Ar­2), 6.96­6.99 (2H, 
m, Ar­5,6), 7.17­7.25 (1H, m, Ar­5), 7.44 (1H, d, J 15.2, ArCH=CH), 7.53 (1H, d, J 
15.6, ArCH=CH), 7.67­7.70 (1H, m, Ar­6), 8.14 (1H, dd, J 2.0, 6.8, Ar­2). δC 
(100MHz, CDCl3): 12.79 (3xCH(CH3)2), 17.90 (6xCH3), 26.58 (CH2), 27.32 (CH2), 
28.16 (CH2), 38.79 (NCH2), 39.28 (NCH2), 47.80 (NCH2), 48.88 (NCH2), 69.47 
(OCH2), 113.22 (Ar), 117.88 (Ar­CH=CH), 118.21 (C=CH2), 119.34 (Ar­CH=CH), 
121.83 (Ar), 124.05 (Ar), 124.48 (Ar), 127.70 (Ar), 128.52 (Ar), 133.03 (HC=CH2), 
134.69 (Ar), 136.59 (Ar), 140.78 (Ar­CH=CH), 145.58 (Ar), 151.50 (Ar), 154.04 
(Ar), 158.25 (Ar), 166.52 (C=O), 167.81 (C=O). [Found: (ES+) 697.3798 [M+H]+, 
C37H54FN4O6Si requires 697.3791]. 
126

60 
[4­(Tetrahydro­pyrimidin­1­yl)­butyl]­carbamic acid tert­butyl ester [129] 
HN N 
H 
N 
O 
O 
A stirred solution of 128 (1.53 g, 9.7 mmol) in absolute ethanol (12 mL), was treated 
with tert­butyl phenylcarbonate (2.09 g, 10.7 mmol). The reaction mixture was stirred 
under reflux overnight, followed by removal of volatiles under vacuum. Purification 
by siliga gel column chromatography with 0­10% MeOH/DCM, then 0.1: 1: 9 NH3 
(aq): MeOH: DCM, gave 129 (1.3 g, 55%) as a yellow oil and the di­acylated side 
product [129b] (10%). δH (270MHz, CDCl3): 1.38 (9H, s, 3xCH3), 1.45­1.51 (4H, m, 
2xCH2), 1.54­1.62 (2H, m, CH2), 2.19 (2H, t, J 6.75, NCH2), 2.46­2.57 (2H, m, 
NCH2), 2.76 (2H, t, J 5.5, NCH2), 3.02­3.06 (2H, m, NCH2), 3.33 (2H, s, NCH2). δC 
(100MHz, CDCl3): 23.09 (CH2), 24.52 (CH2), 27.04 (CH2), 28.50 (C(CH3)3), 45.19 
(NCH2), 53.14 (NCH2), 54.83 (NCH2), 55.29 (NCH2), 69.29 (HNCH2N), 78.80 
(C(CH3)3), 156.05 (C=O). 
3­(4­tert­Butoxycarbonylamino­butyl)­tetrahydro­pyrimidine­1­carboxylic acid 
tert­butyl ester [129b] 
N N 
H 
N 
O 
O 
O 
O 
δH (400MHz, CDCl3): 1.44 (18H, t, J 2.0, 2xC(CH3)3), 1.48­1.55 (4H, m, 2xCH2), 
1.58­1.62 (2H, m, CH2), 2.41 (2H, d, J 6.8, NCH2), 2.61­2.78 (2H, m, NCH2), 3.09­
3.15 (2H, m, NCH2), 3.38 (2H, s, NCH2), 4.07 (2H, s, NCH2), 4.94 (1H, br, NH). δC 
(100MHz, CDCl3): 22.26 (CH2), 24.64 (CH2), 28.09 (CH2), 28.69 (2x CH3), 52.10 
(NCH2), 52.74 (NCH2), 53.93 (NCH2), 58.11 (NCH2), 74.11 (NCH2), 79.72 (2x 
C(CH3)), 156.02 (C=O), 157.90 (C=O). [Found: (ES
+) 358.2683 [M+H]+, 
C18H36N3O4 requires 358.2700]. 
127 
[4­(3­Amino­propylamino)­butyl]­carbamic acid tert­butyl ester [130]

H2N N 
H 
H 
N O 
O 
A stirred solution of 129 (4.15 g, 16 mmol), in absolute ethanol (80 mL), was treated 
with ethylhydrogen malonate (9.52 mL, 80 mmol), and pyridine (5.2 mL, 54 mmol). 
The reaction mixture was stirred for 2.5 h under reflux. The solvent was removed in 
vacuo and the residue 130 was used without further purification in the next step. 
(4­{3­[1­(4,4­Dimethyl­2,6­dioxo­cyclohexylidene)­ethylamino]­propylamino}­
butyl)­carbamic acid tert­butyl ester [131] 
N 
H 
N 
H 
H 
N O 
O 
OO 
A stirred solution of crude 130 (3.93 g crude, 16 mmol) in absolute ethanol (20 mL), 
was treated with 112 (2.95 g, 16 mmol). The reaction mixture was heated under reflux 
for 1.5 h followed by removal of volatiles in vacuo. Purification by silica gel column 
chromatography with 0­10% MeOH/DCM, then 0.1: 1: 9 NH3 (aq): MeOH: DCM, 
gave 131 (5.03g, 76%) as a yellow oil. δH (270MHz, CDCl3): 1.01 (6H, s, C(CH3)2), 
1.41 (9H, s, C(CH3)3), 1.48­1.53 (4H, m, 2xCH2), 1.79­1.91 (2H, m, CH2), 2.34 (4H, 
s, 2xCH2(Dde)), 2.55 (3H, s, CH3 (Dde)), 2.59­2.65 (2H, m, NCH2), 2.69­2.76 (2H, 
m, NCH2), 3.01­3.15 (2H, m, NCH2), 3.47 (2H, q, J 5.5, NCH2), 4.85 (1H, br, NH), 
12.04 (1H, br, NH), 13.40 (2H, br, NH2). δC (100MHz, CDCl3): 17.96 (CH3­Dde), 
26.46 (CH2), 27.65 (CH2), 28.29 (C(CH3)2), 28.46 (C(CH3)3), 28.73 (CH2), 29.96 
(C(CH3)2), 41.26 (2xNCH2), 46.38 (NCH2), 49.03 (NCH2), 51.87 (2xCH2­Dde), 78.99 
128 
(C(CH3)3), 107.86 (C=CCH3), 156.05 (C=O), 173.59 (C=CCH3), 190.03 (2xC=O). 
[Found: (ES+) 410.2995 [M+H]+, C22H40N3O4 requires 410.3013]. 
(4­tert­Butoxycarbonylamino­butyl)­{3­[1­(4,4­dimethyl­2,6­dioxo­cyclohexy 
lidene)­ethylamino]­propyl}­carbamic acid benzyl ester [132] 
N 
H 
N 
H 
N 
O O 
O 
O 
OO 
A stirred solution of 131 (1.40 g, 3.4 mmol) in dry DCM (8 mL) under nitrogen, was 
treated with triethylamine (0.5 mL, 3.4 mmol) followed by benzyl chloroformate (0.5 
mL, 3.4 mmol). The reaction mixture was stirred at 0ºC for 45 min and then diluted 
with DCM (10 mL) and washed sequentially with water (2x 20 mL) and brine (2x 20 
mL), dried (MgSO4) and concentrated in vacuo. Purification by silica gel column 
chromatography with 0­3% MeOH/DCM gave 132 (0.9 g, 60%) as a yellow oil. δH 
(270MHz, CDCl3): 1.00 (6H, s, C(CH3)2), 1.41 (9H, s, C(CH3)3), 1.46­1.61 (4H, m, 
2xCH2), 1.81­1.90 (2H, m, 2xCH2), 2.33 (4H, s, 2xCH2(Dde)), 2.53 (3H, s, CH3 
(Dde)), 2.95­3.15 (2H, m, NCH2), 3.16­3.43 (6H, m, 3xNCH2), 4.63­4.72 (1H, m, 
NH), 5.10 (2H, s, CH2­Ar), 7.31­7.34 (5H, m, Ar), 12.04 (1H, br, NH). δC (100MHz, 
CDCl3):18.12 (CH3­Dde), 25.97 (CH2), 27.50 (CH2), 28.15 (CH2), 28.50 (C(CH3)3), 
28.66 (C(CH3)2), 30.05 (C(CH3)2), 41.25 (2xNCH2), 45.10 (NCH2), 47.44 (NCH2), 
52.66 (2xCH2­Dde), 67.44 (CH2­Z), 79.01 (C(CH3)3), 107.86 (C=CCH3), 127.90 (Ar), 
128.10 (2xAr), 128.51 (2x Ar), 136.56 (Ar), 155.97 (2xC=O), 173.50 (C=CCH3), 
192.73 (C=O). [Found: (ES+) 544.3396 [M+H]+, C30H45N3O6 requires 544.3381]. 
129 
(3­Amino­propyl)­(4­tert­butoxycarbonylamino­butyl)­carbamic acid benzyl 
ester [133] 
H2N N 
N 
H 
O 
O 
O O 
A 2% hydrazine/DMF (10 mL) solution, was treated with allyl alcohol (9.1 mL, 0.31 
mol). This mixture was then added to 132 (1.69 g, 3.1 mmol). The reaction mixture 
was stirred at room temperature for 8 min. The volatiles were removed under vacuum. 
Purification by silica gel column chromatography with 0­10% MeOH/DCM, then 0.1: 
1: 9 NH3 (aq): MeOH: DCM gave 133 (805 mg, 82%) as a yellow oil. δH (270MHz, 
CDCl3): 1.41 (9H, s, C(CH3)3), 1.44­1.68 (2H, m, CH2), 1.98 (4H, br, 2xCH2), 2.58­
2.74 (2H, m, NCH2), 2.94­3.38 (6H, m, 3xNCH2), 5.09 (2H, s, CH2­Ar), 7.31­7.35 
(5H, m, Ar). δC (100MHz, CDCl3): 25.71 (CH2), 27.25 (CH2), 28.38 (C(CH3)3), 
29.44 (CH2), 37.96 (H2NCH2), 40.03 (HNCH2), 44.22 (NCH2), 46.43 (NCH2), 67.18 
(CH2­Z), 79.11 (C(CH3)3), 127.87 (2xAr), 128.03 (2xAr), 128.49 (Ar), 136.59 (Ar), 
155.99 (C=O), 156.63 (C=O). [Found: (ES+) 380.2526 [M+H]+, C20H34N3O4 requires 
380.2544]. 
130 
(4­tert­Butoxycarbonylamino­butyl)­{3­[(E)­3­(4­fluoro­3­nitro­phenyl)­
acryloylamino]­propyl}­carbamic acid benzyl ester [152] 
H 
N N 
N 
H 
O 
O 
O O 
O 
F 
NO2 
A stirred solution of 133 (460 mg, 1.21 mmol) in dry DCM (20 mL), was treated with 
DIPEA (0.2 mL, 1.21 mmol) and activated cinnamic acid 144 (456 mg, 1.21 mmol). 
The reaction was stirred at 0ºC for 90 min. The solvent was removed in vacuo. 
Purification via silica gel column chromatography, with 0­5% MeOH/DCM gave 152 
(380 mg, 55%) as a yellow oil. δH (270MHz, CDCl3): 1.42 (9H, s, 3xCH3), 1.48­
1.57 (4H, m, 2xCH2), 1.64­1.78 (2H, m, CH2), 3.04­3.15 (2H, m, NCH2), 3.21­3.40 
(6H, m, 3xNCH2), 4.49 (1H, br, NH), 4.73 (1H, br, NH), 5.15 (2H, s, CH2­Z), 6.48 
(1H, d, J 15.68, ArCH=CH), 7.17 (1H, m, Ar), 7.29­7.39 (5H, m, 5xAr), 7.55 (1H, d, 
J 15.68, ArCH=CH), 7.71­7.77 (1H, m, Ar), 8.18 (1H, d, J 6.62, Ar). δC (100MHz, 
CDCl3): 25.80 (CH2), 27.63 (CH2), 28.64 (3xCH3), 35.90 (CH2), 36.63 (CH2), 40.15 
(CH2), 43.98 (CH2), 46.61 (CH2), 67.67 (CH2­Z), 79.32 (C(CH3)3), 118.85 (CH), 
124.15 (Ar), 124.63 (Ar), 127.69(Ar­Z), 128.19 (Ar­Z), 128.60 (Ar­Z), 134.52 (Ar), 
136.43 (Ar), 136.76 (CH), 137.53 (Ar­Z), 154.29 (Ar­NO2), 156.03 (Ar­F), 156.95 
(C=O), 157.27 (C=O), 164.84 (C=O). [Found: (ES+) 573.2525 [M+H]+, C29H38FN4O7 
requires 573.2719]. 
131 
(4­Amino­butyl)­{3­[(E)­3­(4­fluoro­3­nitro­phenyl)­acryloylamino]­propyl}­

carbamic acid benzyl ester hydrochloric salt [153]

NO2 
F O O 
H 
N N 
NH2.HCl 
O 
Compound 152 (1.11 g, 2 mmol), was treated with a 4M HCl solution in dioxane (20 
mL). The reaction was stirred under N2 at room temperature for 30 min. Solvents 
were removed in vacuo and the residue was co­evaporated several times with ether to 
give 163 (0.96 g, 94%) as a yellow oil. 153 was used in the next stp without further 
purification. [Found: (ES+) 473.2181 [M+H]+, C24H30FN4O5 requires 473.2195]. 
{4­[(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acryloylamino]­butyl}­{3­
[(E)­3­(4­fluoro­3­nitro­phenyl)­acryloylamino]­propyl}­carbamic acid benzyl 
ester [154] 
H 
N N 
N 
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Si 
A stirred solution of 153 (0.96 g, 1.9 mmol) in dry DCM (20 mL), was treated with 
DIPEA (0.7 mL, 3.8 mmol) followed by 143 (1.03 g, 1.9 mmol). The reaction mixture 
was stirred under nitrogen at room temperature, overnight. Volatiles were removed in 
vacuo. Purification via silica gel column chromatography with 0%­3% MeOH/DCM, 
gave 154 (1.17 g, 75%), as a yellow oil. δH (270MHz, CDCl3): 1.06 (18H, d, J 7.2, 
3xCH(CH3)2), 1.16­1.28 (3H, m, 3xCH(CH3)2), 1.45­1.69 (4H, m, 2xCH2), 1.72­1.80 
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(2H, m, CH2), 3.18­3.50 (8H, m, 4xNCH2), 4.51 (2H, d, J 5.51, CH2CH=CH2), 5.15 
(2H, s, CH2­Z), 5.23­5.42 (2H, m, CH=CH2), 5.66 (1H, br, NH), 5.95­6.09 (1H, m, 
CH=CH2), 6.14 (1H, d, J 15.42, ArCH=CH), 6.51 (1H, d, J 15.96, ArCH=CH), 6.76 
(1H, d, J 8.59, Ar), 6.98 (2H, s, 2xAr), 7.31­7.41 (5H, m, 5xAr), 7.45 (1H, d, J 15.42, 
ArCH=CH), 7.55 (1H, J 15.95, ArCH=CH), 7.65­7.72 (1H, m, Ar), 8.15 (1H, d, J 
5.24, Ar). δC (100MHz, CDCl3): 12.86 (3xCH(CH3)2), 17.89 (6xCH3), 25.74 (CH2), 
27.03 (CH2), 27.55 (CH2), 36.16 (NCH2), 38.93 (NCH2), 44.25 (NCH2), 46.47 
(NCH2), 67.39 (CH2­Z), 69.54 (CH2CH=CH2), 113.36 (CH), 117.86 (CH2CH=CH2), 
118.77 (CH), 118.98 (CH), 119.29 (CH), 121.92 (CH), 124.92 (CH), 124.52 (CH), 
127.72 (C), 128.21 (CH), 128.63 (CH), 132.33 (C), 133.08 (CH), 134.44 (CH), 
136.53 (CH), 137.59 (CH), 137.66 (CH), 141.09 (CH), 145.92 (C), 151.63 (C), 
154.25 (C), 156.91 (C), 165.01 (C=O), 166.64 (C=O). [Found: (ES+) 831.4173 
[M+H]+, C45H60FN4O8Si requires 831.4159]. 
4­Allyloxy­27­nitro­10,21­dioxo­2­oxa­11,16,20­triaza­tricyclo[22.2.2.13,7] non 
acosa­1(27),3,5,7(29),8,22,24(28),25­octaene­16­carboxylic acid benzyl ester 
[224] 
O 
O 
N 
H 
NH 
O 
O2N 
O 
N 
O 
O 
A stirred solution of 154 (553 mg, 0.67 mmol) at 0ºC in dry THF (670 mL), was 
treated with TBAF (67 mL, 0.67 mmol). The reaction was left stirring at room 
temperature for 2 h. The solvent was removed in vacuo. The residue was redissolved 
in EtOAc and was washed with 5% citric acid and brine. Purification via column 
chromatography 1­5% MeOH/DCM gave 224 (369 mg, 85%), as a yellow oil. δH 
133 
(400MHz, CD3OD): 1..35­1.47 (2H, m, CH2), 1.49­1.58 (2H, m, CH2), 1.72­1.82 
(2H, m, CH2), 3.13­3.26 (6H, m, 3xCH2), 3.40­3.52 (2H, m, CH2), 4.75 (2H, d, J 5.2, 
CH2CH=CH2), 5.11 (2H, s, CH2­Z), 5.41 (2H, dd, J 1.2, 10.4, 1.2, 17.2, CH=CH2), 
5.94 (1H, d, J 15.6, ArCH=CH), 6.09­6.18 (1H, m, CH=CH2), 6.44 (1H, d, J 2.0, Ar), 
6.67 (1H, d, J 15.6, ArCH=CH), 7.07­7.11 (2H, m, Ar), 7.31­7.38 (6H, m, 5 xAr, 
ArCH=CH), 7.43 (1H, d, J 8.8, Ar), 7.61 (1H, d, J 15.6, ArCH=CH), 8.05 (1H, dd, J 
2.0, 8.0, Ar), 8.33 (1H, d, J 2.0, Ar). δC (100MHz, CD3OD): 25.52 (CH2), 26.72 
(CH2), 27.35 (CH2), 37.31 (NCH2), 37.62 (NCH2), 39.34 (NCH2), 46.34 (NCH2), 
68.29 (CH2­Z), 71.02 (CH2CH=CH2), 111.52 (Ar), 115.67 (Ar), 117.94 
(CH2CH=CH2), 120.09 (Ar), 125.86 (2xCH), 127.35 (Ar), 127.51 (Ar), 128.89 (Ar­
Z), 129.17 (Ar­Z), 129.59 (Ar­Z), 134.31 (Ar), 134.55 (Ar), 135.55 (Ar­Z), 138.19 
(Ar), 138.66 (Ar), 140.36 (2xCH), 144.92 (Ar­NO2), 150.39 (Ar­O), 150.81 (Ar­O), 
151.09 (Ar­O), 158.25 (C=O), 167.49 (C=O), 168.20 (C=O). [Found: (ES+) 655.2753 
[M+H]+, C36H39N4O8 requires 655.2762]. 
(8E,22E)­4­Allyloxy­27­amino­10,21­dioxo­2­oxa­11,16,20­triaza­tricyclo 
[22.2.2.13,7]nonacosa­1(27),3,5,7(29),8,22,24(28),25­octaene­16­carboxylic acid 
benzyl ester [225] 
O 
O NH 
NH 
O 
NH2OAll 
N 
Z 
A solution of 224 (238 mg, 0.36 mmol) in EtOH (10 mL) at 60ºC, was treated with 
SnCl2.2H2O (411 mg, 1.82 mmol), followed by slow addition of NaBH4 (7 mg, 0.182 
mmol). The reaction was stirred at 60ºC overnight. The reaction mixture was cooled 
over an ice bath; water (15 mL) was added, and basified with 1M NaOH to pH 9. The 
134 
ethanol was then evaporated off, and the aqueous layer was continuously extracted 
with CHCl3. The organic layer was dried (Na2SO4), and evaporated to dryness. 
Purification via silica gel chromatography (0%­10% MeOH/CHCl3, then 0.1:1:9 
NH3(aq):MeOH:CHCl3) gave 225 (196 mg, 85%)as a yellow solid . δH (400MHz, 
CDCl3): 1.40­1.48 (4H, m, 2xCH2), 1.73­1.7­82 (2H, m, CH2), 3.11­3.14 (2H, m, 
NCH2), 3.24­3.28 (4H, m, 2xNCH2), 3.49­3.51 (2H, m, NCH2), 4.68 (2H, d, J 5.2, 
OCH2), 5.10 (2H, s, CH2­Z), 5.32­5.49 (2H, m, HC=CH2), 6.07­6.15 (1H, m, 
HC=CH2), 6.26 (1H, d, J 14.8, HC=CHAr), 6.40 (1H, s, Ar­H), 6.85­6.96 (5H, m, 
5xAr­H), 7.30 (5H, m, 5xArH(Z)), 7.40 (1H, d, J 15.4, HC=CHAr), 7.53 (1H, d, J 
15.4, HC=CHAr). δC (100MHz, CDCl3): 25.72 (CH2), 26.32 (CH2), 27.83 (CH2), 
37.31 (NCH2), 39.34 (NCH2), 46.34 (NCH2), 67.26 (CH2­Z), 69.89 (OCH2), 109.70 
(Ar­H), 113.43 (Ar­H), 115.38 (Ar­H), 118.62 (HC=CH2), 118.88 (Ar­H), 121.57 
(HC=CHAr), 123.82 (Ar­H), 125.24 (Ar­H), 127.81 (ArH­Z), 127.87 (Ar­C), 128.16 
(ArH­Z), 128.57 (ArH­Z), 132.67 (HC=CH2), 133.43 (Ar­C), 136.49 (Ar­C), 139.87 
(HC=CHAr), 140.01 (Ar­C), 140.75 (HC=CHAr), 142.46 (Ar­C), 148.54 (Ar­C), 
149.16 (Ar­C), 156,17 (C=O), 165.81 (C=O(Z)). [Found: (ES+) 625.3050 [M+H]+, 
C36H41N4O4 requires 625.3061]. 
(8E,22E)­4­Allyloxy­10,21­dioxo­2­oxa­11,16,20­triaza­tricyclo 
[22.2.2.13,7]nonacosa­1(27),3,5,7(29),8,22,24(28),25­octaene­16­carboxylic acid 
benzyl ester [226] 
O 
O NH 
NH 
O 
O 
N 
Z 
135 
Method A: In a two neck 25 mL r.b. flask a solution of t­butylnitrite (23 �L) in DMF 
(3.5 mL), at 65°C was stirred vigorously. Once the desired temperature was reached 
compound 225 (80 mg, 0.13 mmol) in DMF (1.2 mL) was added slowly over 15 min 
via a syringe pump. The reaction was stirred for a further 30 min. The reaction 
mixture was then cooled in an ice bath and once cooled, EtOAc (20 mL) was added 
along with 0.1M HCl (20 mL). The layers were separated and the organic phase was 
washed once more with 0.1M HCl (20 mL). The organic phase was dried with MgSO4 
and evaporated to dryness. The resulting crude material was separated by HPLC in 
MeCN/H2O to give the side product compound 227 (14.1mg, 15%) and the desired 
compound 226 (7.2mg, 7.5%). 
Method B: Compound 225 (185 mg, 0.3 mmol) was dissolved in DMF/EtOH (4 mL/4 
mL) and acetic acid (0.8 mL). A solution of NaNO2 (205.5mg, 0.3mmol in water (1 
mL) and NaHSO3 (308.2 mg, 0.3 mmol) in water (1 mL) were added sequentially to 
the stirred aniline solution. The reaction was stirred overnight at room temperature. 
The reaction mixture was evaporated to dryness and redissolved in CHCl3 (30 mL) 
and washed with water (30 mL). The organic layer was dried with MgSO4 and 
evaporated to dryness. The crude material was purified via silica gel column 
chromatography (0%­5% MeOH/DCM) to give the desired product 226 (30.2 mg, 
20% yield) and the side product 227 (6 mg, 3%). δH (400MHz, CD2Cl2): 1.38­1.48 
(4H, m, 2xCH2), 1.52­1.73 (2H, m, CH2), 3.11­3.51 (8H, m, 4xNCH2), 4.65 (2H, dd, 
J 5.2, OCH2), 5.08 (2H, s, CH2­Z), 5.30­5.49 (2H, m, HC=CH2), 5.67 (1H, d, J 14.4, 
HC=CHAr), 6.08­6.17 (1H, m, HC=CH2), 6.30 (1H, d, J 15.2, HC=CHAr), 6.32 (1H, 
s, ArH), 6.89­6.91 (2H, m, 2x ArH), 7.07 (2H, d, J 8.4, 2x ArH), 7.31 (5H, s, 5xArH­
Z), 7.36 (1H, d, J 15.2, HC=CHAr), 7.56 (1H, d, J 15.2, HC=CHAr), 7.57 (2H, d, J 
8.4, 2xArH). δC (100MHz, CD2Cl2): 26.47 (CH2), 26.74 (CH2), 28.27 (CH2), 37.25 
(NCH2), 37.37 (NCH2), 39.67 (NCH2), 46.71 (NCH2), 67.26 (CH2­Z), 70.23 (OCH2), 
111.08 (ArCH), 113.87 (ArCH), 118.58 (HC=CH2), 119.32 (HC=CHAr), 119.37 
(ArCH), 123.01 (ArCH), 123.51 (HC=CHAr), 125.36 (ArCH), 127.99 (ArCH­Z), 
128.07 (ArCH­Z), 128.27 (ArCH­Z), 128.82 (ArC), 129.81 (ArCH), 133.28 (ArCH), 
133.32 (HC=CH2), 137.46 (ArCH), 139.75 (HC=CHAr), 139.81 (HC=CHAr), 149.76 
(ArC), 150.99 (ArC), 156.32 (ArC), 156.65 (C=O), 165.55 (C=O), 165.64 (C=O). 
[Found: (ES+) 610.2917 [M+H]+, C36H40N3O6 requires 608.2912]. 
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Compound 227
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NH N 
Z 
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δH (400MHz, CD2Cl2:MeOD 8:1): 1.57­1.68 (4H, m, 2xCH2), 1.79­1.83 (2H, m, 
CH2), 3.26­3.37 (8H, m, 4xNCH2), 4.78 (2H, dt, J 1.4, 5.2, OCH2), 5.05 (2H, s, CH2­
Z), 5.32­5.50 (2H, m, HC=CH2), 6.09­6.17 (1H, m, HC=CH2), 6.44 (1H, d, J 15.2, 
HC=CHAr), 6.72 (1H, d, J 15.6, HC=CHAr), 7.00 (1H, J 8.0, Ar­H), 7.29 (5H, s, 
5xArH­Z), 7.32 (1H, d, J 8.4, ArH), 7.49 (1H, dd, J 1.4, 8.4, ArH), 7.58 (1H, d, J 
8.4, ArH), 7.59 (1H, d, J 16.0, HC=CHAr), 8.30 (1H, d, J 16.0, HC=CHAr), 8.39 
(1H, s, ArH). δC (100MHz, CD2Cl2:MeOD 8:1): 26.33 (CH2), 28.58 (CH2), 30.06 
(CH2), 37.34 (NCH2), 39.42 (NCH2), 45.76 (NCH2), 47.68 (NCH2), 67.41 (CH2­Z), 
70.52 (OCH2), 112.02 (ArCH), 112.40 (ArCH), 118.68 (HC=CH2), 120.24 (ArCH), 
121.95 (HC=CHAr), 123.00 (ArCH), 123.05 (HC=CHAr), 124.08 (ArC), 124.68 
(ArC), 125.17 (ArC), 128.02 (ArCH­Z), 128.26 (ArCH­Z), 128.80 (ArCH­Z), 129.86 
(ArCH), 131.18 (ArC), 133.15 (HC=CH2), 137.34 (ArC), 138.78 (HC=CHAr), 
139.43 (HC=CHAr), 145.58 (ArC), 146.25 (ArC), 156.83 (ArC), 157.42 (C=O), 
167.11 (C=O), 167.63 (C=O). [Found: (ES+) 608.2769 [M+H]+, C36H38N3O6 requires 
608.2755]. 
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(8E,22E)­4­Hydroxy­10,21­dioxo­2­oxa­11,16,20­triaza­tricyclo[22.2.2.13,7] 
nonacosa­1(27),3,5,7(29),8,22,24(28),25­octaene­16­carboxylic acid benzyl ester 
[228] 
Z 
O NH 
N NH 
O 
O 
OH 
A solution of 226 (34 mg, 0.0 5mmol) in dry THF (2.5 mL) was treated with 
Pd(PPh3)4 (21 mg, 0.018 mmol), followed by dropwise addition of dry morpholine 
(50mg, 0.5 mmol). The reaction was stirred under N2 at room temperature overnight. 
Volatiles were then removed and the crude material was purified by silica gel column 
chromatography 0­5% MeOH/DCM to give 228 (28 mg, 88%) as a yellow oil. δH 
(400MHz, CD3OD): 1.35­1.39 (2H, m, CH2), 1.48­1.51 (2H, m, CH2), 1.73­1.83 (2H, 
m, CH2), 3.17­3.25 (8H, m, 4NCH2), 5.11 (2H, s, CH2­Z), 5.83 (1H, d, J 15.6, 
HC=CHAr), 6.46 (1H, s, ArH), 6.51 (1H, d, J 16.0, HC=CHAr), 6.88 (2H, s, 2xAr­
H), 7.18 (2H, d, J 8.6, 2xAr­H), 7.29 (1H, d, J 15.6, HC=CHAr), 7.34­7.36 (5H, m, 
5xArH­Z), 7.56 (1H, d, J 16.0, HC=CHAr), 7.69 (2H, d, J 8.6, 2xArH). δC (100MHz, 
CD3OD): 27.75 (CH2), 37.62 (NCH2), 40.04 (NCH2), 46.69 (NCH2), 68.32 (CH2­
Z), 112.46 (ArCH), 117.58 (ArCH), 119.15 (ArCH=CH), 123.81 (ArCH=CH), 124.06 
(ArCH), 126.85 (ArCH), 127.60 (ArC), 128.12 (ArCH), 128.86 (ArCH­Z), 129.13 
(ArCH­Z), 129.57 (ArCH­Z), 130.61 (ArCH), 130.87 (ArCH), 134.78 (ArC), 138.25 
(ArC), 140.92 (ArCH=CH), 141.05 (ArCH=CH), 150.01 (ArC), 150.45 (ArC), 157.87 
(ArC), 158.59 (C=O), 168.33 (C=O), 168.59 (C=O). 
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Cadabicine [62]
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A solution of 228 (15.9 mg, 0.028 mmol) in dry DCM (2.5 mL), was treated with 
TMS­I (10 �L, 0.042 mmol) added dropwise. The solution was stirred under N2 for 
20 min at room temperature. MeOH (5 mL) was added, and the mixture was stirred 
for a further 15 min. The solvent was then removed under vacuo and the crude 
material was purified. Purification by silica gel chromatography 5­10% MeOH/DCM 
gave 62 the free base as yellow oil (10.3 mg, 83%). Further purification by 
preparative HPLC gave 62 as the TFA salt in 18% yield. δH (400MHz, D2O): 1.40­
1.65 (4H, m, 2 x CH2), 1.85­1.97 (2H, m, CH2), 2.90­2.99 (4H, m, 2 x NCH2), 3.17­
3.22 (2H, m, NCH2), 3.43 (2H, t, J 5.7, NCH2), 5.82 (1H, d, J 15.7, H­8 or H­21), 
6.33 (1H, s, H­27), 6.52 (1H, d, J 15.9, H­8 or H­21), 6.90 (2H, s, H­24, H­25), 7.13 
(2H, d, J 8.6, H­4, H­28), 7.15 (1H, d, J 15.7, H­7 or H­22), 7.50 (1H, d, J 15.9, H­7 
or H­22), 7.68 (2H, d, J 8.8, H­5, H­29); δC (100MHz, D2O): 22.8 (CH2), 24.9 
(CH2), 25.5 (CH2) 36.5 (NCH2), 39.5 (NCH2), 44.6 (NCH2), 47.3 (NCH2), 111.2 
(C­27), 116.5 (C­25), 118.0 (C­8 or C­21), 121.3 (C­8 or C­21), 123.3 (C­4, C­28), 
126.1 (C­24), 127.3 (C­6 or C­23), 130.1 (C­5, C­29), 132.6 (C­6, C­23), 139.7 (C­7 
or C­22), 140.8 (C­7 or C­22), 147.0 (C­26), 149.0 (C­1 or C­3), 156.4 (C­1 or C­3), 
163.0, 163.4 (C=O, two rotamers), 168.7, 168.9 (C=O, two rotamers). 
(4­tert­Butoxycarbonylamino­butyl)­{3­[1­(4,4­dimethyl­2,6­dioxo­
cyclohexylidene)­ethylamino]­propyl}­carbamic acid tert­butyl ester [237] 
H 
Dde N 
N N Boc 
H 
Boc 
A solution of 131 (1.02 g, 2.5 mmols), in dry DCM (10 mL), was treated with di­tert­
butyl dicarbonate (0.55 g, 2.5 mmols). The reaction mixture was stirred at room 
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temperature overnight. The reaction mixture was diluted with DCM (20 mL) and 
washed consequentially with 10% citric acid (2x 20 mL), saturated NaHCO3 (2x 20 
mL) and brine (2x 20 mL). The organic layer was dried over MgSO4 and evaporated 
to dryness. Purification by silica gel column chromatography with 0%­3% 
MeOH/DCM gave 237 (0.95 g, 75%) as a clear oil. δH (400MHz, CDCl3): 0.99 (6H, 
s, C(CH3)2), 1.41 (18H, s, 2x C(CH3)3), 1.44­1.52 (4H, m, 2xCH2), 1.82­1.92 (2H, m, 
CH2), 2.34 (4H, s, 2xCH2), 2.53 (3H, s, CH3), 3.04­3.18 (4H, m, NCH2), 3.27 (2H, t, J 
6.5, NCH2), 3.37 (2H, q, J 6.5, NCH2), 4.72 (1H, br, NH), 13.45 (1H, br, NH). ). δC 
(100MHz, CDCl3): 17.82 (CH3), 25.71 (CH2), 25.95 (CH2), 27.30 (CH2), 28.20 
(2xCH3), 28.37 (6xCH3), 30.03 (CH2C(CH3)2CH2), 40.01 (CH2), 41.01 (CH2), 44.33 
(CH2), 46.91 (CH2), 52.31 (CH2), 53.41 (CH2), 79.02 (2xC(CH3)3), 108.05 (C=C), 
155.51 (C=O), 155.96 (C=O), 173.49 (C=C), 197.06 (C=O), 200.01 (C=O). [Found: 
(ES+) 510.3528 [M+H]+, C27H48N3O6 requires 510.3535]. 
(3­Amino­propyl)­(4­tert­butoxycarbonylamino­butyl)­carbamic acid tert­butyl 
ester [238] 
H 
N 
H2N N Boc 
Boc 
237 (0.94 g, 1.85 mmols) was treated with 2% Hydrazine/DMF solution (10 mL). The 
reaction mixture was stirred at room temperature for 10 minutes. Volatiles were 
removed under vacuo. Purification via silica gel column chromatography with 5%­
10% MeOH/DCM then 0.5:10:89.5 NH3(aq):MeOH:DCM gave 45 (0.33 g, 52%) as a 
yellow oil. δH (400MHz, CDCl3): 1.43 (18H, s, 2xC(CH3)3), 1.53­1.59 (2H, m, CH2), 
1.62­1.66 (2H, m, CH2), 1.82­1.92 (2H, m, CH2), 3.09­3.11 (4H, m, 2xNCH2), 3.12­
3.14 (4H, m, 2xNCH2), 4.65 (1H, br, NH). δC (100MHz, CDCl3): 25.78 (CH2), 27.39 
(CH2), 28.38 (CH3), 28.42 (CH3), 31.46 (CH2), 38.95 (CH2), 40.15 (CH2), 43.83 
(CH2), 46.48 (CH2), 79.06 (C(CH3)3), 79.39 (C(CH3)3), 155.97 (C=O). [Found: (ES
+) 
346.2694 [M+H]+, C17H35N3O4 requires  346.2700]. 
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{3­[(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acryloylamino]­propyl}­
(4­tert­butoxycarbonylamino­butyl)­carbamic acid tert­butyl ester [242] 
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H 
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O 
OTIPS 
Boc 
Boc 
A stirred solution of 238 (190 mg, 0.55 mmol) in dry DCM (4 mL) at 0ºC, was treated 
with DIPEA (0.1mL, 0.55mmol) and activated cinnamic acid 17 (300 mg, 0.55 
mmol). The reaction was stirred at room temperature overnight. Volatiles were 
removed in vacuo. Purification via silica gel column chromatography, with 0­5% 
MeOH/DCM gave 46 (380 mg, 98%) as a clear oil. δH (400MHz, CDCl3): 1.12 (21H, 
d, J 6.8, 3xCH(CH3)2), 1.27­1.34 (2H, m, CH2), 1.51 (18H, d, J 14.4, 2x C(CH3)3), 
1.55­1.61 (2H, m, CH2), 1.72­1.80 (2H, m, CH2), 3.10­3.23 (4H, m, 2xNCH2), 3.35­
3.46 (4H, m, 2xNCH2), 4.58 (2H, d, J 5.6, OCH2), 5.29­5.45 (2H, m, HC=CH2), 6.04­
6.12 (1H, m, HC=CH2), 6.30 (1H, d, J 15.6, HC=CHAr), 6.84 (1H, d, J 8.4, Ar), 7.07­
7.10 (2H, m, Ar), 7.52 (1H, d, J 15.6, HC=CHAr). δC (100MHz, CDCl3): 12.80 
(3xCH(TIPS)), 17.89 (6xCH3(TIPS)), 25.64 (CH2), 27.38 (CH2), 27.56 (CH2), 28.36 
(3xCH3(Boc)), 28.41 (3xCH3(Boc)), 35.95 (NCH2), 40.05 (NCH2), 43.31 (NCH2), 
46.60 (NCH2), 69.48 (OCH2), 79.33 (C(CH3)3), 79.99 (C(CH3)3), 113.28 (CH­Ar), 
117.81 (HC=CH2), 118.38 (HC=CHAr), 119.60 (CH­Ar), 121.83 (CH­Ar), 127.87 
(ArC­HC=CH), 133.10 (HC=CH2), 140.89 (HC=CHAr), 145.75 (ArC­OTIPS), 
151.46 (ArC­OAll), 156.06 (C=O), 156.68 (C=O), 166.99 (C=O). [Found: (ES+) 
726.4508 [M+Na]+, C38H65N3O7SiNa requires 726.4484]. 
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(4­tert­Butoxycarbonylamino­butyl)­{3­[(E)­3­(4­fluoro­3­nitro­phenyl)­
acryloylamino]­propyl}­carbamic acid tert­butyl ester [241] 
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H 
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Boc 
Boc 
A stirred solution of 238 (170 mg, 0.49 mmol) in dry DCM (4 mL) at 0ºC, was treated 
with DIPEA (0.1 mL, 0.49 mmol) and activated cinnamic acid 144 (185 mg, 0.49 
mmol). The reaction was stirred at room temperature overnight, and volatiles were 
removed in vacuo. Purification via silica gel column chromatography, with 0­5% 
MeOH/DCM gave 241 (260 mg, 98%) as a yellow oil. δH (400MHz, CDCl3): 1.47 
(18H, d, J 16.8, 2x C(CH3)3), 1.51­1.58 (2H, m, CH2), 1.62­1.71 (4H, m, 2xCH2), 
3.10­3.15 (4H, m, 2xNCH2), 3.31­3.56 (4H, m, 2xCH2), 6.50 (1H, d, J 15.6, 
HC=CHAr), 7.27­7.32 (2H, m, 2xArH), 7.45 (1H, br, NH), 7.56 (1H, d, J 15.6, 
HC=CHAr), 7.72 (1H, br, NH), 8.18 (1H, dd, J 7.2, 4.8, ArH). δC (100MHz, CDCl3): 
25.63 (CH2), 27.46 (CH2), 28.38 (3xCH3(Boc)), 28.41 (3xCH3(Boc)), 35.73 (NCH2), 
43.09 (NCH2), 46.09 (NCH2), 46.65 (NCH2), 79.33 (C(CH3)3), 80.12 (C(CH3)3), 
118.85 (CH(Ar)), 124.27 (HC=CHAr), 132.25 (CNO2(Ar)), 134.54 (ArC­HC=CH), 
136.68 (HC=CHAr), 137.62 (CF(Ar)), 154.28 (C=O), 156.05 (C=O), 164.90 (C=O). 
[Found: (ES+) 561.2690 [M+Na]+, C26H39FN4O7Na requires 561.2695]. 
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{3­[(E)­3­(4­Allyloxy­3­triisopropylsilanyloxy­phenyl)­acryloylamino]­propyl}­
(4­tert­butoxycarbonylamino­butyl)­carbamic acid tert­butyl ester [243] 
N 
H 
N 
H 
N 
O 
O 
OH 
Boc 
Boc 
A stirred solution of 238 (190 mg, 0.55 mmol) in dry DCM (4 mL) at 0ºC, was treated 
sequentially with DIPEA (0.1mL, 0.55 mmol) followed by activated cinnamic acid 17 
(300 mg, 0.55 mmol). The reaction was stirred at room temperature overnight, and 
volatiles were removed in vacuo and residue was purified by silica gel column 
chromatography 0%­5% MeOH/DCM to give 243 (380 mg, 98%) as a yellow oil. δH 
(400MHz, CDCl3): 1.42 (18H, d, J 13.6, 9xCH3), 1.47­1.54 (4H, m, CH2), 1.64­1.68 
(2H, m, CH2), 3.08­3.18 (4H, m, 2xNCH2), 3.20­3.34 (2H, m, 2xNCH2), 4.57 (2H, d, 
J 5.6, OCH2), 4.65 (1H, br, NH), 5.26­5.40 (2H, m, HC=CH2), 5.97­6.06 (1H, m, 
HC=CH2), 6.27 (1H, d, J 15.6, HC=CHAr), 6.77 (1H, d, J 8.2, Ar­H), 6.92 (1H, d, J 
8.2, Ar­H), 7.04 (1H, br, NH), 7.11 (1H, s, Ar­H), 7.48 (1H, d, J 15.6, HC=CHAr). δC 
(100MHz, CDCl3): 25.62 (CH2), 27.35 (CH2), 27.61 (CH2), 28.33 (3xCH3), 28.37 
(3xCH3), 35.75 (NCH2), 39.99 (NCH2), 43.32 (NCH2), 46.54 (NCH2), 69.69 (OCH2), 
79.10 (C(CH3)3), 79.78 (C(CH3)3), 112.00 (CH­Ar), 113.16 (CH­Ar), 118.48 
(HC=CH2), 119.47 (HC=CHAr), 120.99 (CH­Ar), 128.69 (ArC­HC=CH), 132.47 
(HC=CH2), 140.08 (HC=CHAr), 146.00 (ArC­OAll), 146.96 (ArC­OH), 156.00 
(C=O), 156.44 (C=O), 166.25 (C=O). [Found: (ES+) 548.3323 [M+H]+, C26H46N3O7 
requires 548.3330]. 
143 
[3­((E)­3­{4­Allyloxy­3­[4­((E)­2­{3­[tert­butoxycarbonyl­(4­tert­
butoxycarbonylamino­butyl)­amino]­propylcarbamoyl}­vinyl)­2­nitro­phenoxy]­
phenyl}­acryloylamino)­propyl]­(4­tert­butoxycarbonylamino­butyl)­carbamic 
acid tert­butyl ester [244] 
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Method A: A solution of 242 (328 mg, 0.47 mmol) and 241 (251 mg, 0.47 mmol) in 
dry THF (30 mL), was treated with TBAF (0.47 mL, 0.47 mmol). The reaction was 
stirred at room temperature for 5 h (until no further change was observed by TLC). 
Solvent was removed in vacuo and residue was redissolved in 5% citric acid (20 mL) 
and extracted with EtOAc (3x 20 mL). The organic extracts were combined and 
washed with brine, dried (MgSO4), and concentrated in vacuo. Purification via silica 
gel column chromatography 0­5% MeOH/DCM gave the desired product 244 (180 
mg, 36%) as a yellow oil, as well as the TIPS deprotected cinnaminc acid 243 (150 
mg), and unreacted 241 (135 mg). 
Method B: A solution of 241 (136 mg, 0.24 mmol) and 243 (132 mg, 0.24 mmol) in 
DMF (15 mL), was treated with K2CO3 (130 mg, 0.83 mmol) and stirred at room 
temperature overnight. Volitiles were removed in vacuo and the residue was 
redissolved in EtOAc (25 mL) and washed sequentially with 5% citric acid (25 mL), 
water (20 mL) and brine (20 mL). The organic phase was dried (MgSO4) nd 
evaporated to dryness. Purification via silica gel coloumn chromatography 0­5% 
MeOH/DCM, gave 49 (252 mg, 98%) as a yellow oil. 
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δH (400MHz, CDCl3): 1.45 (36H, t, J 7.6, 9xCH3), 1.57 (12H, s, 6xCH2), 3.13 (8H, 
br, 4xNCH2), 3.31 (8H, br, 4xNCH2), 4.51 (2H, dt, J 4.8, 1.6, OCH2), 5.12­5.20 (2H, 
m, HC=CH2), 5.75­5.85 (1H, m, HC=CH2), 6.31 (1H, d, J 14.4, HC=CHAr), 6.42 
(1H, d, J 15.2, HC=CHAr), 6.80 (1H, d, J 8.8, Ar­H), 6.97 (1H, d, J 8.4, Ar­H), 7.31­
7.36 (2H, m, 2xAr­H), 7.50 (1H, d, J 15.2, HC=CHAr), 7.51 (1H, s, Ar­H), 7.54 (1H, 
d, J 14.4, HC=CHAr), 8.10 (1H, d, J 2.0, Ar­H). δC (100MHz, CDCl3): 25.55 
(2xCH2), 27.31 (2xCH2), 27.51 (2xCH2), 28.28 (2x(CH3)3), 28.30 (2x(CH3)3), 35.71 
(2xNCH2), 39.91 (2xNCH2), 43.16 (2xNCH2), 46.49 (2xNCH2), 69.93 (OCH2), 79.01 
(2xC(CH3)3), 79.73 (2xC(CH3)3), 114.53 (CH­Ar), 117.65 (CH­Ar), 117.80 
(HC=CH2), 120.62 (Ar­CH), 120.74 (HC=CHAr), 122.64 (HC=CHAr), 124.19 (CH­
Ar), 126.97 (CH­Ar), 128.99 (ArC­HC=CH), 129.52 (ArC­HC=CH), 131.86 
(HC=CH2), 133.03 (CH­Ar), 137.11 (HC=CHAr), 138.59 (HC=CHAr), 139.61(Ar), 
143.00 (Ar), 150.92 (Ar), 151.95 (Ar), 155.96 (2xC=O(Boc)), 156.43 (2xC=O(Boc)), 
165.15 (C=O), 165.71 (C=O). [Found: (ES+) 1088.5864 [M+Na]+, C55H83N7O14Na 
requires 1088.5890]. 
(8E,22E)­4­Allyloxy­27­nitro­2­oxa­11,16,20­triaza­tricyclo[22.2.2.13,7]nonacosa­
1(27),3,5,7(29),8,22,24(28),25­octaene­10,21­dione [233] 
O 
O NH 
NH 
O 
OAll 
N 
H 
NO2 
A solution of 224 (60 mg, 0.09 mmol) in dry DCM (2 mL) was treated dropwise with 
iodotrimethylsilane (20 �L, 0.135 mmol). The reaction mixture was stirred at room 
temperature for 20 min. MeOH (5 mL) was added and the mixture was stirred for a 
further 15 min. Volatiles were removed in vacuo and the residue was purified via 
silica gel chromatography 0%­10%MeOH/DCM to give 233 (44 mg, 93%) as a white 
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solid. δH (400MHz, CD3OD): 1.53­1.57 (2H, m, 2xCH2), 1.74­1.84 (2H, m, 2xCH2), 
1.92­2.02 (2H, m, 2xCH2), 3.02­3.15 (6H, m, 3xNCH2), 3.46­3.56 (2H, m, NCH2), 
4.73 (2H, dt, J 5.6, 1.6, OCH2), 5.29­5.32 (2H, m, HC=CH2), 6.09­6.18 (1H, m, 
HC=CH2), 6.21 (1H, d, J 15.6, HC=CHAr), 6.53 (1H, d, J 2.0, Ar­H), 6.63 (1H, d, J 
16.0, HC=CHAr), 7.01­7.09 (2H, m, 2xAr­H), 7.32 (1H, d, J 15.6, HC=CHAr), 7.41 
(1H, d, J 8.8, Ar­H), 7.57 (1H, d, J 16.0, HC=CHAr), 8.06 (1H, dd, J 8.8, 2.4, Ar­H), 
8.30 (1H, d, J 2.0, Ar­H). δC (100MHz, CD3OD): 24.84 (CH2), 26.41 (CH2), 27.01 
(CH2), 37.41 (NCH2), 40.00 (NCH2), 46.36 (2xNCH2), 71.05 (OCH2), 111.83 (Ar­
CH), 115.62 (Ar­CH), 118.19 (HC=CH2), 120.68 (HC=CHAr), 126.36 (Ar­CH), 
127.16 (Ar­CH), 127.24 (Ar­CH), 127.28 (HC=CHAr), 129.47 (Ar­C), 134.37 (Ar­
CH), 135.48 (Ar­C), 138.47 (HC=CHAr), 140.30 ((HC=CHAr), 144.67 (Ar­C), 
150.12 (Ar­C), 150.91 (Ar­C), 150.98 (Ar­C), 168.09 (C=O), 168.58 (C=O). [Found: 
(ES+) 521.2380 [M+H]+, C28H33N4O6 requires 521.2395]. 
(8E,22E)­4­Hydroxy­27­nitro­2­oxa­11,16,20­triaza­tricyclo[22.2.2.13,7] 
nonacosa­1(27),3,5,7(29),8,22,24(28),25­octaene­10,21­dione [234] 
O 
O NH 
NH 
O 
OH 
N 
H 
NO2 
A solution of 233 (22 mg, 0.04 mmol) in dry MeOH (2 mL) was treated sequentially 
with tetrakis(triphenylphosphine)palladium (6 mg, 0.004 mmol) and morpholine (40 
�L, 0.4 mmol). The reaction mixture was stirred for 30 min. The volatiles were 
removed in vacuo and the residue was purified via silica gel chromatography 0%­10% 
MeOH/DCM then 0.5:10:89.5 NH3(aq):MeOH:DCM to give 234 (8 mg, 40%) as 
white solid. δH (400MHz, CD3OD): 1.45­1.56 (2H, m, 2xCH2), 1.74­1.78 (2H, m, 
2xCH2), 1.93­1.98 (2H, m, 2xCH2), 3.01­3.28 (4H, m, 2xNCH2), 3.34­3.61 (4H, m, 
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2xNCH2), 6.10 (1H, d, J 15.6, HC=CHAr), 6.48 (1H, d, J 1.6, Ar­H), 6.86­6.97 (3H, 
m, 2xAr­H, HC=HCAr), 7.30 (1H, d, J 15.6, HC=CHAr), 7.43 (1H, d, J 8.4, Ar­H), 
7.58 (1H, d, J 15.6, HC=CHAr), 8.05 (1H, dd, J 2.4, 8.4, Ar­H), 8.30 (1H, d, J 2.4, 
Ar­H). δC (100MHz, CD3OD): 22.79 (CH2), 24.48 (CH2), 25.09 (CH2), 35.39 
(NCH2), 38.00 (NCH2), 44.29 (NCH2), 109.87 (Ar­H), 115.87 (HC=CHAr), 117.59 
(HC=CHAr), 124.25 (Ar­H), 124.99 (Ar­C), 125.41 (Ar­H), 125.77 (Ar­H), 126.15 
(Ar­H), 132.78 (Ar­H), 133.44 (Ar­C), 136.58 (HC=CHAr), 138.70 (HC=CHAr), 
142.70 (Ar­C), 147.41 (Ar­C), 148.04 (Ar­C), 148.38 (Ar­C), 166.03 (C=O), 166.76 
(C=O). 
(8E,22E)­4­Allyloxy­27­amino­2­oxa­11,16,20­triaza­tricyclo[22.2.2.13,7] 
nonacosa ­1(27),3,5,7(29),8,22,24(28),25­octaene­10,21­dione [232] 
O 
O NH 
NH 
O 
OAll 
N 
H 
NH2 
A solution of 225 (35 mg, 0.056 mmol) in dry DCM (5 mL) was treated dropwise 
with iodotrimethylsilane (20 �L, 0.135 mmol). The reaction mixture was stirred at 
room temperature for 20 min. MeOH (5 mL) was added and mixture was stirred for a 
further 15 min. Volitiles were removed in vacuo and the residue was purified via 
silica gel chromatography 0%­10%MeOH/DCM to give 232 (21 mg, 80%) as a 
yellow oil. δH (400MHz, CD3OD): 1.48­1.55 (4H, m, 2xCH2), 1.78­1.1.82 (2H, m, 
CH2), 2.64­2.72 (4H, m, NCH2), 3.18­3.28 (2H, m, NCH2), 3.35­3.47 (2H, m, NCH2), 
4.72 (2H, d, J 5.6, OCH2), 5.31­5.53 (2H, m, HC=CH2), 5.92 (1H, d, J 15.6, 
HC=CHAr), 6.12­6.22 (1H, m, HC=CH2), 6.47 (1H, d, J 16.0, HC=CHAr), 6.58 (1H, 
s, Ar­H), 6.88 (1H, d, J 8.8, Ar­H), 6.96­7.07 (2H, m, 2xAr­H), 7.10 (1H, s, Ar­H), 
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7.26 (1H, d, J 8.8, Ar­H), 7.33 (1H, d, J 15.6, HC=CHAr), 7.46 (1H, d, J 16.0, 
HC=CHAr). δC (100MHz, CD3OD): 27.54 (CH2), 29.33 (CH2), 30.75 (CH2), 38.78 
(NCH2), 40.60 (NCH2), 47.93 (NCH2), 49.07 (NCH2), 71.01 (OCH2), 111.07 (Ar­
CH), 115.06 (Ar­CH), 116.97 (Ar­CH), 118.30 (HC=CH2), 118.73 (Ar­CH), 119.92 
(HC=CHAr), 122.99 (HC=CHAr), 124.40 (Ar­CH), 126.33 (Ar­CH), 129.44 (Ar­C), 
129.63 (Ar­C), 134.71 (Ar­C), 135.11 (Ar­C), 140.85 (Ar­C), 141.89 (Ar­C), 150.17 
(Ar­C), 150.89 (Ar­C), 168.62 (C=O), 168.68 (C=O). [Found: (ES+) 491.3000 
[M+H]+, C28H35N4O4 requires 491.2658]. 
(8E,22E)­27­Amino­4­hydroxy­10,21­dioxo­2­oxa­11,16,20­triaza­
tricyclo[22.2.2.13,7]nonacosa­1(27),3,5,7(29),8,22,24(28),25­octaene­16­carboxylic 
acid benzyl ester [230] 
O 
O NH 
NH 
O 
NH2OH 
N 
Z 
A solution of 232 (35 mg, 0.056 mmol) in dry THF (5 mL), was treated sequentially 
with tetrakis(triphenylphosphine)palladium (6.5 mg, 0.0056 mmol) and morpholine 
(50 �L, 0.56 mmol). The reaction was stirred at room temperature for 30min. 
Volatiles were removed in vacuo, and the residue was purified by silica gel column 
chromatography 0%­10% MeOH/DCM then 0.5:10:89.5 NH3(aq):MeOH:DCM to 
give 230 (17mg, 54%) as a white solid. δH (400MHz, CD3OD): 1.31­1.38 (2H, m, 
CH2), 1.40­1.54 (2H, m, CH2), 1.75­1.1.80 (2H, m, CH2), 2.80­3.20 (4H, m, 
2xNCH2), 3.12­3.26 (4H, m, 2xNCH2), 5.11 (2H, s, CH2(Z)), 5.86 (1H, d, J 15.4, 
HC=CHAr), 6.46 (1H, d, J 16.0, HC=CHAr), 6.53 (1H, s, CH(Ar)), 6.87 (2H, s,, 
2xCH(Ar)), 6.96­7.01 (2H,m, 2xCH(Ar)), 7.10 (1H, d, J 1.6, CH(Ar)), 7.31 (1H, d, J 
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15.4, HC=CHAr), 7.35 (5H, br, 5x CH(Z)), 7.46 (1H, d, J 16.0, HC=CHAr). ). δC 
(100MHz, CD3OD): 27.61 (CH2), 27.71 (CH2), 37.49 (NCH2), 40.05 (NCH2), 46.59 
(NCH2), 68.17 (CH2­Z), 110.85 (Ar­CH), 117.02 (Ar­CH), 117.47 (Ar­CH), 118.55 
(Ar­CH), 118.84 (HC=CHAr), 122.84 (HC=CHAr), 124.52 (Ar­CH), 126.84 (Ar­
CH), 128.00 (Ar­C(Z)), 128.85 (Ar­CH(Z)), 129.14 (Ar­CH(Z)), 129.57 (Ar­CH(Z)), 
135.02 (Ar­C), 138.19 (Ar­C), 141.36 (HC=CHAr), 141.95 (HC=CHAr), 142.46 (Ar­
C), 143.87 (Ar­C), 148.87 (Ar­C), 150.02 (Ar­C), 157.78 (C=O), 168.56 (C=O), 
168.69 (C=O). [Found: (ES+) 585.2686 [M+H]+, C33H37N4O6 requires 585.2708]. 
Amino­Cadabicine [231] 
O 
O NH 
NH 
O 
NH2OH 
N 
H 
A solution of 230 (14.5 mg, 0.025mmol) in dry DCM (2.5 mL) was treated dropwise 
with iodotrimethylsilane (10 �L, 0.037 mmol). The reaction mixture was stirred at 
room temperature for 20 min. MeOH (5 mL) was added and the mixture was stirred 
for a further 15 min. Volatiles were removed under vacuo and the residue was 
purified via silica gel chromatography 0%­10%MeOH/DCM to give 231 (8 mg, 72%) 
as a yellow oil. δH (400MHz, CD3OD): 1.42­1.63 (4H, m, 2xCH2), 1.79­1.89 (2H, m, 
CH2), 2.68­2.78 (4H, m, 2xNCH2), 3.22­3.29 (2H, m, NCH2), 3.53­3.50 (2H, m, 
NCH2), 5.89 (1H, d, J 15.2, HC=CHAr), 6.50 (1H, d, J 15.6, HC=CHAr), 6.56 (1H, s, 
Ar­H), 6.87 (2H, s, 2xAr­H), 6.99 (2H, s, 2xAr­H), 7.10 (1H, s, Ar­H), 7.30 (1H, d, J 
16.0, HC=CHAr), 7.46 (1H, d, J 16.0, HC=CHAr). (100MHz, CD3OD): 27.07 (CH2), 
27.17 (CH2), 28.97 (CH2), 38.62 (NCH2), 40.50 (NCH2), 47.74 (NCH2), 50.24 
(NCH2), 110.91 (ArCH), 116.99 (ArCH), 117.56 (ArCH), 118.65 (ArCH), 118.81 
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(HC=CHAr), 123.08 (HC=CHAr), 124.49 (ArCH), 126.83 (ArCH), 127.83 (ArC), 
135.09 (ArC), 141.32 (HC=CHAr), 141.88 (HC=CHAr), 142.45 (ArC), 143.93 (ArC), 
148.92 (ArC), 150.37 (ArC), 168.74 (C=O), 168.89 (C=O). 
Tetrahydro­cadabicine [229] 
O 
O NH 
NH 
O 
OH 
N 
H 
A stirred mixture of 228 (11 mg,) and Pd/C (11 mg) in MeOH/HCl (2 mL), was 
reacted under H2 overnight. The mixture was then filtered through celite and 
concentrated to dryness. The resulting crude material was purified via silica gel 
column chromatography 0%­3% MeOH/DCM to give 229 (6.5 mg, 77%) as a white 
solid. mp: 171°C, δH (400MHz, CD3OD): 1.39­1.48 (4H, m, 2xCH2), 1.73 (2H, t, J 
6.0, CH2), 2.43­2.47 (2H, m, COCH2), 2.55 (4H, t, J 6.8, 2xNCH2), 2.64­2.67 (2H, m, 
COCH2), 2.83­2.87 (2H, m, ArCH2), 2.92­2.95 (2H, m, ArCH2), 3.12 (2H, t, J 6.2, 
NCH2), 3.26 (2H, t, J 6.2, NCH2), 6.80 (1H, d, J 2.0, Ar­H), 6.84­6.87 (3H, m, 3xAr­
H), 6.91 (1H, dd, J 2.2, 8.2, Ar­H), 7.18 (1H, d, J 8.4, Ar­H). (100MHz, CD3OD): 
24.16 (CH2), 27.49 (CH2), 27.65 (CH2), 31.13 (ArCH2), 31.99 (ArCH2), 36.10 
(NCH2), 36.82 (COCH2), 38.91 (NCH2), 39.03 (COCH2), 45.64 (NCH2), 48.45 
(NCH2), 117.53 (ArCH), 118.34 (ArCH), 123.31 (ArCH), 126.62 (ArCH), 130.57 
(ArCH), 133.86 (ArC), 135.44 (ArC), 143.89 (ArC), 148.62 (ArC), 157.99 (ArC). 
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5. APPENDIX

Standard curve of 2­nitro­5­thiobenzoic acid
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Determination of protein concentrations by Lowry assay 
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